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Abstract
The importance of growth factors and nutrition in cancer cachexia was 
investigated in a group of patients with advanced malignant disease, in mice 
bearing the Lewis lung tumour, and in cultures of the human hepatoma cell 
line HEP G2. In addition, the effect of treatment with medroxyprogesterone 
acetate was also studied.
The patients studied show that, in addition to poor appetite and weight loss, 
cancer cachexia is associated with low levels of serum IGF-I, and high levels
of TNF-a and ferritin. Levels of the mean growth hormone and serum
cortisol were in the high normal range.
Treatment with medroxyprogesterone acetate (MPA) for 4 weeks associated 
with an improvement in appetite in all patients. This was accompanied by an 
increase in fasting plasma insulin levels but no change in serum albumin, 
total proteins or mean levels of IGF-I. A weight gain of more than 3 kg was 
observed in 28% of patients. This degree of weight gain was associated with 
a decrease in fasting levels of growth hormone, tumour necrosis factor and 
cortisol, followed by a significant increase in the levels of IGF-I.
Patients who failed to gain or who lost further weight showed an increase in 
plasma levels of ferritin, cortisol and tumour necrosis factor. While levels of 
both growth hormone and IGF-I remain low.
In the study of tumour-bearing mice, it was found that overall plasma and 
liver levels of IGF-I were lower in tumour-bearing than normal animals, levels 
were also lower in muscle but showed evidence of recovery in the later
stage of the study. Treatment with MPA had no effect on food intake and no 
significant effect on non-tumour weight but appear significantly to increase 
tumour weight. It also prevented the fall in plasma IGF-I levels seen in non­
treated animals. Levels of tumour necrosis factor -a (TNF-a) were
undetectable in plasma in all animals but were markedly increased in 
muscle of all tumour-bearing animals, particularly those treated with MPA. 
This was accompanied by a decrease in muscle glycogen contents and an 
apparent increase (possibly only relative) in muscle protein content.
The low IGF-I and high TNF-a levels in the muscle of tumour-bearing
animals may be important factors in the development of muscle wasting in 
these animals.
In studies on the human hepatoma cell line in culture, the addition of insulin 
and human growth hormone (hGH) together resulted in an increase in the 
synthesis of IGF-I. While the addition of each separately was without effect. 
The addition of TNF-a along with insulin and hGH counteracted their ability 
to increase IGF-I synthesis. Reduction in the glutamine content of the 
medium resulted in a significant reduction in IGF-I release by the cultured 
cells. MPA had no direct effect on either cell growth or IGF-I production.
In patients with cancer who are losing weight, a reduction in TNF-a levels
appears to allow IGF-I levels to rise in response to the prevailing high levels 
of growth hormone, with restoration of the normal relationship between IGF-I 
and growth hormone. These changes probably predispose to weight gain.
n
The increase in tumour growth seen in animals treated with MPA suggests 
that it may be preferable to give such treatment only after removal of the 
tumour or radiation therapy.
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ACTH adrenocorticotrophic hormone.
ADP adenine diphosphate.
AIDS acquired immune deficiency syndrome.
ALP alkaline phosphatase.
ATP adenine triphosphate.
AST aspartate aminotransferase.
BMI body mass index.
BMR basal metabolic rate.
BSA bovine serum albumin.
CE cholesterol esterase.
CO cholesterol oxidase.
CT chemotherapy.
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DNA deoxyribonucleic acid.
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GFs growth factors.
gGT gamma glutamyl transferase.
GH growth hormone.
GK glycerokinase.
GOD glucose oxidase.
VI
HEP G2 human hepatoma cell line.
hIGF-l human insulin-like growth factor-!/ somatomedin-C.
ICRF Imperial Cancer Research Fund.
IDDM insulin dependent diabetes mellitus.
IGF-I insulin-like growth factor-!/ somatomedin-C.
IGF-II insulin-like growth factor-!!.
IGFBP-1 insulin-like growth factor-binding protein-1.
IGF-R insulin-like growth factor-receptor
IGFs IGF-I and IGF-ll/somatomedins.
IL-1 interleukin -1
IRMA immuno radiometric assay.
kDa kilo Dalton.
LDH lactate dehydrogenase.
LH luteinizing hormone.
LLT Lewis lung tumour.
LPS lipopolysaccharide.
Mabs monoclonal antibodies.
MAMC mid-arm muscle circumference.
MPA medroxyprogesterone acetate.
MUAC mid upper arm circumference.
NAD nicotinamide adenine dinucleotide.
NADH nicotinamide adenine dinucleotide hydrogenase.
NETRIA North East Thames Regional Immunoassay.
NIDDM non - insulin dependent diabetes mellitus.
NS not significant.
PEG polyethylene glycol.
PEP phosphoenol pyruvate.
PTH parathyroid hormone.
vn
rhTNF recombinant human tumour necrosis factor 
RMR resting metabolic rate.
RNA ribonucleic acid
RT radiotherapy.
TIBC total iron binding capacity.
TMB tetramethylbenzidine
TNF-a tumour necrosis factor alpha/ cachectin.
TNF-p tumour necrosis factor beta.
TSF triceps skin fold.
TSH thyroid stimulating hormone
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Chapter 1.0
GENERAL INTRODUCTION
1:1 Cancer Cachexia
Weight loss is a common problem in patients with cancer. It may exacerbate 
the severity of the disease by depleting body reserves of protein and 
energy, and, when it is extreme, survival is decreased (Theologides, 1972; 
Theologides, 1979; Nixon et al.. 1980; Rnekdeskhel et al.. 1986). Cachexia 
may be defined as an extreme state of general ill-health associated with 
malnutrition, wasting, and circulatory and muscular weakness.
Any loss of body weight must arise from an inability of dietary intake to meet 
the metabolic demands for energy expenditure or obligatory loss of body 
nitrogen. However in some cases of cancer cachexia the cause of loss of 
weight is far from clear. Loss of lean body mass in the cancer-bearing state 
has led to the use of a variety of methods of nutritional support in an attempt 
to meet potentially enhanced dietary requirements for protein and energy 
(Nixon et al.. 1981a: Nixon et al.. 1981b). However, even full parenteral 
nutrition may not always completely reverse the advancing cachexia seen 
in some patients with cancer (Brennan, 1981 ; Nixon et al.. 1981b).
Studies in both volunteers (Clemmons et al.. 1981a; Isley et al.. 1983) and 
patients (Hintz et al.. 1978; Smith et al.. 1981) have demonstrated a 
relationship between insulin -like growth factor (IGF-I) and nutrition. These 
have shown that circulating IGF-I levels are decreased in states of 
undernutrition and rise with improvement of nutrition.
Whatever is meant by “nutritional status”, its assessment is difficult, and 
many of the objective measurements used have proven to be
unsatisfactory. Anthropometeric criteria and measurements of the levels of 
proteins such as albumin (Young et al., 1978) and transferrin remain useful 
for screening purposes, but they are insensitive to short-term changes in 
nutrition and are frequently affected by other non-nutritional factors (Shetty 
et al.; 1979). Because the levels of IGF-l in large part are regulated by 
nutrition, the assessment of IGF-I is potentially a useful measure of 
nutritional status. IGF-I is a peptide with a high degree of structural 
homology to proinsulin and which has important effects on metabolism 
(insulin-like activity), cell growth, differentiation and cell division.
Although the precise cause of the development of cachexia during the 
progression of a tumour may be unknown, it is believed to be due, in part at 
least, to an increase in endogenous production of cytokines (Oliff et al.. 
1987; Tracey et al.. 1988). The injection of recombinant cytokines into 
normal animals can cause tissue wasting, and raised serum levels of 
tumour necrosis factor alpha (TNF-a) have been observed in cachetic 
patients with cancer (Beulter et al.. 1988)
It is therefore possible to speculate that, in the presence of cancer, among 
other factors, there may be an interaction between IGF-I, TNF-a and 
nutrition, the net result of which is to produce severe wasting.
This thesis attempts to bring together some of the more recent 
developments in a cohesive manner, and to update our concepts on the
relationship between hormonal factors (IGF-I, and TNF-a) and nutrition in
the development of cancer cachexia.
It has been shown that in the cachexia accompanying malignant disease, 
caloric expenditure remains high ( Warnold et al.. 1978; Burke et al.. 1980; 
Peacock et al.. 1987; Fearon et al.. 1988; and Hyltander et al.. 1991) with 
an elevated basal metabolic rate despite reduced dietary intake. These 
findings indicate that this phenomenon results from a profound systemic 
derangement of the host metabolism.
The pathogenesis of weight loss in some cancer patients remains unclear, 
although elevated protein turnover in some organs or tissue compartments 
(Heber et al.. 1982; Eden et al.. 1984a) and increased glucose-carbon 
cycling (Holroyde et al. 1984; Eden et al.. 1984b) have been reported.
1:1:1 Energy Metabolism
Energy is the capacity to do work. In biological systems it is measured in 
kilocalories (kcal) or kilojoules (kJ). One kcal (equivalent to 4.18 kJ) is the
amount of heat required to raise the temperature of 1.0 kg of water by 1°C. 
A subject is in energy balance if energy intake equals energy expenditure 
and energy stores remain constant. If expenditure exceeds intake, then 
there is negative balance and stored energy such as glycogen or fat must 
be utilised; in severe cases there may be breakdown of muscle to provide 
energy. The highly complex series of inter-relationships of energy balance 
which, although not fully understood, determine whether an individual will 
be lean or obese. In order to understand the regulation of energy balance, 
the regulation of both energy intake and energy expenditure should be 
considered.
1:1:2 Energy Intake
The control of energy intake in man is complex, and research on the subject 
has proven very difficult. Available data suggest that appetite, social 
pressure, and illness are factors which are known to control energy intake. 
Health, social and religious reasons may also influence the type of energy 
intake. The distinction between hunger and appetite is that, hunger is a 
sensation which makes one want to eat, appetite is a sensation which 
makes one want to eat a particular food (Garrow, 1978).
Satiety is difficult to define precisely. It is a sensation intermediate between 
the relief of hunger and the nausea which ultimately limits overeating. 
Satiety is a mechanism by which overeating acts as a way of reducing 
intake (Booth et al.. 1976), alternatively it may mean generating an 
unpleasant sensation from the act of overeating. Booth et al.. (1976) have 
demonstrated that in man satiety is a learned response.
1:1:3 Energy Expenditure
The energy or “caloric expenditure" is the total heat output of a subject 
including the equivalent of water vaporised. Energy expenditure in man is 
affected by many factors which include body size, environmental 
temperature, activity and food intake. Energy expenditure has been related 
to basal metabolic rate (BMR) which has been defined as the energy output 
of an individual under standardised resting conditions: bodily and mentally 
at rest, 12-18 hours after a meal in a neutral thermal environment (Garrow, 
1978). It is difficult to achieve the condition of basal metabolic rate, and it is
easier and more practical to measure the resting metabolic rate (RMR), 
which is defined as the energy output of an individual 2-4 hours after a light 
breakfast. Any increase in the rate of energy expenditure in the body will 
be reflected by an increase in RMR (Garrow, 1978).
It is well recognised that in healthy individuals, a sustained reduction in 
energy intake results in a fall in energy expenditure (RMR) which tends to 
reduce the expected weight loss in starvation (Miller et al.. 1975).
The metabolic changes which occur in cancer cachexia differ markedly 
from those which result from simple starvation as shown in table below.
Starvation Cachexia
Appetite Good poor
Energy expenditure - Basal metabolic rate. — + +
Oxidative metabolism — + +
Ketosis ++ No change
Blood amino acids — ++
— = decrease, + += increase
In healthy human subjects, the administration of TNF-a results in a 34% 
increase in resting energy expenditure (Van der poll et al.. 1991). Others 
have reported that, TNF-a increased the metabolic rate when administered
to cancer patients (Starnes et a!.. 1988; Seaton et a!.. 1990).
The possible pathogenesis of cancer cachexia is as follows: 
peptides (?TNF-a)
Cancer -----------------------> Normal cells ± cancer cells —>
& small molecules e.g. liver
Stimulation/ inhibition of hormones (?IGF,IGFBP) and enzymes — > 
Metabolic rate alteration ------> cachexia.
1:2 Insuiin-Like Growth Factors
Growth factors (GFs) are polypeptides that regulate both cell replication and 
the differentiation of cellular function. They are synthesised by a variety of 
cell systems and tissues. GFs are present in the systemic circulation, either 
in the free state or bound to specific binding proteins or platelet granules. 
They may act both as systemic or local regulators of cell metabolism. The 
number of known .GFs is extensive and includes insulin-like growth factors 
(IGFs), platelet-derived growth factors (PDGFs), and the transforming 
growth factor p family. This review will be limited to IGFs.
1:2:1 Historical Perspective of IGFs
It was first shown in 1957 that the growth-promoting effect of growth 
hormone (exemplified by incorporation of sulphate into cartilage) was 
mediated by another peptide factor which was termed “ sulfation factor” (sic) 
(Salmon & Daughaday, 1957). Quite independently in 1963, Froesch and 
colleagues demonstrated for the first time the presence of protein factors in 
serum with insulin-like activity which is not inhibited by anti-insulin
7
antibodies, so called non-suppressible insulin -like activity (Froesch et al.. 
1963). In early 1970’s, these proteins were shown also to mediate the 
mitogenic activity of serum ( Pierson & Temin 1972) and medium condition 
by rat hepatocytes (Dulak & Temin 1973). It was subsequently revealed by 
sequence analysis that these functions are subserved by two main 
peptides: IGF-I which is identical to somatomedin-C (Klapper et al., 1983) 
and IGF-II (Rinderknecht & Humbel, 1978b; Marquardt et al.. 1981). The 
IGF terminology is now preferred as there is no somatomedin designation 
for IGF-II (Daughaday et al.. 1978).
The somatomedins were originally identified on the basis of their ability to 
stimulate sulphate incorporation into cartilage (Salmon & Daughaday, 
1957). Insulin mimicked this effect but only at supraphysiologic 
concentration . Conversely, IGF-I possesses insulin -like activity and will 
stimulate glucose transport into fat cells in the presence of anti-insulin 
antibody, (Froesch et al.. 1963; Rinderknecht & Humbel, 1976), also only at 
high concentration.
1:2:2 Structure and Sequence Analysis of IGFs 
The term IGF is applied to a group of peptides which includes IGF-I and 
IGF-II whose structure is highly similar to proinsulin, with 50 % amino acid 
sequence homology (Rinderknecht & Humbel, 1978a). The A and B chains 
of insulin, with their interchain disulphide bridges are closely parallelled to 
the IGF peptide and it is here that the sequence homology is most evident, 
while the proinsulin C-peptide region is represented by much shorter 
sequences in both IGF-I and IGF-II. In addition, the growth factors have a
8
short carboxy-terminal extension (D-region ) which is not present in 
proinsulin (Figure 1:1).
IGF-I is a basic, single chain polypeptide of 70 amino acids (see Figure 
1:1), which has a molecular mass of 7.6 kDa, and contains 3 disulphide 
bridges (Rinderknecht & Humbel,1978a; Clemmon, 1989). IGF-II, a slightly 
acidic peptide with a molecular mass of 7.5 kDa, contains 67 amino acids, 
over 60% of them corresponding to those in IGF-I (Rinderknecht &
Humbel,1978 b). The first 16 residues of the B domain in IGF-I and II 
contain the region that is critical for recognition by binding proteins (Bayne 
et al.. 1988). Insulin, which does not bind to these binding proteins, has 
significant structural differences in that region.
The purification and sequence analysis of human somatomedin-C has 
indicated that it is identical to IGF-I (Svoboda et al., 1980; Klapper et al.,
1983). A basic somatomedin isolated from rat serum is strikingly similar to 
human somatomedin-C in its amino-terminal sequence, and may be 
regarded as the equivalent of IGF-I in the rat ( Rubin et al.. 1982). 
Purification and analysis of one of the multiplication-stimulating activity 
(MSA) fractions in the rat has revealed partial homology with human IGF-II; 
this peptide is now regarded as the rat equivalent of IGF-II (Marquerdt 
al., 1981).
Although both insulin and IGF-I are important for the maintenance of 
normal carbohydrate homeostasis and long-term growth.The significant 
differences between them are:
(1) IGFs circulate bound to binding proteins and their concentration in 
blood is more stable than that of insulin. On the other hand, plasma insulin 
levels fluctuate widely particularly in response to carbohydrate intake.
(2) Insulin and the IGFs have structurally distinct receptors.
10
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1:2:3 Control of Synthesis and Secretion of IGFs
The control of IGF-I activity is possibly more complex than that of any other 
hormone because it can be synthesised in most tissues in the body, 
particularly in the liver.
Growth hormone (GH) was shown to be the most important factor 
controlling IGF-I secretion (Dauchaday et al.. 1976; Kooawa et al..1982: 
Clemmons & Van Wyk, 1984; Schlecter et al..1986). the level of IGF-I being 
decreased by hypophysectomy and increased by GH producing tumours. 
GH is essential for skeletal and lean tissue growth and differentiation either 
directly or indirectly through IGF-I. GH can stimulate mRNA for IGF-I in bone 
growth plate (Isgaard et al..1988T cultured hepatocytes and skeletal muscle 
(Turner et al..1988).
In addition to GH, a number of other factors are major determents of IGF-I 
concentration in blood. Of these, nutritional status is one of the most 
important (Prewitt et al. 1982; Van Wyk & Underwood, 1988). Blood IGF-I 
concentrations are very responsive, not only to the level of nutrition but also 
to the composition of the diet (Prewitt et al. 1982; Isley et al.. 1983; Elasser 
êLâl..1989). Both protein and energy intake are regulators of serum IGF-I 
concentration in adult humans (Isley et al.. 1983). On an individual nutrient 
basis, energy and protein are the major stimuli for IGF-I secretion.
Nutrients, however, are rarely ingested alone but more usually in the form of 
a complex mixed meal. The effects of the interaction (s) of stimulatory 
nutrients must also be considered. Studies in human volunteers utilising 
radioimmunoassay techniques have shown that circulating IGF-I falls with
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fasting for a period of 5 days and rises again with refeeding (Clemmons et 
al., 1981; Islev et al.. 1983).
Many cell types (especially endocrine tissues) have been shown to 
respond to a specific trophic stimulus for that organ with an increase in the 
secretion of IGF-like peptides. For example the granulosa cell responds to 
luteinizing hormone (LH) with an increase in IGF-I secretion (Adashi et al.. 
1985) while thyroid follicular cell respond similarly to thyroid stimulating 
hormone (Tramontane et al.. 1988). Fetal rat fibroblasts have been shown 
to secrete increased amounts of IGF-II in response to human placental 
lactogen, whereas postnatal fibroblasts do not, indicating that IGF-II 
secretion is developmentally regulated (Adams et al.. 1983). For other 
factors that control IGF-I concentration see table 1:1.
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Table 1:1 Factors that Control Blood IGF-I Concentration’
1 Age Peak at adolescence.
2 Sex Females 20%>males.
3 Pregnancy Levels highest third trimester.
4 Nutritional status Fasting causes 70% decline in 10 days 
Refeeding response requires -15-18 kcal/kg 
energy and 1.0 g m/kg protein .
5 Growth hormone Decreased by hypophysectomy. Increased 
by GH producing tumour.
6 Thyroxine Decrease in hypothyroidism in proportion to the 
decrease in GH secretion.
7 Prolactin In the absence of GH prolactin is a weak 
stimulus in rats ( Francis & Hill, 1975).
8 Oestrogen Physiologic oestrogen replacement causes an 
increase.
9 Negative feedback IGF-I suppresses GH secretion by the pituitary 
and therefore, indirectly controls IGF-I secretion.
* Adapted from Clemmons, British Medical Bulletin 1989.
1:2:4 Synthesis of IGF-I
Two different human IGF-I precursor peptides have been predicted from 
cDNA cloning studies (Jansen et al.. 1983; Rotwein et al.. 1986). The 
primary translation product of IGF-IA m RNA contains 153 amino acids, and
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proteins are identical for the initial 134 residues (Figure 1.2).
The IGF-IA precursor contains an additional 19 residues, and IGF-IB, 61. 
From data obtained by cell-free translation studies, it appears that the entire 
48 initial amino acids of human IGF-I A or B can function as a 
cotranslationally cleaved signal sequence (Rotwein et al.. 1987), targeting 
IGF-I to the secretory pathway. However, these experiments have not been 
performed in the whole cell, and the data do not pertain to subsequent, 
posttranstional processing events. For both IGF-IA and IGF-IB, the function 
and fate of the carboxyl-terminal E domains are unknown.
In both IGF-I precursors there is a single arginine residue at the first position 
after the carboxyl end of the mature protein, suggesting that a cleavage 
enzyme with a monobasic recognition site is involved in posttranslational 
proteolytic processing.
The factors which mediate the effect of GH ( with nutrition and other stimuli) 
on IGF stimulation is not known. There is no evidence for example, of a 
second messenger system such as that involved in insulin secretion 
whereby the metabolism of glucose by B-cells of the pancreas enhances 
adenosine triphosphate (ATP) production, raising the cyclic adenosine 
monophosphate (cAMP) concentration of the B-cells which mediates the 
effects of glucose on insulin stimulation.
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Figure 1:2 The synthesis of insulin like growth factor-1
Two different human IGF-I precursor peptides have been predicted. 
The initial 134 amino acids are identical. The fate and function of E 
domains are unknown.
IGF-IA precursor = 153 amino acids IGF-IB precursor = 195 amino acids
1-48
♦
49-118 
(IGF-I molecule)
119-134 134-
(E-domain) (additioanal residue)
49-118
*
*** Cotranslationally cleavage 
signal targetting IGF-I to the 
secretory pathway
119-134 134-
i
1
?Cleavage enzyme with 
a monobasic recogition
r
IGF-I (70 amino acids)
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1:2:5 Sites of Production of IGFs
The role of the various tissues in contributing to the blood pool of IGF-I has 
been the subject of intensive investigations. Specifically, the autocrine/ 
paracrine hypothesis has been applied to the analysis of IGF-I synthesis 
and secretion. IGF-like peptides have been shown to be secreted by 
multiple types of cells in culture. IGF-I mRNA is present in many tissues, 
although it is 50- fold more abundant in the liver than elsewhere (Murphy et 
al.,1987)
Work in many laboratories has indicated that the liver is the major source of 
IGF-I in the circulation. This has been demonstrated directly in studies of 
isolated perfused liver ( Kogawa et al 1982; Schwander et al.. 1983), and 
both fetal (D’Ercole et al.. 1980; Rechler et al.. 1979), and adult liver in 
organ culture (Binoux et al..1982: Schimpff et al.. 1981). These studies are 
supported by the observations that partial hepatectomy (Uthne & Uthne, 
1972) and liver disease (Schimpff et al.. 1977;Takano et al.. 1977) result in 
low circulating IGF levels, especially IGF-I.
The main source of IGF-II in adults is unknown. Fetal rat liver produces IGF- 
II, but it is not clear whether it is produced by normal adult liver.
After the liver, fibroblasts are perhaps the most widely studied source of 
IGF-I (Han et al.. 1987; Atkinson et al.. 1986). Han and co-workers 
demonstrated that the human embryonic lung fibroblast produces a 
substance detectable by IGF-I radioimmunoassay (RIA). Human skin 
fibroblasts also release immunoreactive IGF-I (Clemmons et al.. 1981), the 
production of which is enhanced by addition of GH and a range of other
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hormones and growth factors.
In addition to its presence in a number of tissue, IGF-I has been reported in 
human milk (Baxter et al.. 1984a), and semen (Baxter et al.. 1984b), and 
IGF-II has been identified in ovarian follicular fluid (Hammond et al.. 1984), 
and amniotic fluid (Merimee et al.. 1984).
Table 1:2 The Tissues Which Are Known to Secrete IGF-I
Organ Author Year Title
Liver D’Ercole et al. 1984 Tissue concentrations of somatomedin
Kidney D’Ercole et al. 1984 Tissue concentrations of somatomedin
Lung D’Ercole et al. 1984 Tissue concentrations of somatomedin
Synder et al 1987 IGF-I production by fetal lung tissue
Heart D'Ercole et al. 1984 Tissue concentrations of somatomedin
Brain D’Ercole et al. 1984 Tissue concentrations of somatomedin
Fibroblast Atkison et al. 1980 Release of IGF-I by human fibroblasts.
Clemmons et al.,1981 IGF-I production by cultured human 
fibroblast
Adams et al. 1983 Alveolar macrophages release an IGF 
type molecule.
Uterus Murphy&Friesen 1988 Oestrogen &GH effects on IGF-I.
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Table 1:3
The Factors Which Stimulate the Secretion of IGF-I in Different Tissues
Organ The Factor Author and Year
Liver Growth hormone Clemmons & Van Wyk, 1984
Nutritional status Smith, 1981; Hintz, 1978
Uterus Oestrogen Murphy&Friesen, 1988.
Granulosa cell luteinizing hormone Adashi et al., 1985.
Thyroid follicular cell. Thyroid stimulating Tramontane et al.,1988.
hormone.
1:2:6 IGF Binding Proteins
A spectrum of low to high molecular weight IGF-I binding proteins (IGFBP’s) 
has been identified in a number of tissues and biological fluids including 
serum (Hintz & Lui, 1977; Furlanetto, 1980; White et al.. 1981), 
cerebrospinal fluid (Hossenlopp et al.. 1986), amniotic fluid (Chochinov et 
al., 1977) and seminal fluid (Rosenfeld et al.. 1990). A total of at least six 
IGF binding proteins have now been identified, of which three have been 
well-characterised and are believed to be the major binding proteins in 
normal serum (IGFBP-1-3).
The amino acid composition of binding proteins reveals that they all have a 
high content of cysteine residues, suggesting a significant degree of
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disulphide bridge conservation (Wood et al.. 1988). The IGFBPs are 
increasingly recognised as mediators of both the inhibitory and stimulatory 
effects of IGF's, and understanding of their metabolism has led to a better 
understanding of the diverse anabolic, mitogenic and differentiative roles of 
IGFs and the way in which these actions are regulated.
IGFBP-3 (molecular weight of 85 kDa) is the most abundant binding protein 
in adult serum, where it exists predominantly in a ternary complex which 
also contains an acid-labile 35 kDa glycoprotein in addition to either IGF-I 
or IGF-II (Baxter & Martin 1989). The three components of the complex have
been termed the a (acid labile), p (IGFBP) and y (growth factors) subunits.
IGFBP-3 has a high affinity for IGF-I, leading to a low concentration (1-2%) 
of unbound IGF-I in serum. It is this unbound fraction which is thought to be 
biologically active (Daughaday et al.. 1982). The half-life of IGF in BP-3 
complex is 15-18 hours whereas unbound IGF-I has a half-life of 10 
minutes (Guler et al.. 1987). IGFBP-3 is synthesised in many cell types, but 
quantitatively the liver is the major source of this protein.
In animal models the synthesis of IGF-binding proteins has also been 
shown to be modulated by GH, thyroxine and cortisol (Schalch et al.. 1979; 
White et al.. 1981). Impure preparations of IGFBPs have been shown to 
inhibit insulin-like action of IGF-I on fat cells (Clemmons,1989).
IGFBP-2 ( molecular weight of 34 kDa) is present in the plasma, and the 
cerebrospinal fluid. It binds IGF-II with a six-fold greater affinity than IGF-I 
(Binoux et al.. 1982).
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The IGFBP-1 (molecular weight of 25 kDa) is growth hormone (GH) 
independent. The concentration in serum of IGFBP-1 varies with nutritional 
intake. The concentration is inversely proportional to insulin levels with a 
rise during short term fasting, and a rapid fall in response to feeding. A 
significant decrease in concentration has also been demonstrated during 
the pubertal growth spurt which parallells a rise in insulin level (Holly et al.. 
1988; Holly et al.. 1989). This may lead to an increase in the level of free 
IGF-I, which may contribute to the rapid growth and puberty.
After an overnight fast, the plasma concentration of IGFBP-1 rises 
approximately 8 fold and it is reduced following ingestion of a mixed meal 
or glucose infusion (Baxter & Colwell, 1987). This illustrates the possible 
role of IGFBP-1 if not in cachexia, then at least in fasting or early starvation 
in which the levels of cortisol and GH are increased, and the levels of 
IGFBP’s are higher than normal. Thus the regulation of IGFBP-1 is similar to 
that of hormones involved in glucose counter-regulation (Baxter et al..
1986).
1:2:6:1 The Function of IGFBPs
IGF-I is produced in many cell types, and exerts a wide variety of biological 
activities including insulin-like and mitogenic actions, and stimulation of a 
diverse group of differentiated cell functions such as sex steroid synthesis 
by gonadal cells (Baxter et al.. 1986). It is believed that in some tissues 
local IGF activity, either autocrine or paracrine is regulated at the cellular 
level by IGFBPs, the concentration of which influences the activity of IGF by 
altering the concentration of free fraction (Baxter et al.. 1989).
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Baxter (1991) concluded that the availability of circulating IGFs appears to 
be under the dual control of the binding proteins, and exert their insulin-like 
activity (IGFBP-1) and growth promoting activities (IGFBP-3) at the cellular 
level in a closely regulated way as described below:
(i) Control of insulin-like potential, which is fully blocked in IGFs present in 
the ternary complex, may primarily be due to the regulatory effect of IGFBP- 
1 on uncomplexed IGFs. This protein (IGFBP-1) responds acutely to 
hormonal and nutritional signals in a manner consistent with its role in 
glucose counter-regulation, inhibiting insulin-like IGF activity in response to 
hypoglycemia, and allowing expression of this activity following food intake.
(ii) Control of growth-promoting potentials which occurs at the level of the
circulating ternary complex between IGFs, IGFBP- 3 and the a- subunit.
Due to its size, this complex is largely confined to the vascular space, and 
must undergo partial dissociation before IGFs, or binary IGF-IGFBP-3 
complex can enter the extracellular space of potential target organs. The 
“steady state" concentration of the ternary complex, which effectively 
determines both the total and uncomplexed IGF concentrations, is 
regulated by the same factors that control IGF-I: age, nutrition and growth 
hormone (Baxter 1991).
The mechanism by which IGFs are transferred from the circulatory pool to 
the tissue receptors is not clear. The presence of an IGFBP-specific 
circulating protease has been described (Giudice et al., 1990; Hossenlopp 
et al., 1990), which appears to be very specific within the family of highly 
homologous IGFBPs. The possibility of other substrate has not been 
excluded (Giudice et al., 1990). Davies and co-workers (1991)
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demonstrated the presence of a heat-sensitive cation-dependent proteolytic 
enzyme specific for IGFBP-3 in serum of severely ill patients. The activity of 
this protease was found ^ e  more apparent during fasting than to be when 
studied after commencement of parenteral nutrition, indicating that one of 
the influencing factors in the activity of this protease is the nutritional intake 
of the patient (Davies et al., 1991).
1:2:7 Receptors for IGFs
Hormones elicit their biological response at the cellular level following 
interaction with specific receptors. There are two specific receptors for IGF-I 
and IGF-II that are found in a variety of tissues including placental 
membranes ( Daughaday et al.. 1981), myoblasts ( Hill et al.. 1984) and 
fibroblasts (Clemmons et al.. 1986).
The 130 kDa receptor (type R1) has a binding site with a high affinity for 
IGF-I and a structure which is similar to that of insulin receptor; both are
tetrameric a2 p2 complexes in which extracellular a and transmembrane p 
subunits are linked by disulphide bonds. The a subunits contain the ligand-
binding domains, and the intracellular portion of the p domain has a
tyrosine kinase domain (Massague & Czech, 1982). The other receptor 
(type R2) has a molecular weight of 260 kDa and has a high affinity for IGF- 
II; the presence of insulin increases the number of these receptors on the 
cell surface.
The insulin and type Rl IGF receptors have a high degree of structural
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homology. This is most pronounced (84%) in the tyrosine kinase domains
(Ullrich êlâ!-. 1986).
In addition to binding to the two types of cell surface IGF receptor, the IGFs 
receptors also cross-react with the human insulin receptor. Both insulin 
and IGF receptors can mediate acute metabolic and longer-term mitogenic 
effects. In vitro effects on glucose transport appear similar, but chimeric 
receptors possessing the cytoplasmic domain of IGF receptor are 10 times 
more active in simulating DNA synthesis and are more stable (Lammers 
âl-, 1989). It is this receptor which probably mediates the mitogenic effects 
of both IGFs and insulin (Van WykgLâ!-, 1985). Other in vivo differences in 
the action of IGF-I and insulin may relate to the tissue distribution of their 
receptors (Czech, 1989).
Rl receptor binding exhibits a high degree of specificity (IGF-I >IGF-II > 
insulin) which differs from the specificity of the insulin receptor (insulin > 
IGF-I>IGF-II) (Nissley & Rechler, 1984). Receptor specificity studies (Kiess 
et al.. 1987) have been further strengthened by demonstrating that anti­
insulin receptor antibodies will block IGF binding to the insulin receptor; 
likewise a monoclonal antibody directed against the type Rl IGF receptor 
will block insulin binding. This specificity of binding is critical to the 
maintenance of the specificity of the metabolic actions of each peptide.
It is not known whether the free (non-protein bound) fraction or a complex of 
IGF-I / II with one of the specific binding proteins is the trigger for the 
intracellular events that follow receptor binding. It has been suggested
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(Clemmons et al. 1989) that the binding of growth factors to receptors 
(e.g.fibroblasts) is dependent not only on their adequate synthesis but also 
on receptor number, avidity, and age. Tissue IGF receptors appear to alter 
developmentally and, possibly, pathologically. The effect of age on 
receptor binding of IGF-I was well illustrated in a study of IGF binding to 
receptors in pre-and post-natal rat cartilage (Hill et al.. 1981). Thus, rat liver 
type Rl IGF receptors are dominant in newborn animals and in adult 
regenerating liver but are virtually absent in adults (Caro et al. 1988). 
Similarly, human adult liver has practically no type Rl IGF receptor 
compared with the HEP-G2 Hepatoma cell line (Caro et al. 1988). It 
therefore appears that IGF-I can have no receptor-mediated effects in adult 
liver, but that such activity is present In the growing liver. It is possible that 
IGF-I could act through the type R2 IGF receptor in adult liver although 
IGF-I has a much lower affinity for this receptor compared with IGF-II which 
is present at much higher level. Exposure to dexamethasone also 
increases type Rl receptor numbers (Kaplowitz, 1987).
Antibody blocking studies have shown that both IGF-I and IGF-II mediate 
their growth-promoting effect through the type Rl receptor and not through 
binding to the type R2 receptor (Kiess et al.. 1987). Following binding of 
IGF or insulin, there is down-regulation of each receptor, and this may 
function as a mechanism for protecting cells from over stimulation.
1:2:8 Serum Concentrations of IGF-I in Man
The concentration of IGF-I in serum during childhood has been extensively
studied because of its regulatory role in growth. At birth, the concentration
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of IGF-I in cord blood is about half that found in normal adult serum. Bala 
and co-workers (1981) reported a drop in IGF-I in serum during the first 
three days of life. This change probably reflects the delay in achieving full 
calorie nutrition during the neonatal period. A slow progressive rise in IGF-I 
concentration occurs during childhood. Serum IGF-I concentration tends to 
be higher in girls than in boys, consistent with their more rapid maturation.
Serum IGF-I level reaches the normal adult level just before puberty 
(Silbergeld et al.. 1986). During puberty, there is two to three fold rise in 
serum IGF-I concentration. This rise correlates better with Tanner pubertal 
age (Luna et al.. 1983) and sex hormone concentration than with 
chronological age. Thus, the rise in serum IGF-I which occurs in puberty is 
clearly linked to the increase in sex steroid hormones which occurs at this 
time.
After the age of 25 years, serum IGF-I levels remain relatively constant until 
after the age of 60. Thereafter, a slow decline in serum IGF-I concentration 
occurs ( Hammerman, 1987 ; Johnson & Blizzard 1981), although Rudman 
and co-workers (1981) found that serum GH and IGF-I concentrations 
decreased progressively from the third to the ninth decades. Johnson & 
Blizzard (1981) also reported a decrease in IGF-I and GH secretion with 
aging and a rise in IGF-I in response to GH administration in old age 
subjects.
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1:2:9 Metabolic Effects of IGF-I 
IGF-I has been shown to stimulate the uptake of sulphate into 
proteoglycans (Salmon & Daughaday, 1957); the incorporation of uridine 
into RNA, and thymidine into DNA (Garland et al.. 1972 ), conversion of 
proline to collagen hydroxyproline (Daughaday et al.. 1962), and also to 
stimulate the uptake of sulphate and leucine into glucosaminoglycan 
(Salmon et al.. 1970), and to regulate growth. It also demonstrates mitotic 
activity, that is the ability to stimulate DNA synthesis and cell proliferation in 
selected cell lines e.g. fibroblasts, Sertoli cells, fetal brain cells, myoblasts,
lens epithelium, and pancreatic p-cells. Stiles and co-workers (1979)
demonstrated that other factors acting synergistically with IGF-I are 
probably required for a maximal mitogenic response.
In adipose tissue, IGF-I stimulates glucose metabolism (glycolysis and 
conversion to lipids, and glycogen), and inhibits epinpherine- stimulated 
lipolysis and of glycogen breakdown (Underwood et al.. 1972: Zapf et al.. 
1978). These are, of course, also all the well-known actions of insulin. In 
addition to its insulin-like activity which can be demonstrated following 
neutralisation of endogenous insulin with insulin antibody (Rinderknecht & 
Humbel, 1976), intravenous injection of IGF-I causes hypoglycemia. Guler 
and co-workers (1987) suggested that these insulin-like responses were 
probably mediated via the insulin receptor. In their experiment, they 
compared the short term metabolic effect of recombinant human IGF-I at
100 |ig (13.3 nmol) per kg body weight, and insulin 0.15 lU (1.0 nmol) per
kg body weight in eight healthy volunteers. They concluded that the 
hypoglycemic responses to both hormones were identical. The
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hypoglycemia produced by IGF-I is probably due to the supraphysiologic 
concentration of the free peptide that results from its rapid intravenous 
injection. Fifteen minutes after the injection, the serum level of IGF-I 
increased from 144 ±38 ng/ml at baseline to 424±56 ng/ml, of which 80 
percent was free in the plasma (not bound to IGF carrier proteins).
IGF-I has been implicated in the regulation of circulating 1, 25- 
dihydroxyvitamin D (1,25(0H)2 D) levels in rats (Gray, 1987).
IGF-I may exert negative feedback on GH secretion, although the 
evaluation of this GH- IGF-I axis is difficult (for more detail see section 1:6).
1:3 Autocrine, Paracrine and Endocrine Metabolic 
Effects of iGF-i
The original IGF-I hypothesis suggested that growth hormone secreted 
from the pituitary exerts its growth- promoting effects by stimulating IGF-I 
release from the liver which then mediates the GH action in the target tiss­
ues (Salmon & Daughaday, 1957). However, it has been shown that IGF-I is 
produced in many tissues (for example kidney, brain, heart, thyroid, ovary 
and the uterus) in addition to the liver (D’Ercole et al 1984): this has led to 
an alternative concept of IGF-I action, with, in addition to the effect of GH 
acting upon hepatic IGF-I production, other trophic hormones stimulating 
IGF-I production in target tissues where it acts in an autocrine or paracrine 
manner on local cells. Modulation of steroid synthesis induced by trophic 
hormone binding to specific ACTH or LH receptors in the adrenal or gonad 
respectively, for example has been attributed to local synergistic effects of
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IGF-I (Reed & James, 1989).
Recent studies have demonstrated that the paracrine hypothesis of IGF-I 
action may provide insight into our understanding of the mechanism(s) that 
regulate tissue repair after injury. Following toxic injury to skeletal muscle, 
there is muscle cell regeneration accompanied by expression of high level 
of IGF m-RNA by satellite cells (Jennische & Hannson, 1987). These cells 
subsequently differentiate into myotubes under the direct influence of IGF-I. 
Studies suggest that these regulatory mechanisms are independent of both 
GH secretion and changes in the blood IGF-I concentration (Jennische & 
Hanson, 1987; Clemmon, 1989).
In situ hybridisation studies have shown that IGF-I and II m-RNA’s can be 
detected in fibroblast-like cells of multiple tissues (Han et al.. 1987).
In contrast, IGF-I is detected on the surface of many cell types that do not 
express its m-RNA. This is believed to be due to transport of locally /or 
liver-derived IGF-I by binding proteins, and the subsequent association of 
IGF-I with binding protein on the cell surface. This provides a mechanism by 
which IGF-I and II may function as paracrine regulators of growth in cell 
types that do not actually synthesise these growth factors.
It has been calculated that synthesis in the liver accounts for approximately 
55% of the total IGF-I in the circulation (Kogawa et al 1982: Schwander êl 
âi-, 1983; Binoux et al..1982: Schimpff eLâl-, 1981). Since the liver cell 
membranes of adults contain very few ( if any) IGF-I receptors (Caro et al..
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1988), it has been postulated that the liver and possibly the kidney act as 
endocrine organs in producing IGF-I mainly for export to cells at distant 
sites. In other words, if the adult the liver remains the major source of 
circulating IGF-I but does not possess IGF-I receptors, then this IGF-I must 
be targeted at extrahepatic tissues and must therefore be endocrine in 
action.
Impure preparations of IGFBPs have been shown to inhibit insulin-like 
action of IGF-I on adipocytes (Clemmons et al 1989). This illustrates the 
dependence of fat cells (and possibly other tissues) on IGF-I secreted 
elsewhere, and on transport by IGF-binding proteins to fat cells where IGF-I 
exerts its endocrine function. In contrast, in lung, kidney and other vital 
organs where IGF-I mRNA has been found, GH is believed to act by directly 
stimulating IGF production in these tissues where it acts as in autocrine or 
paracrine manner on local cells (Underwood et al.. 1986).
1:4 IGF-I and Nutrition
As mentioned in the previous section of this chapter, blood IGF -I 
concentrations are very responsive, not only to the level of nutrition but also 
to the composition of the diet (Prewitt et al.. 1982; Isley et al. 1983; Isley et 
al, 1984; Elasser et al..1989). The importance of IGF-I in different 
nutritional states has been investigated mainly with respect to its serum 
concentration. This is increased in well-nourished animals and low in 
children with protein-calorie malnutrition (Grant et al.. 1973; Hintz et al.. 
1978), starved rats (Phillips & Young, 1976) and during fasting in humans 
(Clemmons et al.. 1981a). This may be due to decreased mRNA for IGF-I,
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which is restored on refeeding. Alternatively, it could be due to primary or 
secondary reduction in somatotrophic receptor in the liver (Phillips & 
Young, 1976; Baxter et al.. 1981), or a fall in the concentration of the major 
binding protein (IGFBP). Alternatively, it may be due to a contribution of 
these factors. It is, however, unlikely to be due to a fall in GH levels which, if 
anything, tend to be raised during starvation.
It has been shown that in a group (n=28) of malnourished adult patients 
hospitalised with a wide variety of diseases, who had anthropometeric 
measurement at the time of nutritional assessment, that although neither 
skin fold thickness nor mid arm muscle circumference was significantly 
reduced, the IGF-I level was low. Moreover, the IGF-I level was reduced 
more than the albumin or transferrin level, suggesting that it may be a more 
sensitive indicator of malnutrition than either biochemical or 
anthropometeric parameters (Unterman et al.. 1985). After nutritional 
therapy in six of the patients with 2,000- 3,000 calories and 65 -105 grams 
of proteins (total parenteral nutrition in five patients and enteral feeding in 
the sixth) the IGF-I level rose more consistently than the albumin level, 
transferrin level, or the total lymphocyte count. IGF-I concentration 
increased by more than 70 percent in all six patients receiving nutritional 
therapy and appeared to be the only parameter which reflected recent 
calorie and protein intake (Unterman et al.. 1985). IGF-I can be used as a 
reliable and specific nutritional parameter, with apparent advantages to the 
others currently used ( Francesco et al.. 1989).
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1:5 The Role of Growth Factors in the Pathogenesis of 
Disease.
Growth factors are closely regulated by blood and tissue-specific 
mechanisms. Disturbances of these mechanisms in disease or after injury 
can disrupt the homeostasis of both local tissue stores and levels of GFs in 
blood. This may contribute to abnormal tissue growth. Examples of 
conditions associated with disturbed levels of IGF include:
i. Malnutrition, in which a low serum IGF-I has been observed (see 
Section 1:4).
ii. Acromegaly, which is characterised by chronic hypersecretion of 
GH, and high circulating level of IGF-I which mediates most effects of GH 
(Melmed, 1990).
iii. Ovarian dysgenesis (Tunner’s syndrome) in which the expected 
increase in serum IGF-I at puberty does not occur. When such girls are 
treated with low doses of estrogens, there is a significant rise in serum IGF- 
I (Guttler et al., 1985).
vi. A number of abnormal patterns have been described in diabetes 
mellitus. Poor growth occurring in diabetes is associated with low 
circulating levels of IGF-I, which largely reflects decreased release of 
growth factors by the liver (Goldstein et al., 1988). Insulin increases plasma 
IGF-I concentration in adults with Typel diabetes even in the absence of a 
growth hormone response (Grant et al,.1989). Treatment of diabetic rats
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with IGF-I has been shown to result in an increase in body weight, nitrogen 
retention and increased muscle protein synthesis (Thomas et al., 1991).
In non-insulin dependent (Type 2) diabetes, a number of authors (for 
example Baxter 1986) have found low IGF-I when compared to the general 
population. On the other hand, in a study of hyperinsulinaemic children 
with either normal or impaired GH secretion, IGF-I was normal (Buther et al.. 
1983). Gama et al.. (1990) reported no correlation between plasma IGF-I 
and body mass index (BMI) or body weight in obese hyperinsulinaemic 
patients treated with low calorie diets for a short time.
1:6 GH, IGF-I axis
The existence of a negative feedback system has been reported (Phillips & 
Unterman 1984, Yamasaki et al., 1992). To fulfil the criteria for a negative 
feedback role, the substance (hormone) must be liberated in response to 
GH, and, in turn, the hormone (or its metabolites) must inhibit the secretion 
of GH by the pituitary. The consequence of a feedback system is that tissues 
are protected from inappropriate circulating IGF-I levels. Clinical 
observations and experimental evidence have suggested the existence of 
an endocrine GH-IGF-I axis (Phillips & Unterman 1984, Yamasaki et al., 
1992), with GH stimulating the liver to secrete IGF-I, and the secreted IGF-I 
inhibiting GH secretion (Figure 1:3). However, a number of factors appear 
inconsistent with this proposal. Since insulin as well as GH can stimulate 
hepatic synthesis of IGF-I (Ceda et al.. 1985; Daughaday & Phillips, 1976), 
it is difficult to understand how the pituitary can distinguish IGF-I stimulated 
by GH from that stimulated by insulin or nutrients. It is therefore important to
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consider the involvement of the other stimuli to IGF-I such as nutrients and 
insulin in a feedback system. Other workers (Gama et al..1990) have 
argued that the attenuated GH in obesity fails to support the concept of IGF-I 
mediated feedback inhibition on the hypothalamic-pituitary axis.
1:6:1 GH, IGF-I Axis in Relation to Nutrition 
Complex processes such as muscle and bone growth, adipose tissue 
accumulation and lactation depend upon the coordinated action not only of 
GH and IGF-I but also a variety of other hormones, particularly insulin. It 
was proposed by Green et al., (1985) that both GH and IGF-I action were 
required at target tissues for complex GH-dependent processes such as 
growth.
Another role of GH is in protein sparing during fasting for up to 24 hours. 
Body protein is spared at the expense of fat degradation which is used to 
meet the energy deficit. Jacob and co-workers (1989) reported that IGF-I 
inhibited weight loss after starvation, indicating that IGF-I can function in an 
anabolic role in a severe catabolic state; they concluded that IGF-I was 
involved in the suppression of whole-body protein turnover. In a short­
term (14 days) study, infusion of IGF-I was found to reverse the catabolism 
caused by dietary restriction in normal human volunteers (Clemmons et al.. 
1992).
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Figure 1:3 Schematic representation of potential GH-IGF-I axis
Pituitary gland
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-ve feedback
Tissue receptors
Liver-IGF-I productionIGF-I production
locally at site of action into the blood
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There is experimental evidence to suggest a direct influence of IGF-I on 
cellular growth. IGF-I is an important mediator of the nutritional regulation of 
growth, and changes in plasma concentration are an important component 
of the regulatory response.
There is the evidence that IGF-I is depressed in severe wasting such as 
cancer cachexia, marasmus, anorexia nervosa and untreated diabetes 
mellitus. This may permit the catabolism of non-essential tissues, for the 
preservation of vital function. The precise role of IGFs in catabolic 
selectivity is unclear. Their effects may be mediated by either the autocrine 
or paracrine function of IGF-I or, alternatively, by changes in the level of IGF 
binding proteins. Similarly, the precise hormonal interactions which occur 
during prolonged fasting or in similar conditions such as cachexia is 
unclear; one would expect changes in hormones such as insulin, GH, IGF- 
I, TNF, and cortisol which favour the utilisation of non-vital tissues for 
provision of energy.
There is a marked decrease in the level of IGF-I in response to nutritional 
and non-nutritional stresses which induces changes in tissue growth 
(Yah va et al.. 1987; Yah va et al.. 1989). Cancer cachexia may be seen as a 
good example of the end- result of such a stress.
Medroxyprogesterone acetate (MPA) has been reported to improve 
appetite and to increase body weight in patients with cancer-associated 
weight loss (Niiranen et al.. 1990), but the mechanism of appetite 
stimulation and its anabolic effect is unknown although it has been 
suggested that IGFs may be involved.
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The second chapter of the thesis presents the results of a study of the 
relationship between nutrition, IGF-I and other hormonal factors in patients
with cancer cachexia.
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Chapter 2.0
CACHEXIA IN CANCER PATIENTS
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2:1 Introduction
Severe wasting or cachexia is a major problem in the management of 
patients with diseases such as cancer. It is associated with anorexia, loss of 
tissue mass, increased susceptibility to infection and treatment toxicity.
In patients with lung and other cancers, weight loss (loss of fat and lean 
body mass) is common in advanced cancer and when cachexia is extreme, 
survival is decreased (Nixon et al.. 1980; Theologides, 1972; Rnekdeskhel 
êLâl-, 1986).
Severe malnutrition and emaciation occur with malignant disease of the 
alimentary tract at any site from the lips down to the large intestine. This is 
readily explicable by mechanical interference with eating, swallowing, 
digestion and absorption of food. Anorexia may be a cause in some cases 
of malignant cachexia but the reason for loss of weight in other patients is 
far from clear.
2:1:1 Malignant Cachexia and the Metabolism of Tumours 
In addition to local effects, tumours may also affect the host by their own 
metabolic activities. This may occur:
(i) When the total mass of tumour tissue is very large in relation to the 
body weight, with diversion of essential nutrients from the tissues of the host 
to the tumour. Such effects are well known to occur in experimental animals 
bearing tumours that are very much larger in relation to the body weight 
than is the case in even most advanced metastatic disease in man.
(ii) As a result of metabolic effects of substance or substances liberated 
by the tumour. Malignant cachexia in man has been ascribed to these
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effects but strong experimental evidence is lacking. However, cachexia 
sometimes occurs in association with small tumours, most often lung 
cancer, and resolves following their excision.
(iii) As a result of substance(s) released in response to the presence of 
the tumour.
2:1:2 Possible Causes of Cancer Cachexia 
Weight loss in patients with malignant disease is often associated with 
anorexia and in this situation, it can be largely attributed to reduced energy 
and protein intake. Vomiting and diarrhoea may also be obvious 
contributory factors. The net result is loss of lean body tissue and 
disturbance of metabolic regulatory functions.
An alternative explanation is the release of a metabolically active 
substance or substances by the neoplasm ( e.g. lipid mobilising factor) 
which may produce an increase in lipolysis and metabolic rate ( Russell 
âi-,1984; Eden et al.. 1984), and an increase in both fasting amino acid flux 
and glucose production (Eden et al.. 1984).
A third possible mechanism is that it might be due to the effects of other 
endogenous factor(s) such as cytokines (e.g. TNF-a) or hormones (e.g. 
growth factors or cortisol) produced in response to the tumour and affecting 
cellular metabolism. A raised serum level of TNF-a, for example, has been 
observed in cancer patients with cachexia (Beulter et al.. 1988).
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It is not established whether the pattern of utilisation of endogenous 
sources of fuel is altered, or whether there is simply an increase in energy 
expenditure resulting in increase of metabolism of muscle or fat.
2:1:3 Carcinoma of the Bronchus
Carcinoma of the bronchus is an example of a non hormone-dependent 
tumour. In most technically advanced countries, lung cancer is the 
commonest cancer in men and is rapidly approaching the same position in 
women. For example, the tumour currently causes approximately 40000 
deaths annually in U.K. (Spiro , 1991). There has been a recent downturn 
in younger men and the death rate in men is now stabilising, but in women 
it continues to rise and will probably continue to do so if current smoking 
trends are maintained (Spiro, 1991).
While there has been a significant improvement in survival in some 
malignant diseases, such as Hodgkin's disease, and to lesser degree 
leukemia and cancer of the kidney and larynx, there has really been no 
improvement in the survival rate from lung cancer. Between 17-20 % of 
patients survive for one year after registration, but only 6-8 % are alive two 
years later (Spiro, 1991), compared with over 50 % for the breast and 
cervical cancer.
Despite the very poor prognosis of lung cancer, a few patients can be cured 
by early surgery. It is very important that each patient with the disease be 
carefully assessed so that every effort is made to relieve the suffering of 
patients.
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2:1:4 Nutrition and Cancer
The nutritional management of cancer patients is often difficult. The 
disease is frequently associated with rapid weight loss, loss of muscle bulk 
and of subcutaneous fat, and sometimes an increase in the basal metabolic 
rate, features which are generally considered to be those of “neoplastic" 
cachexia (Theologides, 1979; Nixon et al.. 1980). It should come as no 
surprise that there is a high incidence of protein-energy malnutrition in 
patients with advanced cancer, even though its cause is not fully 
understood. Nutrition is potentially important since not only the ability to 
withstand anti-cancer therapy but also overall prognosis, appear to be 
improved by adequate nutrition.
Although anorexia may be major element in the cause of neoplastic 
cachexia, causes of weight loss may be more complex than this. The 
resting metabolic rate of patients with solid tumours is usually elevated 
(Warnold et al.. 1978; Peacock et al.. 1987; Hvltander et al. 1991) but there 
is frequently a discrepancy between the reduced energy intake and 
continuing energy utilisation. Nutritional supplementation, including total 
parenteral nutrition does not always completely reverse the advancing 
cachexia (Brennan, 1981).
Improved appetite and weight gain have been reported in patients with 
cancer receiving medroxyprogesterone acetate (Pannuti et al. 1978; 
Ganzina, 1979; Niiranen et al.. 1990).
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2:1:5 Medroxyprogesterone acetate (MPA)
Steroid hormones have a multitude of effects at all different levels of 
biological organisation; different steroid hormones act via a similar pathway 
to produce the same general effects: the induction of RNA and protein 
synthesis. Synthetic progestational agents have been investigated for use 
in patients with hormone- responsive tumours, i.e. breast, kidney, uterine 
and prostate cancer. However their clinical use is limited by side effects 
including nausea, vomiting, masculinisation, Cushingoid effects and liver 
damage (Stoll,1967).
Medroxyprogesterone acetate (MPA), is a synthetic analogue of 17-alpha - 
hydroxyprogesterone (see Figure 2:1). It is poorly absorbed and rapidly 
metabolised when given orally (Stockdale et al..19871. Investigators have 
been impressed by a feeling of well-being associated with increased 
appetite and weight gain due to the drug, which were thought to be benefit 
of the patient. In many patients, there is, prompt dose - related
improvement in bone pain (Pannuti et al. 1978; Ganzina, 1979).
MPA has also been shown to have an endocrine effect. Simon and co­
workers reported that administration of MPA orally was associated with 
blunted growth hormone (GH) responses to arginine infusion and to insulin 
-induced hypoglycemia (Simon et al.. 1966). Other investigators 
demonstrated in 12 acromegalic patients a substantial reduction in basal 
GH levels was achieved in ten patients. However, two patients failed to 
show any significant decrease during a six day therapeutic trial (Lawrence 
& Kirsteins, 1970).
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Bhatia and co-workers reported that progesterone administration 
decreases the GH response to insulin-induced hypoglycemia possibly by 
an effect on glucose metabolism, but no consistent effect on the GH 
response to arginine was demonstrated (Bhatia et al..19721.
Malarkey and Daughaday (1971) reported that when MPA (40-80 mg) was 
given daily by mouth to eleven acromegalic patients, three patients had a 
significant elevation of mean 24 hour GH concentration, another five 
patients showed a significant reduction of mean 24 hour GH concentration 
from pretreatment level 5 month post MPA. An exacerbation of acromegalic 
signs and symptoms, which included increases in acral soft tissues, 
occurred in one patient who had elevated GH. Malarkey and Daughaday 
(1971) also reported that MPA produced no abnormality of insulin, 
thyroxine, triglyceride, cholesterol and folic acid.
Medroxyprogesterone acetate probably has direct inhibitory effects on 
prostatic tumour cells. Such an effect was shown in a group of rats bearing 
the tumour treated with MPA (Damber et al.. 1991).
Improved appetite and weight gain have been reported in elderly patients 
with lung cancer receiving MPA (Niiranen et al.. 1990). Interestingly, they 
did not complain of the usual side effects of the chemotherapy (CT) which 
they were also receiving . MPA has not been shown to affect response to 
CT or survival, although it may result in improved quality of life. High doses 
of MPA have been demonstrated to have a better effect in cancer patients
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than small doses (Mattson 1978; Hortobagyi et al.. 1982; Davil et al.. 1988).
MPA has also been shown to have a number of unrelated effects. For 
example, at high level in rats it stimulates the activities of the small intestine 
brush border enzymes (sucrase, lactase and leucine aminopeptidase) 
whereas the activity of alkaline phosphatase in serum was depressed 
(Nagpaul et al., 1990). In rats with hepatic cirrhosis induced by carbon 
tetrachloride and phenobarbitone, treatment with MPA in vivo results in 
normalisation of cellular structure and function, accompanied by a 
decrease in fibronectin deposits (Stenback et al.. 1989).
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Figure 2:1
The structure of medroxyprogesterone acetate 
6a-m ethyl-3, 20-dioxopregn-4-en-17a-yl acetate
CH3
CH3
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2:2 The Aim of the Study
As discussed earlier, when cachexia is extreme, survival in advanced 
cancer is decreased. The study described in Chapters two and three was 
designed to investigate the relationship between cancer cachexia and 
nutrition in patients treated with MPA which has been shown to produce 
symptomatic improvement, and to investigate the role of hormonal and
biochemical factors (including IGF-I, TNF-a).
Extending knowledge of this relationship, should enable a more rational 
approach to treatment and, hopefully, an improvement in prognosis. In 
addition it may be of value in other conditions associated with marked 
weight loss such as AIDS cachexia and anorexia nervosa.
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2:3 Subjects, Details of Protocol and Blood Samples
2:3:1 Subjects:-
Sixteen patients with advanced malignant disease, who were attending the 
radiotherapy centre at St. Lukes Hospital, Guildford were recruited to the 
study. Five of the sixteen patients withdrew from the study for a variety of 
reasons (see Section 2:6). All patients had lost approximately 15% of body 
weight in a short period of time (less than six months).
Ethical committee approval for conducting the study had been obtained 
from the South West Surrey District Research Ethics Committee. Prior to 
entry into the study, all patients received information about the study (see 
appendix 1 page 271), and their signed consent to participation was 
obtained. Patients were requested to answer a questionnaire on each visit 
(day 1, 7,14 and day 28) to obtain information about appetite and other 
related parameters (see appendix2 page 272).
2:3:2 Assessment of Nutritional Status
Methods of assessment of nutritional status rely on many different areas of 
study as no single clinical or laboratory parameter will determine nutritional 
abnormalities. It is recognised that precise assessment of dietary intake of 
protein and energy is difficult. In this study there were particular difficulties, 
largely related to the nature of the patient group, and a number of methods 
were considered inappropriate; these included note book recording (which 
depends on considerable motivation, understanding and interest from the 
patient since its success depends on his/her willingness to record every 
thing he eats/drinks over a given time period), and telephone enquiry.
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Alternative methods were therefore used to assess nutritional status. These 
included a linear analogue scale to assess appetite (1= very poor appetite; 
10 very good appetite). Although as an assessment of food intake, this has 
only limited value as it indicates only current eating habits and may have 
little relevance to previous patterns of food consumption) this is adequate 
for the purpose of this study. In addition anthropometeric measurements 
and measurement of blood parameters such as albumin and IGF-I were 
made.
The following anthropometeric indices were measured
(i) Body mass index (BMI) = weight /height^, (wt. in kg and height in m^).
(ii) Mid upper arm circumference(MUAG) using tape measure.
(iii) Triceps skinfold (TSF) measured at the mid-point of the posterior aspect 
of the upper arm using skinfold callipers.
Anthropometeric measurements are non-invasive readily and quickly 
applied, and compared to laboratory techniques, require the minimum of 
equipment. They can, therefore, be easily used in the clinical setting to 
identify those patients who may be under- or over-nourished and to 
evaluate the effectiveness of nutritional intervention. The body weight 
provides a rough estimate of body energy stores. A positive energy balance 
results in weight gain and a negative balance promotes weight loss. Body 
weight is the sum of water, protein, fat and bone mineral mass; changes in 
one of these may invalidate the body weight as a nutritional index for 
example body weight will increase in edematous states as a result of water 
retention. Assessment of body fat can be assessed by measurement of
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skinfold thickness (such as triceps skinfold). Approximately one third of the 
total body fat is located subcutaneously (it is also found in the bone marrow, 
central nervous system and breast, which consider the major storage of fat). 
Mid-arm muscle circumference (MAMC) can be used to assess the total 
body muscle mass and is derived from measurement of mid-upper arm 
circumference (MUAC) and triceps skinfold (TSF) and calculated from the 
following equation:
MAMC= M UAC-3.142 X TSF 
(It should be noted that this equation is valid only when all measurements 
are in the same units)
2:3:3 Patient Details
In many cases access to medical records was limited, and in view of the fact 
that patients were frequently too ill to provide a coherent history, many of 
the clinical details are incomplete
(1) Male aged 51 years
Diagnosis: renal carcinoma.
Previous history of cholecystectomy and left nephrectomy 
Recent (2month) weight loss of 14 kg: current weight 60.5 kg 
Receiving radiotherapy (from 13.11.90)
Treatment with MPA 800 mg daily commenced on 30.11.90.
On 18.01.91 chest X-ray showed multiple secondary deposits: 
radiotherapy was discontinued but treatment with MPA was continued.
On 21.01.91 weight had fallen to 58.5 kg: biochemical investigations 
showed normal serum calcium but markedly elevated alkaline phosphatase
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(probably of liver origin) and elevated GOT (181U/L)
He died at home on 20.02.91.
(2) Male aged 60 years
Presented with symptoms and sign of superior vena caval obstruction.
Later diagnosed as carcinoma of the bronchus. Cytology showed 
undifferentiated adenocarcioma.
Treated with radiotherapy plus dexamethasone from 16.10.90.
Body weight increased from 64.9 to 66.7 kg in two months.
The patient started to lose weight again, body weight on 15.01.91 was 59.0 
kg, and treatment with MPA started on the same day. Treatment with MPA 
was continued and another course of radiotherapy was started (on 
13.02.91).
Weight fell to 57.2 kg in next six months and at the end of this period he died 
of pleural effusion and chest infection.
(3) Female aged 75 years
Presented with hoarseness of voice and increasing shortness of breath. 
Biopsy showed squamous cell carcinoma of the larynx.
She received radiotherapy between 22.01.91 and 19.03.91.
Treatment with MPA started on 23.01.91 at which time her body weight was 
only 34.5 kg. She continued treatment with MPA and on 12.02.91 her body 
weight was 38.9 kg.
She died in April 1992.
(4) Male aged 66 years old.
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Diagnosed as carcinoma of the bronchus: cytology showed poorly 
differentiated squamous cell carcinoma.
Treatment with MPA was started after completing a course of radiotherapy 
(27.02.91). At that time his body weight was 60.0 kg; four weeks later it had 
risen to 74.0 kg and ten weeks after start of treatment was 79.0 kg.
He died eleven months later.
(5) Male aged 68 years
Diagnosis: carcinoma of the bronchus.
Recent weight loss of 2 kg in two weeks.
Started treatment with MPA with body weight 69.2 kg: four weeks later it had 
risen to 72.4 kg.
He died seven months after starting treatment with MPA.
(6) Male aged 67 years
Diagnosis: transitional cell carcinoma of the renal pelvis.
He underwent a left nephrectomy on 03.05.91.
Treatment with MPA was started on 05.07.91.
Patient gained 2.5 kg body weight in the following four weeks.
He died on 08.08.91.
(7) Male aged 75 years old.
Diagnosed as carcinoma of the bronchus: cytology showed large cell 
undifferentiated carcinoma. He received radiotherapy treatment between 
04.04 and 21.04.91.
Treatment with MPA was started on 05.07.91. Patients gained 2.5 kg body
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weight in the following four weeks.
He died one month later.
(8) Male aged 65 years
Diagnosis: carcinoma of the right main bronchus: cytology showed 
squamous cell carcinoma.
He lost 9.0 kg weight between 01.01. and 24.09.91.
He received radiotherapy treatment between 06.09 and 24.09.91. During 
this time he was also treated with predinsolone 15 mg/day.
Treatment with MPA was started on 24.09.91 (body weight 67.2 kg).
He died on 29.10.91 (body weight 69.0 kg).
(9) Male aged 58 years
Diagnosis: recurrent lymphoma of the stomach.
He was initially treated with radiotherapy in 1988. At that time his weight 
was 78.0 kg.
On 05.12.89 treatment with zantac and predinsolone was started.
On 15.11.91 his body weight was 76.2 kg. Treatment with MPA was started 
on the same day.
On 14.04.92 his body weight was 79.0 kg and three month later it had 
increased to 80.1 kg.
Until 10.11.92 patient was progressing well.
(10) Male aged 46 years
Diagnosis: Lymphoma of the stomach
Received treatment with chemotherapy between 03.09 and 21.09.91.
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Treatment with MPA was started on 25.10.91. After four weeks treatment, he 
had not gained weight.
He received a further course of chemotherapy but died on 25.12.91.
(11) Male aged 76 years
Diagnosis: carcinoma of the rectum (inoperable), cytology showed 
adenocarcinoma.
Recent weight loss of 8.0 kg in the last three months.
Body weight on the 19.11.91 was 59.9 kg.
Radiotherapy treatment was started on 03.12.91 and continued for 50 days. 
Seven days later, treatment with MPA was started.
He subsequently gained 1.1 kg in four weeks.
2:3:4 Details of Study Protocol
Patients with severe weight loss associated with malignant diseases 
(mostly bronchial carcinoma) were studied before and during treatment with 
MPA.
In this study there was no control for a number of reasons:
(i) Ethical considerations. The patients in this study were very ill and 
frequently in terminal stage. It was considered acceptable to subject such a 
group of patients to the study in view of the anticipated benefits of treatment 
with MPA. However, it was not felt acceptable to ask a similar control group 
to undertake the commitment to the study in the absence of any anticipated 
benefit.
(ii) Recruitment. In view of the nature of the patients involved and the
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commitment required of them during the study, recruitment was difficult and 
numbers were small. Recruitment of a control group in the time available 
was not considered feasible.
2:3:5 Dose schedule of MPA;
All patient were requested to take 800 mg of MPA orally daily for at least 
four weeks. Although the study was terminated after four weeks treatment, it 
was suggested that patients who showed an improvement in appetite will 
continue taking the MPA. To ensure the patients were taking the drugs, MPA 
in blood was measured by high performance liquid chromatography on day 
1, 7,14 and 28 of the study. On these days patients took the daily dose of 
MPA in the clinic with the breakfast after taking the blood samples.
2:3:6 Blood Samples
A fasting blood samples was taken on day 1, 7,14 and 28 of the study. In 
day one, second blood samples was taken 2 hours after taking the MPA 
and breakfast.
Venous blood (20 ml) was collected and dispensed into plain glass (8.5 ml), 
lithium heparin (9 ml) and fluoride - oxalate (2.5 ml) tubes. The lithium 
heparin and fluoride-oxalate were centrifuged immediately at 2500 x g for
10 minutes, plasma separated and stored at -20®C in LP3 tubes and 5 ml 
glass vials until analysed. Serum samples were allowed to clot for 15 
minutes at 4®C, then similarly centrifuged. Serum was separated and kept 
frozen at -20®C in LP3 and 5 ml glass vials until analysis.
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2:4 Materials and Methods
The following assays were performed on the blood samples collected from 
the patients as described in section 2:3:6:-
2:4:1 -Total Protein
Plasma total protein was determined in duplicate using Biuret method 
(Reinhold, 1953).
Principle
The Biuret method measures functional peptide groups forming a coloured 
copper complex. It is relatively specific for proteins. Copper ions react with 
amide, amine and imino groups of proteins form a tetra-coordinated 
complex. The absorption maximum was measured at 550 nm.
Instrument and reagents
Encore analyser. Baker Instrument (MT). Total protein kit; the stock reagent 
comprises sodium potassium tartrate, copper sulphate, sodium hydroxide 
and potassium iodide, pH 12. Reagent ready for use.
Interferences:- Gross lipaemia and moderate or gross haemolysis interfere 
with the assay. Linearity :- This method is linear from 20-100 g/L.
Method The samples , controls and standards were loaded into the 
sample ring, the reagent was tipped into the reagent boat, and purified 
water poured into the diluent reservoir. The pi petto r and analyser of the 
GentrifiChem was set to the required specifications.
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2:4:2- Albumin
Serum albumin was determined in duplicate by an immunochemical 
method. This method is more sensitive than dye-binding methods (e.g. 
bromocresol green ) most of which overestimate albumin at low levels.
Principle
The method depends upon the antigen antibody reaction between albumin 
and an anti-albumin antibody which forms the basis for a specific end point 
turbidimetric method for determination of plasma albumin.
Stock and working reagents
All samples and controls were diluted to 1 in 101 in 0.9% saline.This was 
done by taking 20 \i\ of each sample and adding it to 2 ml 0.9% NaCI in 5 
ml glass stoppered bottles followed by thorough mixing.
Standards
1- 30|xl +2.0 ml 0.9% saline =60.57 g/1
2- 22.5 \i\ + 2.0 ml 0.9% saline = 45.43 g/1
3- 15 pi +2.0 ml 0.9% saline = 30.29 g/1
4- IOp.1 +2.0 ml 0.9% saline =20.19 g/1
5- 10 111 +4.0 ml 0.9% saline =10.10 g/1
Method
The samples , controls and standards were loaded into the sample ring, the 
reagent was tipped into the reagent boat, and a purified water poured into
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the diluent reservoir. The pi petto r and analyser of the GentrifiChem were 
set to the required specifications.
2:4:3 - Triglyceride
Serum triglyceride was determined in duplicate by an enzymatic method 
(Fossati & Prencipe 1982).
Principle
The triglycerides in serum are converted to glycerol in the presence of 
lipase. The glycerol formed is converted to glycerol -1-phosphate by 
glycerokinase (GK) with the production of magnesium adenine 
diphosphate (Mg ADR) from Mg adenine triphosphate (ATP) in the process. 
The ATP then reacts with phosphoenol pyruvate (PEP) under the action of 
pyruvate kinase (PK) and the pyruvate produced is converted to lactate by 
lactate dehydrogenase (LDH), NADH being oxidised to NAD in the 
process . The decrease in absorbance at 340 nm due to this conversion of 
NADH to NAD is used to monitor the reaction.
Stock and working reagent
Sigma kit, catalogue number 336 -20, vial = 20 ml. Ready to use.
Method
The samples , controls and standards of triglyceride were loaded into the 
sample ring, the reagent was tipped into the reagent boat, and DW poured 
into the diluent reservoir. The GentrifiGhem was set to the required 
specifications by programming the pipettor and analyser.
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2:4:4 Glucose
Plasma glucose was determined in duplicate by an automated glucose 
oxidase procedure (Stevens, 1971), using Yellow Springs Instrument (YSI) 
analyser.
Principle
The instrument uses oxygen electrode to detect the oxidation of glucose by 
glucose oxidase (GOD).
GOD
D glucose + Og + HgO-------------> Gluconic acid + Hydrogen perioxide.
The rate of Og utilisation is monitored by an oxygen electrode, located 
within the side of the reaction vessel, which responds to the concentration 
of Og in the reaction solution. The electrode compares the rate of use of an 
unknown sample, with that of a standard glucose solution of 6.0 mmol/L.
Stock and working reagent
Sigma kit catalogue number 315-100 ready for use, vial = 100 ml.
Method
The machine is calibrated with the standard to provide a digital oxygen 
display reading then checked with controls before assaying the unknown 
samples.
2:4:5 -Total cholesterol
Cholesterol was assayed by an enzymatic method.
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Principles
The cholesterol reagent combines the use of the enzymes cholesterol 
esterase [CE] and cholesterol oxidase [00], with a modified Trinder system 
to measure total cholesterol.
CE
Cholesteryl Ester > Cholesterol + Fatty acid
CO
Cholesterol +O2 ---------------> Cholesten - 3 - one + H2O2.
Perioxidase
2H2O2+ 4- Aminoantipyrine + 2,4- dichlorophenol---------------->
Quinoneimine+4 H20
The quinoneimine has a maximum absorbance at 520 nm .
The method is linear to 18.0 mmol/L. Samples with values above this 
should be diluted (usually 1 in 3 ) in 0.9% saline .
Stock and Working reagents
Lyophilised, from Beckman kit, product no 684006, with diluent. 
Reconstitute with 50 ml of diluent.
Method
Automated method (same as total protein methods).
2:4:6- Cortisol
Serum cortisol was assayed using a radio-immunoassay method. 
Principle
RIA depends on the fact that proteins are immunogenic in nature, and that
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specific antibodies to them can be raised, large proteins tend to be more 
antigenic than small polypeptides. In order to raise antibodies to non 
immunogenic substance such as steroid and drugs, the hapten needs first 
to be conjugated to a protein.
A standard preparation of the purified antigen can be labelled with a radio­
isotope (Ag*) and a known amount added to a limiting quantity of antibody 
(Ab). Unlabelled test hormone is then added (Ag) and competition between 
the labelled and unlabelled hormone for the antibody is such that the 
amount of the radioactive hormone bound to the antibody is inversely 
proportional to the amount of non-labelled hormone in the sample. The 
degree of binding is obtained by measurement of the radioactivity in the 
bound antibody-labelled antigen fraction. Standard curves of known 
antigen concentrations are prepared and estimation of the unlabelled 
hormone obtained from them.
Stock reagent
Citric acid, gelatin, thiomersal and disodium hydrogen orthophosphate 
anhydrous from BDH Poole U K.
Cortisol antiserum obtained from Guildhay, for use diluted 1:1000. 
lodinated cortisol label obtained from Southampton General Hospital (via 
Dr. Derek Teale).
Working reagent
Citrate/phosphate assay buffer, 13.025 gram of citric acid and 10.79 g Na2 
HPO4 anhydrous dissolved in about 500 ml DW. 0.2g thiomersal and 1 .Og
gelatin were added. Placed in water bath at 37°C to dissolve the thiomersal
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Solution was made up to 1 litre and kept on bench at room temperature. 
Standards
A solution of cortisol in stripped serum is made up to a value of 3000 
nmol/L. This is stored at-20°C. This was double diluted in stripped serum to 
produce a range of standards with the following values 
(47,94,188,375,750,1500,3000 nmol/L).
Control 1,2 and 3 obtained from Biorad.
Method
20 |il aliquots of standard, control and samples were pipetted into plastic 
LP3 tubes (in duplicate) using an Oxford pipette, and 300 pi of the working 
cortisol label was added to each tube including the total tubes, and mixed. 
100 pi of diluted antibody added to all tubes except the total tubes, All tubes
mixed and incubated at 37^C for 30 minutes in water bath, and 100 pi of
solid phase added to all tubes except the total. Then the solid phase was 
washed twice with washing buffer, the buffer was poured off by inverting the 
tubes having covered them with fine netting. All tubes were then counted on 
the LKB 1260 Multigamma counter. A standard curve was plott-ed and 
cortisol in the samples was read from the standard by the system.
2:4:7 Growth hormone
Serum growth hormone (GH) was assayed using an immunoradiometric
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assay (IRMA) method (Celriker et al., 1989).
Principle
An anti-growth hormone antiserum (solid phase) and anti-growth hormone 
(labelled) antibody have been used as the basis for IRMA for hGH. The 
sample is incubated with the solid phase antiserum and labelled antibody 
at room temperature overnight. Separation is carried out by centrifugation 
and the solid phase pellet is washed to minimise the assay blank.
Stock Reagents
125| anti-growth hormone label.10 uCi from NETRIA and Growth hormone 
solid phase from NETRIA. Stored at 4°C.
Standards are obtained from NETRIA in 2 mL Lyophilised vial. 
Reconstituted in 2 ml. of deionised water. Values as follow m U/m l 
A = 0.0, B = 0.48, 0 = 0.95, D = 4.75 mU/ml.
E = 9.5, F = 47.5, G = 95.0, H = 190.0 mU/ml.
Controls
Controls are Lyphochek 1, 2, and 3 obtained from Biorad . Ranges in mU/L 
are:- LI = 13.7-17.7, L2 = 29-51 and L3 =61-111 mU/ml.
Method
100 pi aliquots of standard, control and samples were pipetted into plastic 
LP3 tubes (in duplicate) using an Oxford pipette 50 pi of the solid phase
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was added to each tube except the total tubes, and 100 pi of labelled 
antibody added to all tubes. All tubes were mixed and incubated overnight 
at room temperature on a rotary mixer. The solid phase complex was then 
washed twice with washing buffer, the buffer was poured off by inverting the 
tubes having covered them with fine netting.. All tubes were then counted 
on the LKB 1260 Multigamma counter. A standard curve was plotted and 
hGH in the samples was read.
2:4:8 Thyroid stimulating hormone
Plasma thyroid stimulating hormone (TSH) was assayed using IRMA. 
Principle
An anti-TSH antiserum and anti- TSH antibody have been used as the 
basis for a specific and sensitive IRMA for human TSH. The sample is 
incubated with the solid phase antiserum and labelled antibody at room 
temperature overnight; and then washed to minimise the assay blank 
before counting on the LKB 1260 Multigamma counter.
Stock Regents
Anti-TSH Label. 10 MCI from NETRIA, stored at -20^0 TSH solid 
phase from NETRIA. Stored at 4®C.
All other procedure same as GH assay.
2:4:9 Insulin
Plasma insulin was measured by a double antibody radioimmunoassay
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method developed at St.Luke’s Hospital, Guildford.
Principle (see section 2:4:6)
Stock reagent
Antiserum and second antiserum, donkey anti-guinea pig serum (Batch: 
HP/D/8/XI-B) supplied by Guildhay, Guildford UK.
Labelled insulin supplied by Amersham International; product No 1M38. 
Standards supplied by National Institute of Biological Standards and 
Controls, South Mimms, UK. (NIBSC 66/ 304).
Working reagents
a- Buffer (0.04 M phosphate, pH 7.4 , containing 0.01 M EDTA) 
b - Assay diluent add BSA 0.5% to the required volume of buffer. 
c- Charcoal-stripped serum. Insulin-free serum is used for diluting the 
insulin standard.
d- Antiserum 1.0 ml vial sufficient for 1000 tubes .
e- lodinated insulin is stored in solution at 4°C and diluted for use (1:80) so
that 50 pg (2 nCi)is added to each assay tube . 
f- Standards; Dissolve the ampule content (3 units ) in 1.0 ml 0.07M 
barbitone buffer o.5% pH 8.6 and make up to 30 ml with 0.04 M phosphate 
buffer pH 7.4 containing 0.5% BSA . 1.0 ml aliquots(100 mU/ml) of stock 
solution are stored frozen . Further dilute 1 ml of stock solution to 500 ml
with BSA/ buffer. 1.0 ml aliquots of this solution (1500 pmol/L or 200 pU/ml ) 
are stored freeze -dried at -20 ° C . For use, add 1.0 ml of stripped serum
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to each aliquots to produce the top standard of 1500 pmol /L. Double 
dilute with stripped serum to produce standard containing 750 , 375 , 187 
,93.7 , 46.9 ,and 23.5 pmol/L . 
g- Second antiserum
Is stored at 4°C . Dilute to 1:20 for use .
h- PEG solution (15%) 15 g PEG 6000 on 100 ml distilled water, 
i- Quality Controls
Serum pools are spiked with insulin to three levels . Aliquots are freeze- 
dried and stored at 4°C . Reconstitute each with 500 pi distilled water.
Method see the protocol table 2:1 
50 pi aliquots of standard, control and samples were pipetted into plastic 
LP3 tubes (in duplicate) using an Oxford pipette; 200 pi of diluted insulin
antiserum was added to all tubes except the total tubes, and 200 pi of
working label insulin was added to each tube including the total tubes, and 
mixed. All tubes were mixed and incubated at room temperature for 24
hours, and 200 pi of diluted second antiserum added to all tubes except the
total tubes. After two hours all tubes were centrifuged ( except the total) at
3000 revolutions per minute (rpm) for 30 minutes at 4®C, and aspirated. All
tubes were then counted on the LKB 1260 Multigamma counter.
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Table 2:1 Protocol of insulin assay. (Additions in pi)
DAY1 Day 2
Tube Antiserum Stripped Std*. 
serum
Control Test Label Second**
+PEG
Total ----------- —  — - ---- ---- 200 ----
Zero 200 50 — 200 200
Stand. 200 —  50 ---- ---- 200 200
Control 200 —  — 50 ---- 200 200
Test 200 —  — ---- 50 200 200
Std*. = Standard, ** = Antisemm.
2:4:10 Insulin -like growth factor-1
Insulin -like growth factor-1 (IGF-I) was measured by radioimmunoassay 
(Teale & Marks 1986).
Principle
Same as section 5:4:1.
Stock reagent
a-Biosynthetic IGF-I (obtained from Ciba-Geigy)
b-Mouse monoclonal antibodies (batch BPL/M23) were supplied by the
blood Products Laboratory, Elstree .The antibodies were raised against
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purified IGF-I produced at the Institute of Child Health, Great Ormond St, 
London.
c-Second antibody (Guildhay ,batch D/80/I-B).
Instrumentation See section 5:4:3.
Working reagents 
a- Assay diluent
0.05M phosphate buffer,pH 7.4, containing 0.01% azide was made up 
(5.75g Na2HP04 anhydrous , 1.50 g Na H2 PO4 2H2O ,1g sodium azide
dissolved in 1 litre distilled deionised water) and stored at 4° C. Before
use BSA (0.2%) and protamine sulphate (0.01%) were added, 
b- IGF-I solution
Biosynthetic IGF-I was used for iodination and standards. A sufficient 
amount was weighed out accurately to produce a 125pg/ml solution in
0.01 N HCI. Aliquots (20 pi) are dispensed into Akes cups and stored at -
20°C until iodination.
The acid solution was further diluted to 25ng/ml in assay diluent. Aliquots 
(1.0 ml) are stored at -20°C and used as assay standard, 
c- Monoclonal antibody
Mouse monoclonal antibodies. The antibody solution is diluted 1:4000 for 
assay use . Normal mouse carrier serum is diluted 1:800.
Diluted IGF-I antibody: 40 ml diluent
50 pi normal mouse serum (1:800)
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10 pi neat M23 (1:4000).
d- Standard preparations
(i) - A normal, adult serum pool is used as serum standard . This pool is 
assigned the arbitrary value of 1 U/ml. It is extracted by the same method 
used for test serum, and the extract diluted in assay diluent to produce a 
range of values (0.031, 0.062 , 0.125 , 0.25 ,0.5 and 1 U/ml)
(ii)- Biosynthetic standard; Aliquots of standard solution (100 pi of 500 
ug/ml) are made up to 1.0 ml and double -diluted in assay diluent to 
produce a range of values (0.8 ,1.5 , 3.1 , 6.2 ,12.5 , 25.0 and 50 ng/ml) 
e- Diluted IGF-I label: 40 ml diluent
200 pi stock label (1:200)
f- Second antiserum
Assay separation is by PEG- accelerated second antibody . The antiserum 
is diluted 1:20 and added to an equal volume of 15% PEG 6000 solution . 
Diluted second antibody/ PEG : 19 ml diluent
1.0 ml donkey anti-mouse serum (1:40) 
20 ml 15% PEG
Method
The method is performed in two steps (A and B) as shown below.
A- The extraction of IGF-I from the binding proteins, see Figure 2:2.
200pl sample and 800 pi acid / ethanol (1 part HCI + 7 parts ethanol ) 
were added into tubes (LP3), mixed, stand for 10 minutes at 4®C, and 
centrifuged for 15 minutes [3000 rpm at 4°C]. 500 pi of the supernatant
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was taken into LP3 tube, and 200 pi 10%Tris was added, and mixed. Tubes 
were allowed to stand for 60 minutes, and then centrifuged for 30 minutes
(3000 rpm at 4°C). The supernatant was taken and diluted 1:4 in assay
diluent.
B- A 50 pi aliquots of standard, control and samples were pipetted into 
plastic LP3 tubes (in duplicate) using an Oxford pipette, 200 pi of diluted 
IGF-I antiserum added to all tubes except the total tubes, and 200 pi of 
working label IGF-I was added to each tube including the total tubes, and 
mixed. All tubes were mixed and incubated at room temperature for 24 
hours, and 200 pi of diluted second antiserum was added to all tubes 
except the total tubes. After two hours all tubes were centrifuged ( except
the total) at 3000 revolutions per minute (rpm) for 30 minutes at 4^0, and
aspirated. All tubes were then counted on the LKB 1260 Multigamma 
counter.
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Table 2:2
Assay protocol of IGF-I
Additions Total Zero Standard Sample
Diluent ---- 50 ---- ----
Standard ---- ---- 50 ----
Sample ---- ---- ---- 50
IGF-I antibody ---- 200 200 200
IGF-I label 200 200 200 200
Second antibody ---- 200 200 200
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Figure 2:2 Plasma IGF-I Extraction
Plasma + acid/ethanol 
1 : 4
Mixed and stand for 10 minutes at 4°C
Centrifuged for 15 minutes
i
Supernatant (500pl) + 10% ’ris (200pl)
i
Measurement of IGF-I
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2:4:11 - Other Methods
Sodium and potassium are measured by ion selective electrode. The 
sodium electrode consists of a sodium-selective glass membrane. The 
potassium electrode has a potassium-sensitive neutral carrier. Each 
analysis is accomplished by the measurement of the potential difference 
between the ion selective electrode and a reference electrode. The 
reference electrode is filled with a gel containing 3.0 M Kcl.
Calcium is measured by spectrophotometric analyser. A violet coloured 
complex is formed when calcium ions react with o-cresophthalein 
complexone in an alkaline medium. The absorbance of the complex at 570 
nm is directly proportional to calcium concentration.
Urea was measured by an enzymatic rate urease reaction. Urea is 
hydrolysed by the enzyme urease yielding ammonia and carbon dioxide, 
the ammonia produced aminates a-ketoglutarate to glutamate with the 
concurrent oxidation of NADH to NAD which can be measured at 340 nm. 
The rate of absorbance is directly proportional to the urea present in the 
sample.
For urate Trinder's method was used, uric acid plus water in the presence 
of oxygen and the enzyme uricase yielding allantoin with CO2 and H2 O2. In 
the presence of the enzyme peroxidase, H2 O2 reacts with 4-amino 
antipyrine yielding quinoneimine which can be measured at 550 nm which 
is proportional to uric acid concentration in the samples.
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The principle for creatinine measurement is based on Jaffe reaction; 
creatinine reacts with alkaline picrate forming a red-orange coloured 
complex. The increase in absorbance at 500 nm within a fixed time is 
proportional to creatinine concentration.
The method for gamma glutamyl transferase (yGT) is based on its activity; 
the enzyme catalyses the transferase of the glutamyl group of the substrate 
L-y-p-nitroanilide to glycylglycine, liberating p-nitroanilide which can be 
measured directly at 405 nm.
The principle of lactate dehydrogenase [ LDH ] measurement uses the 
following enzyme reaction, monitored at 340 nm, and assay performed 
according to the recommendation of the Scandinavian Committee on 
Enzymes.
LDH
Pyruvate + NADH+ + H+ -------------- > L- Lactate + NAD
The method used for alkaline phosphatase [ALP] measurement based on 
the fact that ALP catalyses the hydrolysis of P-nitrophenyl phosphate to p- 
nitrophenol and inorganic phosphate. The rate of formation of p - 
nitrophenol is monitored at 405 nm , and is directly proportional to enzyme 
activity.
All the above methods are precise and accurate, and used for the routine 
work at St Luke's Hospital.
To validate the methods used to analyse the samples the GV of each
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method was calculated, The calculation of the CV for albumin is shown 
below as an example.
Accuracy Agreement between the best estimate and i t ‘s true value 
Precision Agreement between replicate measurements. It is measured in 
term of SD and C.V. A low CV is an indication of a precise method .
SD
CV =   x100
X
Table 2 :3a -The precision of albumin method.
Control (Results) mean SD CV
L 23.06 (22.2, 22.9, 23.6) 22.9 0.7 3%
M 40.70 (41.1,40.4, 39.3) 40.3 0.9 2%
L & M are controls.
This method is accurate and precise. The validation was employed for other 
methods see table 2:3b.
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Table 2:3b Precision of analytical methods used
Analyte Concentration Achievable precision
Total protein 70 (g/L) 2.5
Albumin 40 (g/L) 1.2
Glucose 5.5 (mmol/L) 0.8
Cholesterol 6.5 (mmol/L) 0.9
Cortisol (nmol/L) 12-15*
GH (mU/ml) 8.-13*
TSH (mu/ml) 5-8*
Insulin (pmol/L) 8-12*
IGF-I (lU/ml) 11-14*
= Three different concentrations have been used.
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2:5 - Statistical Analysis
Results were expressed as mean ± standard error of the mean 
(mean ± SEM). Standard deviations are also given. Values within and 
between individual patients were compared using Student’s paired and 
unpaired ‘t’ test respectively. Differences were considered to be statistically 
significant when p< 0.05.
77
2:6 RESULTS
The patients recruited to the clinical trial all showed evidence of severe 
weight loss (8-12 kg body weight in short period of time) associated with 
poor appetite (Figure 2:3), and low skin fold thickness (mean =6.4mm), and 
mid-arm muscle circumference (calculated mean =21.4mm) compared with 
published reference values (Blackburn, 1979).
MPA was well-tolerated by all patients; only one developed symptoms 
which may have been due to MPA treatment. He complained of diarrhoea 
and vomiting and linked this to the drug but this patient was also 
undergoing radiotherapy treatment which could be another explanation for 
his symptoms. He later withdrew from the study. In total five patients 
withdrew. In two cases, relatives felt that the demands of the trial were too 
much for the patients. In two cases, patients were lost to follow-up because 
of transfer to other treatment centres.
2:6:1 Anthropometeric parameters
There were an increase in appetite in all patients. The mean increase is 
shown in Figure 2:3; this was highly significant (p <0.001). There was no 
significant change in either mid-arm muscle circumference or triceps skin 
fold after taking the MPA; both were low compared to the normal population 
(results not shown). There was a slight increase in body weight of patients 
involved in this study after 4 weeks, with a mean weight 59.2 ± 3.2 kg, 
(ranging from 35.4 -75) before treatment versus 60.9 ± 3.2 kg, (ranging from 
38.9 - 77.1 ) after treatment.
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2:6:2 Assessment of compliance to MPA
MPA was measured by high performance liquid chromatography in blood 
samples taken on day 1,7,14 and 28 (results not shown). All blood 
samples contained MPA apart from the day 1 fasting samples in which MPA 
was undetectable.
2:6:3 Plasma protein and triglycerides
Although there was a slight increase [not significant ] in mean total plasma 
protein (table 2:4) from 66.0 ± 1.6 to 69±1.5 + 1.5 {mean ± SEM} grams 
per litre, there was no significant change in serum albunm (2j5)j|espite the 
significant increase in appetite. In patients who gained >3kg body weight (3 
patients), there was a slight increase in serum albumin from 28.0 ±3.9 to 
32+ 3.7 grams per litre (mean ±SEM).
The results shown in table 2:6 indicate no significant change in serum 
triglyceride before or after treatment with MPA, although the mean level 
did increase slightly. There were no significant differences between patients 
who showed an increase in body weight compared with those who had not 
gained weight.
2:6:4 Serum IGF-I, GH and cortisol
The results shown in table 2:7 indicate a significant increase (p<0.05) in 
plasma IGF-I in patients who gained more than 3 kg body weight. There 
was no change in plasma IGF-I in patients who gained 1-3 kg, or patients 
who failed to gain body weight during the study period. The results of GH 
(table 2 :8) indicate a significant decrease (P<0.05) in the second week in
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those patients who gained more than 3 kg in weight. A 50-70% decrease 
(NS) in the level of plasma hGH was observed in week four in all patients 
who had gained weight, with no change in patients who failed to gain 
weight.
Fasting serum cortisol results also showed a significant reduction (P<0.05) 
in serum level in patients who gained > 3.0 kg after treatment with MPA 
compared to patients who did not gain weight (Figure 2:4). Patients who 
gained < 3.0 showed no significant change. In patients who failed to gain 
weight, serum cortisol increased 60 % during the study period.
2:6:5 Other results
TSH results were within the normal range both before and after the 
treatment period (results not shown here); other thyroid function tests were 
not measured. Na, K, Ca, phosphate, urate, bilirubin and AST were within 
the normal range before and after taking MPA. Urea and creatinine levels 
were normal in all patients except for one patient, who had high levels of 
both urea and creatinine associated with secondary deposits in the kidney.
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Figure 2:3 Relationship between plasma insulin and IGF-I, and appetite in 
patients after 4 weeks treatment with MPA.
Values are mean of 11 patients
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Table 2:4 Total plasma protein in the study group over
the period of study, (grams / Litre)
Time 0.0 2-4 hours Day 7 Day 14 Day 28
1 63 69 70 73 73
2 58 69 73 74 74
3 61 67 68 65 69*
4 74 76 75 67 76*
5 70 65 79 77 71*
6 69 69 65 65 67
7 67 67 65 67 66
8 69 76 67 68 68
9 66 67 65 63 63
10 57 60 — 63 59
11 70 69 70 — 70
X- 66 68 70 68 69
±SEM 1.6 1.1 1.4 1.5 1.5
1 -11 = No of patient, X" = The mean; SEM = Standard error of the mean.
* = patients who gained more than 3 kg body weight.
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Table 2:5 Plasma albumin in the study group over the
period of the study ( grams / Litre).
Time 0.0 2-4 hours Day 7 Day 14 Day 28
1 27 29 27 28 24
2 25 28 45 34 36
3 23 26 28 26 30
4 27 26 28 27 29
5 34 32 36 40 39
6 35 46 37 29 29
7 24 24 22 22 22
8 26 26 24 23 25
9 37 36 36 33 33
10 26 27 27 31 28
11 33 31 31 31 32
X" 29 30 31 30 30
SEM± 1.5 1.9 1.6 0.9 0.8
1-11 = number of patients, X" = The mean; SEM = Standard error of the mean
* = patients who gained more than 3 kg body weight.
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Table 2:6 Serum triglyceride In the study group
over the period of study (mmol/Litre).
Time 0.0 2-4 hours Day 7 Day 14 Day 28
1 1.6 1.7 1.2 1.6 1.2
2 0.8 1.3 1.0 1.0 0.9
3 1.1 1.0 1.5 0.8 1.4*
4 0.9 0.8 0.7 0.7 0.9*
5 1.8 2.0 1.8 1.1 1.5*
6 1.5 1.8 2.5 2.7 3.6
7 1.0 0.9 1.2 1.4 1.5
8 0.7 0.9 1.0 1.2 1.2
9 0.9 1.0 0.9 1.0 0.9
10 0.7 1.0 0.8 0.7 0.9
11 1.0 0.8 1.4 1.4 1.3
X" 1.1 1.2 1.3 1.2 1.4
SEM± 0.1 0.1 0.2 0.2 0.2
1-11 = Patients number, X '= The mean; SEM = Standard error of the mean,
* = patients who gained >3 kg body weight.
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Figure 2:4 Serum cortisol level in patients involved 
in the study.
Values expressed as mean ±SEM,
**= P<0.05 compares%ith patints who fail to gain weight.
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Table 2:7 The relationship between plasma IGF-I and body
weight status of the patients involved in the study.lU/ml.
Time Day1 Day 7 Day 14 Day 28
No increase (n=4) 0.40±.10 0.43±.10 
Increase 1-3 kg (n=4) 0.36±.07 0.42±.07 
Increase >3 kg (n=3) 0.26+07 0.50+.14
0.371.08
0.371.05
0.401.10
0.381.08 (NS) 
0.361.10 (NS) 
0.611.07**
Values expressed as mean ± SEM. No increase = no increase in body weight; n = number of 
patients, NS = Not significant, ** =P<0.05 compared to day 1.
Table 2:8 Plasma growth hormone during the study
period
mU/ml
Time Day 1 Day 7 Day 14 Day 28
No increase (n=4) 3.7+0.4 3.3+1.3 
Increase 1-3 kg(n=4) 11.8±2.7 5.8+2.0 
lncrease>3 kg (n=3) 9.5±2.1 6.511.2
2.910.7
5.712.1
3.210.7*
3.512.0(NS)
4.012.0(NS)
5.710.6(NS)
Values expressed as mean ± SEM; No increase = No increase in body weight; 
n = number of patients; NS = not significant. * = P<0.05 compared to day 1.
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Figure 2:5 The relationship between appetite, insulin and IGF-1
in the patients involved in the study in relation to body weight change.
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2:7 DISCUSSION
The study described in this chapter was designed to determine the role of 
growth factors (IGF-I and GH) and nutrition in cancer cachexia and the 
effect of treatment with medroxyprogesterone acetate (MPA). Cancer 
cachexia was again found to be associated with loss of weight and poor 
appetite. Body weight provides a rough estimate of body energy stores; 
under normal circumstances, daily weight varies by less than ± 0.5% 
(Garrow, 1974).
Levels of the mean growth hormone and serum cortisol were in the high 
normal range compared to the normal population, whereas the IGF-I level 
was low in the fasting samples before patients received treatment with 
MPA. These findings confirm the loss of the normal relationship between 
IGF-I and GH in severely ill patients; Jeevanandam and co-workers (1992), 
for example, demonstrated that the hypermetabolic and highly catabolic 
state of multiple trauma victims is characterised by a diminished level of 
IGF-I with increased levels of stress hormones including GH. In view of the 
fact that GH is normally secreted in a pulsatile manner with a marked 
diurnal variation. In addition, plasma levels are also influenced by a 
number of other factors such as stress and feeding. For these reasons, 
single measurements of plasma GH give only limited information and must 
be interpreted with caution. However, in view of the nature of the patients 
involved in this study, neither multiple blood sampling or timed urine 
collection for GH measurement was not possible.
The finding of an improvement in appetite with a slight increase in body
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weight after 4 weeks in patients who were taking MPA is consistent with 
the finding of other investigators; Niiranen et al., (1990) reported improved 
appetite with weight gain in elderly patients with lung cancer receiving 
MPA. Falase and co-workers (1988) reported weight gain in 36% of the 
patients receiving MPA and weight loss in 10.6%. Weight gain has also 
been reported by other authors (Davil et al., 1988). MPA used in patients 
with hormonal responsive tumour, i.e. breast, uterine and prostate cancer 
is well documented (Stockdale et al., 1987; Pannuti et al., 1978; Ganzina, 
1979). The therapeutic value of MPA was established in in vitro tests which 
show direct cytotoxicity in ovarian carcinoma (Sevelda, 1990).
Of the patients in the present study, 36% did not gain weight, while a 
further 36% gained less than 3 kg. Meanwhile, 28% of the patients 
involved in this study (3 out of 11) gained more than 3 kg in four weeks. 
One patient (of the three) gained another 5.0 kg between week 4 and 
week 12. This weight gain was accompanied by significant increase in 
both plasma IGF-I and plasma insulin although there was no significant 
change in either MUMC, TSF, or plasma albumin in this group. The fact 
that only IGF-I appeared to reflect recent calorie and protein intake is 
consistent with previous reports in the literature (Unterman et al., 1985). 
This study provides further evidence for the suggestion that measurement 
of plasma IGF-I concentrations is a more sensitive index of acute 
directional change in nutritional status than other plasma proteins which 
are commonly used. After total parental nutritional therapy of patients with 
malnutrition, the plasma IGF-I has previously been shown to rise more 
consistently than albumin and transferrin level, and increased by more
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than 70 % in all patients receiving nutritional therapy (Unterman et al., 
1985). The increase in IGF-I appears to correlate with the development of 
positive nitrogen balance (Phillips & Young, 1976). However, in some 
studies IGF-I has been shown not to respond to nutritional 
supplementation. This probably reflects a more severe catabolic state in 
the patients in these studies, with failure of IGF-I to respond either as result 
of the severe catabolism itself or because of the failure of conventional 
nutritional support to meet the increased nutritional requirements of these 
patients.
In the present study, the patients who gained more than 3 kg in four weeks 
showed an increase of IGF-I which was preceded by a significant 
decrease in serum levels of GH in the second week. The decrease in GH 
may be due to normalization of GH-IGF-I axis, with GH stimulating the liver 
and other organ (s) to synthesis / secrete IGF-I, and IGF-I suppressing GH 
secretion.
Following improvement of appetite and initial fall in GH and weight gain of 
more than 3 kg, there was a secondary increase in GH although 
pretreatment levels were not attained. On the other hand, in patients who 
gained less than 3 kg, there was a continued decrease in GH. In patients 
who failed to gain weight or actually lost weight, GH levels were low at 
day one ( about 30 % of the other two groups who gained weight) with no 
change even by the end of the study period. These findings suggest that 
a low serum GH level in patients with cancer cachexia is a poor prognostic 
sign; it may also indicate that cachetic patients with low GH may not
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benefit from nutritional therapy. The reason why other patients (36%) did 
not gain weight despite the fact that their appetite improved significantly in 
the first two weeks of the study is not clear.
In the present study, the relatively high levels of GH and cortisol in cachetic 
patients before starting treatment with MPA may have modulated the 
synthesis of IGFBP resulting in increased binding and a reduction in the 
concentration of free IGF-I with a loss of its physiological activity. In animal 
models, the synthesis of IGF-binding proteins is modulated by the 
presence of GH, thyroxine and cortisol (Schalch et al., 1979; White et al., 
1981). Impure preparations of IGFBPs have been shown to inhibit insulin­
like action of IGF-I on fat cells (Clemmons, 1989).There was a reduction in 
cortisol level in patients who gained >3 kg (Figure 2:4). It is possible that 
the lower cortisol levels in patients who gained weight contributed to a fall 
in IGFBP levels and consequent increase in free IGF-I. In this group of 
patients who gained weight, possibly the liver and blood IGF-I level is 
adequate to the required metabolism. However, this theory lacks 
supporting evidence.
Many tissues including liver, kidney, lung , heart, pancreas, submaxillary 
gland, testes and neural tissues, contain acid extractable IGF-I (Sara et al., 
1982; Clemmons et al., 1981 ; Kawai et al., 1979). It has been postulated 
that these GFs exert their biological effects on cells which produce them or 
on nearby cells; that is, they act by autocrine or paracrine, rather than 
endocrine mechanisms (D’Ercole et al., 1980; Clemmons et al., 1981). 
There is an early rise in tissue levels of somatomedin following GH
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treatment after hypophysectomy (Uthne & Uthne, 1972; Phillips & 
Unterman, 1984).In normal animals, liver cell membranes contain very 
few IGF-I receptors, and very few actions of this peptide have been 
demonstrated in normal liver. It has been postulated that the liver and 
possibly a few other tissues act as endocrine organs in producing IGF-I 
mainly for export to cells at distant sites. The activity extractable from non - 
producing tissues could represent peptides which accumulated on cell 
receptors. This may be more important in the normal state than in 
abnormal conditions such as severe wasting. The main site of endocrine 
IGF-I production appears to be the liver from which it is constantly 
released into the blood-stream. Since the IGF-I is not stored in any organ, 
IGFBP’s are needed to control this IGF-I secreted by the liver into the 
bloodstream. One of the sites of endocrine action of IGF-I is the adipose 
tissue but IGF-I is only effective at high doses, probably working through 
insulin receptors since typel IGF-R level is low in mature adipocytes; 
hence adipose tissue is probably not an important physiological target 
tissue. In adipose tissue, IGF-I stimulates glucose metabolism to C02, 
lipids, and glycogen, and inhibits epinpherine- stimulated lipolysis and 
glycogen breakdown (Underwood et al., 1972; Zapf et al., 1978). Jacobs 
and co-workers (1989) reported that IGF-I inhibited weight loss after 
starvation, indicating that IGF-I can be anabolic in severe catabolic state. 
The authors concluded that IGF-I had suppressed whole-body protein 
turnover.
In a number of vital organs, IGF-I appears to act predominantly in either a 
paracrine or autocrine manner, and, by its anabolic activity may act to
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preserve these tissues even in catabolic state in response to GH and/ or 
other factor (Clemmons et al., 1981). This hypothesis can be supported by 
the following observation. Regional infusion of IGF-I anti-bodies into a 
perfused limb has been shown to block both IGF-I and GH stimulated 
growth, suggesting that the paracrine increase in IGF-I secretion in 
response to GH infusion, may also be a growth regulatory signal (Sevelda, 
1990).
2:8 Conclusions of Chapter 2.0
The relationship between growth factors and nutrition in cancer patients 
was investigated. The results indicated that cancer cachexia is associated 
with poor appetite and loss of weight. MUMC and triceps skin folds were 
low compared to the normal population of same age. The fasting blood 
levels demonstrated a low IGF-I level, and the expected levels of hGH and 
cortisol in similar patients.After taking 800 mg orally of the drug MPA daily 
for 4 weeks, appetite improved in all patients. This was accompanied by 
an increase in fasting plasma levels of insulin but no change in serum 
albumin or plasma total proteins. A weight gain of more than 3 kg was 
observed in 28% of patients. This weight gain was accompanied by a 
significant increase in fasting blood IGF-I levels preceded by a decrease in 
both GH and cortisol.
Other parameters measured showed no difference between these patients 
and the general population.
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Chapter 3.0
The Role of Tumour Necrosis Factor In Patients 
with Cancer Cachexia
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3:1 Introduction
Several physiological and biochemical derangements are commonly seen 
in the mammalian host in response to infections and cancer. The increased 
rates of whole-body energy expenditure, lipolysis, protein turnover as well 
as anorexia, anaemia, and loss of body mass associated with chronic
infections or critical illness are similar to the alterations induced by TNF-a
(Tracey et al.. 1988). While it is clear that a variety of mechanisms 
participate in the pathogenesis of cachexia, the precise aetiology of this 
syndrome is not known, although it has been postulated that cytokines may 
be involved.
Cytokines occupy a central place in the interaction between tumour and 
host. In part, they are involved in the development of a defence reaction 
against the tumour. Certain cytokines possess cell growth-inhibitory 
properties, for example alpha or beta interferon (De Maeyer et al.. 1988), or 
cytotoxic properties, for example tumour necrosis factor and lymphotoxin 
(Wallach, 1986; Paul et al.. 1988). Others have activating effects on immune
cells such as mononuclear phagocytes (IFN- y) or lymphocytes (interleukin
1) (Nathan et al.. 1983; Dijkmans et al.. 1988; Dinarello, 1985).
The response of animals to infection or cancer includes fever, lecuocytosis
and an increase in acute phase proteins. TNF-a has been implicated in the
tissue wasting that often accompanies prolonged infections and 
malignancy.
Lipopolysaccharide (LPS), the cell-wall component of gram-negative 
bacteria (endotoxin), is a potent stimulus for TNF-a production by
macrophages; TNF-a is also an important mediator of the well known
endotoxin effects in vivo such as tumour haemorrhagic necrosis, fever, 
activation of neutrophils and shock.
An increase in circulating triglycerides, attributable to systemic suppression
of lipoprotein lipase by TNF-a, is one of the biochemical disturbances
which has been described in humans and animals responding to infection 
or tumour (Brenneman êlâi-. 1975; Rouzeret al.. 1980).
3:2 Tumour Necrosis Factor-a
3:2:1 Historical Perspective of TNF-a.
In 1975 Carswell and his colleagues discovered a substance responsible 
for haemorrhagic necrosis in transplanted murine sarcoma after 
administration of endotoxin, the LPS portion of the gram-negative bacterial
cell wall. In 1985, the amino acid sequence homology of TNF-a with
cachectin was reported (Beulter et al., 1985). Subsequently, the ability of
TNF-a, to inhibit transcription of the adipocyte lipoprotein lipase gene has
been described (Torti et al.. 19851.
3:2:2 Isolation and Identification of TNF-a.
Tumour necrosis factor-a was originally described as activity present in the 
serum of mice infected with Bacillus Calmette-Guerin (BCG) and
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subsequently the stimulus of TNF-a by endotoxin (cell wall component of
gram-negative bacteria) was demonstrated (Carswell et al., 1975).
Serum from such mice was capable of producing haemorrhagic necrosis of 
subcutaneous tumours, and the activity was found to be due to the protein 
TNF-a (Aggarwal et al.. 1985). TNF-a was not toxic for mouse embryo
culture (Carswell et al.. 1975). A variety of studies indicate that TNF-a is
not residual endotoxin. TNF-a, also called cachectin, is a 157 amino acid,
non-glycosylated polypeptide cytokine produced mainly by activated 
macrophages/monocytes in response to endotoxin (Caput et al.. 1988; 
Pennica et al.. 1985).
3:2:3 Synthesis of TNF-a.
TNF-a is synthesised by a number of cells of the monocyte/macrophage-
lineage, notably microglial cells of the brain, astrocytes, Kupfer cells of the 
liver, lymphocytes, natural killer cells, and glomerular mesangial cells 
(Tracey et al.. 1989). Beulter and colleagues, have demonstrated that
macrophages contain a pool of TNF-a mRNA that is not normally translated
into protein (Beulter et al.. 1986a). However following LPS stimulation, the 
cells and tissues (Beulter et al.. 1985 ) markedly increase their content of
TNF-a mRNA that is immobilised for translation, with the production of the
bioactive peptide (Beulter et al.. 1986a; Beulter glâi., 1986b). While gene
transcription is accelerated approximately threefold, TNF-a mRNA levels
rise within the cell by a factor of 50-100, and the secretion of mature 
hormone rises by a factor of about 10,000 (Beulter et al.. 1986b).
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TNF-a does not exist in a stored form but is synthesised de novo following
cell activation. The biosynthesis of TNF-a is tightly regulated by 
transcriptional and post-transcriptional mechanisms (Beulter et al.. 1986b).
Glucocorticoid hormones inhibit TNF-a biosynthesis provided that they are
administered before the cells have been exposed to LPS (Beulter et al.. 
1986b). Glucocorticoid hormones inhibit both gene transcription and
mRNA translation, thus preventing the synthesis of TNF-a. However, once 
translation of TNF-a mRNA is in progress, glucocorticoids are unable to 
suppress the production of TNF-a (Beulter et al.. 1986b).
The main stimuli for TNF-a synthesis are bacterial endotoxin/ Lipopolysa-
^bâride ; virus, fungal, and parasite antigens; enterotoxin, immune 
complexes, interleukin -1 (Beulter et al.. 1986) and complement C5a. The 
nature and variety of these stimuli underline the importance of this cytokine
in infection and inflammation, TNF-a may also trigger its own synthesis in
an autocrine manner (Tracev et al.. 1989).
3:2:4 Biochemistry of TNF-a.
TNF-a is produced as a prohormone of 233 amino acids, which is
processed to a 157 residue mature protein with a molecular weight of 17 
kDa by cleavage of a 76 residue single peptide ( Tracey et al.. 1986;
Tracey et al.. 1989). Mature TNF-a shares 28 % amino acid sequence
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homology with lymphotoxin (TNF-p), another cytokine. This explains the
similarity of biological activity of these molecules which may compete for a
common receptor (Tracey et al.. 1986). TNF-a is bound to high affinity
receptors in many tissues including liver, lung, kidney, muscle and 
intestine.
The receptor- ligand complex is internalised and degraded but details of 
the receptor and post receptor response remain unclear (Bakouche et al.. 
1988; Kriegler et al.. 1988).
3:2:5 The Function of TNF-a.
TNF-a possesses a range of effects which include stimulation of cell
proliferation, and activation of cellular functions including expression of 
enzymes and macromolecules. It also has antitumoral and growth- 
regulatory activities, and it displays a selective toxicity for tumour cells and 
cells infected by virus.
TNF-a also possesses immunomodulatory and pro-inflammatory
properties. By activating macrophages, neutrophils and esinophils, it 
induces the production of several other inflammatory mediators such as IL- 
1 (Tracey et al.. 1989), IL-6, collagenases and platelet activating factor 
(Bussolino et al.. 1988). In addition, it regulates the production of 
antibodies by B lymphocytes and stimulates cytotoxic T cells (Ghiara et al..
1987). TNF-a induces synthesis of transforming growth factor, an anti­
inflammatory cytokine that inhibits H2O2 production and adhesion of
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leukocytes. It also stimulates endothelial cells which display procoagulant 
activity and induce capillary thrombosis (Pober, 1987). Leukocyte 
adherence is followed by the release of oxygen-derived radicals and 
prostaglandins. Vascular damage results in increased permeability with a 
loss of intravascular fluid volume which, if severe, results in systemic
hypotension. This demonstrates the role of TNF-a in endotoxic shock.
This is further supported by that fact that a peak concentration of TNF-a
occurring 4 hours after the start of an infusion coincides with the peak of 
fever, rigours, myalgia, headache and nausea (Henne et al.. 1988).
Metabolically, chronic administration of TNF- a may induce cachexia,
accompanied by catabolic changes in adipose tissue and muscle (Tracey 
et al.. 1988). Lipoprotein lipase is inhibited, and net lipolysis and 
glycogenolysis occur (Torti et al.. 1985; Lee et al.. 1987). (See Section 3:2)
3:2:6 The Role of TNF-a in the Pathogenesis of Disease.
Raised serum levels of TNF-a have been observed in cachetic patients
with cancer (Beulter B, 1988), acquired immunodeficiency syndrome 
(Lahdervirta et al.. 1988), parasitic infections (Scuderi et al.. 1986) and 
severe heart failure (Levine et al 19901.
Persistence of TNF-a production may provoke cachexia. TNF-a regulates 
the biosynthesis of several metabolic enzymes. Adipocytes and skeletal 
myocytes incubated with TNF-a become catabolic with a marked increased 
in lipolysis (Torti et al.. 1985) and glycogenolysis (Lee et al.. 1987). In
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hépatocytes, TNF-a increases the production of acute phase proteins and 
accelerates glucagon- mediated amino acid uptake (Warren et al.. 1987).
On the other hand, TNF-a may coordinate tissue remodelling. It stimulates
resorption of bone (Bertolini et al.. 1986) and cartilage (Saklatvala, 1986).
It may also participate in the mechanisms of normal tissue remodelling or 
of healing following inflammatory injury. In fact, by acting as a growth
factor, TNF-a stimulates fibroblast and mesenchymal cell proliferation
directly (Vileek et al.. 1986) and induces the production of other cytokines 
that stimulate cell proliferation and matrix production (Tracev et al.. 1989).
In addition, TNF-a may increase the mitogenic effect of epidermal growth
factor by increasing the number of cell surface receptors for this cytokine
(Palombella et al.. 1987). Furthermore, TNF-a may promote
neoangiogenesis (Frater- Schroder et al.. 1987).
Human recombinant TNF-a (rh TNF-a ) as been shown potently to
enhance the antibody response in vivo at a much lower dose range than 
that reported to cause cachexia and severe tissue toxicity (Ghiara et al..
1987). TNF-a shares many biological properties with IL-1, which has been
shown to regulate a number of immunological functions.
TNF-a may regulate or switch the normal synthesis of proteins in the liver
to synthesis of other factors. In response to injury, there is a dramatic 
change in the pattern of proteins synthesised by the liver. The synthesis of 
a set of acute phase proteins, including C-reactive protein, serum amyloid
101
A, a1-antichymo-trypsin, fibrinogen, a1-acid glycoprotein, haemopexin,
caeruloplasmin, complement C3 and a1- antitrypsin, is increased several­
fold, while there is an acute reduction in the synthesis of other proteins 
including albumin, transferrin, HS2-glycoprotein, and apolipoprotein A-1 
(Kushner et al.. 1982).
There are also important interactions between TNF-a and other cytokines 
and hormones. For example, IL-1 induces TNF-a synthesis and vice versa, 
whereas dexamethasone inhibits it (Beulter et al.. 1986b). TNF-a is a 
primary mediator of host defence in response to infection, injury, and 
malignant disease. The biological activity of TNF-a depends on its 
concentration, duration of cell exposure and the presence of other factors. 
The net effect of TNF-a may ultimately benefit or injure the host.
The acute phase response comprises a spectrum of physiological changes 
ranging from, at one extreme, all the systemic effects of inflammation such 
as fever, endocrine changes, changes of fluid and electrolyte balance and 
characteristic changes in protein synthesis. In a more restricted sense, the 
term is used to describe only the changes in synthesis of certain liver - 
derived proteins (acute phase proteins). The acute phase proteins 
increase in plasma by 25% or more in the first 7 days following tissue 
damage (Kushner, 1982). Studies have identified IL-1, TNF,and IL-6 as the 
prime inducers of hepatic acute phase protein synthesis (Baumann et al.. 
1987; Gauldie et al.. 1987). Evidence also suggests that endocrine factors 
also affect the ability of the hepatocytes to respond (Whicher &
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Evans,1990).
TNF-a was initially described in the serum of endotoxin-treated mice as the
mediator of the necrosis of some transplantable tumours (Carswell et 
al.,1975). It has subsequently been recognised to have a much wider role 
in coordinating much of the physiological response to stress, acting as a 
mediator between the immune system, and the endocrine and nervous 
systems.
3:2:7 TNF-a and Cachexia
The metabolic and hormonal alterations that maintain physiological 
homeostasis during the systemic reaction to tissue injury or infection 
include a shift from energy storage to energy utilisation and accelerated net 
breakdown of skeletal muscle (Millward, 1985). This is accompanied by a 
change to anabolic metabolism in the liver (Beisel, 1975), with an increase 
in the hepatic uptake of amino acids released by peripheral tissue for use 
as gluconeogenic substrates (Long et al.. 1976; Lang et al.. 1984), and 
synthesis of acute phase proteins, the plasma levels of which rise several­
fold in sepsis and injury (Pepys & Baltz, 1983). This exchange of amino 
acids from muscle to the liver, bone marrow and wounds provides support 
for the anabolic activities of the liver, for cellular proliferation within the 
immune system, and for healing of injured tissue (Rosenblatt et al.. 1983).
This process is called the acute phase response, and is accompanied by 
an increase in the levels of the "stress" hormones (cortisol, GH, 
catecholamines, glucagon) and insulin (although there is usually relative
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insulin deficiency). However, this complex metabolic process cannot be 
attributed solely to the action of these hormones. Experimental support 
has accumulated for the involvement of the immune system in the 
endocrine and metabolic changes of the acute phase response, probably
mediated by the TNF-a.
Thus, when cachectin/TNF-a is added to adipocytes in culture, the major
lipogenic enzymes (lipoprotein lipase, acetyl-CoA carboxylase and fatty 
acid synthetase) are suppressed within one hour (Pekala et al., 1983), and 
there is rapid inhibition of mRNA's for a number of adipocyte-specific 
proteins, rendering the cell unable to synthesise triacylglycerol, and the 
development of a catabolic state (Torti et al.. 1985).
3:2:8 Relationship Between GH, IGF-I and TNF-a in Critically III 
Patients
Administration of GH results in a rise in serum IGF-I levels (Johnson & 
Blizzard 1981) and an increase in nitrogen retention. The administration of 
biosynthetic GH to patients recovering from uncomplicated gastrointestinal 
surgery has been shown to improve nitrogen balance ( Jiang et al..1989. 
and Douglas et al.. 1990). GH treatment in critically ill, septic patients has, 
however, shown no effect of treatment on nitrogen balance or serum IGF-I 
levels ( Dahn et al.. 1988), suggesting that this group of patients may differ 
from uncomplicated post-operative patients. This resistance to GH 
appears to be proportional to the degree of metabolic stress and may be
related to a high level of TNF-a in septic patients.
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When TNF-a was infused into a group of iambs, the plasma TNF-a
concentration fell between 3-4 hour, despite the TNF-a being infused at a 
constant rate over this period (Douglas et al.. 1990). This indicates that the 
blood level of TNF-a may not be correlated with the amount of TNF-a in the 
body in sepsis or cancer cachexia.
3:3 Ferritin as a Non- Specific indicator for Severity of 
Cancer
Ferritin is an iron and protein complex, and is the form in which iron is 
stored in the reticuloendothelial system, the liver, spleen and bone marrow. 
Serum levels are thought to be a reflection of these stored levels. Ferritin 
has been used as a non- specific tumour marker.
Ferritin is widely-distributed and multiple molecular forms have been 
isolated from various tissues. In cancer patients, serum ferritin has been 
shown to correlate positively with the extent and severity of the disease, 
and to decrease in response to treatment (William et al.. 1990). Moroz et al 
(1987) found placental ferritin concentration to be increased in the sera of 
patients with Hodgkin's lymphoma. During remission, placental ferritin 
values fell to those of healthy subjects.
William et al (1990) used ferritin to monitor the response to treatment in 
patients with breast cancer. They reported that serum ferritin concentrations 
were significantly higher at presentation in patients with advanced disease
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advanced disease (266 patients) than in tumour- free controls. There was a 
positive correlation between increasing serum ferritin levels and tumour 
burden at presentation. A strong correlation was also found between 
therapeutic response and changes in ferritin serum (William et al.. 1990). 
The same group also reported that in women with breast cancer stage V,
the ferritin level was markedly raised (above 200 pg/L) during the initial 
treatment.
Although ferritin is a non-specific tumour marker, there is some evidence 
that the plasma level may be a useful indicator of the extent of malignant
disease, and that it may be helpful, along with measurement of TNF-a in
determining prognosis and in monitoring the progress after treatment.
3:4 The Details of the Study protocol
The measurement of TNF-a and related parameters was carried out on the 
blood samples taken during the course of the study described in chapter 
2.0 (Section 2:3).
3:4:1 Blood Samples
A fasting blood samples were taken on day 1, 7,14 and 28 of the study as 
described previously (See section 2:3: 6).
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Materials and Methods 
3:5 Determination of Serum TNF-a
TNF-a was assayed by enzyme amplified sensitivity immunoassay 
(EASIA), based on the method described by Leroux-Roels (1988).
Principle of the test 
TNF-a EASIA is a solid phase enzyme amplified sensitivity immunoassay 
performed on a microtiter plate. It is based on the oligoclonal system in 
which several monoclonal antibodies (Mabs) directed against distinct
epitopes of TNF-a are used. The use of several distinct Mabs avoids 
hyperspecificity and allows for highly sensitive assays with extended 
standard range and short incubation time. The assay is performed directly 
on serum, plasma or culture media samples without any prior treatment or 
extraction.
Stock Reagents
Microtiter plate with anti-TNF-a coated wells.
Standards 0 pg/ ml, in human serum and preservatives, 2 
vials (lyophil.)
Standards 15, 50, 150, 500, 1500 pg/ml in human serum 
and merthiolate (lyophil.)
Controls 1 and 2 in human serum and merthiolate.
Incubation buffer: Tris - Maleate buffer, with BSA and 
preservatives. This was also use as conjugate (2 vials each 
contain 6 ml).
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Anti-TNF-a- horse radish perioxidase (HRP) conjugate in
Tri- maleate buffer, with BSA and preservatives 0.75 ml. 
Tween 20, 20%.
Chromogen: tetramethylbenzidine(TMB) 1 vial containing 1 
ml.
Substrate buffer: H2O2 in acetate/citrate buffer 3 vials, each 
containing 21 ml.
H2SO4 11.8N stopping reagent.
All reagent were purchased from Medgenix Diagnostics Brussels.
Working Reagents
The standard of TNF-a (0 pg/ml per vial) was diluted with 8 ml of DW; 
standards 15, 50, 150, 500,1500 pg/ml were each diluted into 2 ml DW. 
Control 1 and 2 were each diluted into 2 ml DW. The conjugate solution
was prepared by pipetting 600 \i\ of anti- TNF- a- HRP into 6 ml conjugate
buffer. Washing solution: 2 ml of Tween 20 , 20%, diluted into 400 ml DW.
Revelation solution was prepared by pipetting 200 pi of the chromogen
TMB into 21 ml of substrate buffer. Samples were diluted 1:5 prior to 
analysis.
Assay procedure
The strips were fitted into the holding frame. 200 pi of standard, control or
sample was dispensed into the appropriate wells. 50 pi of incubation buffer 
was added to all wells. The plate was incubated for 2 hours at room
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temperature on a horizontal shaker set at 700 RPM.
The plate was then washed. The liquid from each well was first aspirated; 
400 pi of washing solution was dispensed into each well, and the content
of the wells was aspirated again. 100 pi of standard 0 pg/ml was dispensed
into each well; 50 pi of anti- TNF-a- HRP conjugate was dispensed into
each well. The plate was incubated for 2 hours at room temperature on an 
horizontal shaker set at 700 RPM. The plates were washed again as
described above. 200 pi of freshly prepared revelation (substrate) solution
was dispensed into each well, and the plates were incubated for a further
30 minutes at room temperature on horizontal shaker set at 700 RPM. 50
pi of stopping reagent ( H2SO4) was dispensed into each well. Finally, the 
absorbance was read, and results were calculated by the computer. The 
minimum detectable concentration of TNF-a in serum was 3 pg/ml and the 
reference range < 10 pg/ml. The assay showed no detectable cross­
reactivity with TNF-p or IL-1. The inter batch imprecision (%CV) was 9.8
and 8.0% at TNF-a concentrations of 41 and 161 pg/ml respectively.
3:6 Determination of Serum Ferritin
Ferritin was assayed using an immunoradiometric assay (IRMA). In this 
assay, the antigen (here the hormone) is reacted simultaneously with 
antibodies bound to solid phase and a labelled antibody. This procedure 
has the advantages of improved specificity, sensitivity and speed when 
compared with conventional RIA.
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Principle
Sheep anti-ferritin antiserum ( solid phase antibody) and labelled mouse 
anti-ferritin antibody are used as the basis for a specific and sensitive 
immunoradiometric assay (IRMA) for human ferritin.
Stock Reagents
Sodium dihydrogen orthophsphate (NaH2P04.2H20), 
disodium hydrogen orthophosphate (Na2HP04) and 
sodium
azide from BDH Poole U. K.
Tween 20 also from BDH (Product No. 66368).
Bovine serum albumin from Sigma (Product No. A4503).
125| labelled Anti- ferritin antiserum from North East 
Thames Regional Immunoassay (NETRIA) stored 
at - 20° C.
Ferritin solid phase from NETRIA.
Working Reagents
10% sodium azide was prepared by dissolving 10 grams of sodium azide 
in 100 ml deionised water in 100 ml volumetric flask.
20% bovine serum albumin (BSA) was prepared by dissolving 20 grams of 
BSA in 100 ml of DW and mixing thoroughly on a magnetic stirrer until all 
BSA was dissolved.
10% Tween 20 prepared as follow: 100 ml of Tween 20 was made up to 
litre with DW in a 1 litre measuring cylinder.
Phosphate buffer ( 0.25 M pH 7.4) was prepared by dissolving 15.3 grams
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of NaH2P04.2H20 and 57.6 grams of Na2HP0^ in 2 litres of DW in a 
volumetric flask; pH was adjusted to 7.4. The solution was stored at 4®C.
The assay buffer was prepared the in the same way as that used for TSH 
(2:3:7): 50 ml of 0.25M phosphate buffer, plus 2.5 ml of 10% sodium azide, 
plus 12.5 ml of 20% BSA, plus 12.5 ml of 10% Tween were mixed and 
made up to 250 ml with DW.
Washing buffer. This buffer which is used to wash the solid phase after 
incubation is common to all IRMA assays used (i.e. TSH, ferritin and hGH). 
It was made up as follows: 800 ml. of 0.25M phosphate buffer, plus 40 ml. 
of 10% sodium azide, plus 200 ml. of 10% Tween 20 were mixed and 
made up to 4 litres with DW.
Ferritin standards ( A-H) are obtained ready -made from Amersham 
International, product No. ZDN 1051.
A = 0.0, B = 5.0, C = 15, D = 30 mg/L 
E = 60, F = 200, G = 500 H =1000 mg/L 
Controls 1, 2 and 3 were obtained from Biorad ( product No. 0370-5)
Method
Aliquots (20 pi) of standard, control and samples were pipetted into plastic
LP3 tubes (in duplicate). 50 pi of diluted mixed solid phase and 100 pi of
assay buffer was added to all tubes except the total. All tubes were mixed
and incubated for 1 hour at room temperature on a rotary mixer. After
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incubation the solid phase complex was washed twice with wash buffer
(IRMA wash buffer see chapter 2.0). Working ferritin label (150 pi ) was
added to each tube including the total tubes, mixed and incubated for 1 
hour at room temperature on a rotarymixer. All tubes were then washed 3 
times with wash buffer, and then counted on the LKB 1260 Multigamma 
counter. A standard curve was plotted and the concentration of ferritin in 
the samples was read from the standard curve by the system.
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3:7 Results
3:7:1 Serum TNF-a.
The minimum detectable concentration of TNF-a in serum was 3 pg/ml and 
the reference range is < 10 pg/ml. There were significant increases 
(P<0.05) in plasma TNF-a (from day 1 to day 28) in patients who did not 
gain weight. In patients who gained more than 3kg (>3kg) there was a 
significant reduction in the plasma TNF-a. There was no significant
change in plasma TNF-a in patients who gained less than 3kg in this 
period (Table 3:1).
3:7:2 Serum Ferritin.
Figure 3:2 shows that prior to treatment with MPA, the ferritin levels were 
higher in those patients who subsequently failed to gain weight or gained 
less than 3kg. Following treatment with MPA, there was a further increase 
in ferritin levels in these two groups compared with patients who gained 
more than 3kg in weight in whom baseline ferritin levels were low (although 
higher than the normal reference range) and remained low on treatment.
Relating the results of TNF-a and the IGF-I levels in the patients studied
(see Chapter 2.0). the increase (P<0.05) in plasma TNF-a was
accompanied by a suppression or a failure to increase plasma IGF-I (Figure
3:3a). In those patients in whom TNF-a decreased, there was a
corresponding significant increase in plasma IGF-I, preceded by a 
significant decrease (P<0.05) in GH in patients who gained >3kg body
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weight (Figure 3:3).
Relating the levels of IGF-I and serum ferritin (Figure 3:4), the high level of 
ferritin was accompanied by a low level of plasma IGF-I at day one. After 
treatment with MPA (week 4) the serum ferritin significantly increased in 
patients who did not gain or who gained <3kg weight. In patients who 
gained more than 3kg, the observed increase in plasma IGF-I was 
associated with a slight decrease (not significant) in ferritin.
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Figure 3:1 A typical standard curve for enzyme amplified 
sensitivity immmunoassay procedure of TNF-a.
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Table 3:1. Relationship Between Plasma TNF-a and body
weight change, (pg/ml)
Day 1 Day 28
No increase (n = 4) 14.1 ±2.1 27.1 *± 4.1
Increase <3 kg (n = 4) 13.6 ± 1.6 17.1 ± 3.4 (NS)
Increase >3 kg (n = 3) 31.2 ±4.0 21.1*4:1.4
Values expressed as mean ± SEM, n = No of patients, NS = Not significant, 
* = significant (P<0.05).
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Figure 3:2 Ferritin serum levels in the patients
involved in the study.
No increase = No increase in body weight,
n= number of patients, *=P<0.05 to patients who gain >3kg.
1400 1 **=p<o.oi compared to day one in the same group.
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Figure 3:3 The relationship between T N F -a , IG F-1  
and G H  in  cancer patients treated 
w ith M PA .
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Figure 3:4 Relationship between plasma IGF-1 and ferritin
in cancer patients treated with MPA
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Figure 3:4b Patient who gained >3 kg in 4 weeks.
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3:8 Discussion
The patients in the present study showed the characteristic rise in counter 
regulatory hormone release and hyperinsulinaemia that are commonly
observed in septic patients, with elevated concentration of TNF-a, ferritin
and insulin (Figure 2:2 and Figure 2:5). These results raise the possibility of
a causal relationship between TNF-a and other hormones which is
consistent with the results of Douglas and co-workers (Douglas et al.. 
1989), who reported elevated cortisol, insulin, glucagon after the infusion of
recombinant TNF-a in lambs. An increase in glucagon levels has also
been reported such patients but glucagon was not measured in this study
The levels of TNF-a in this study were not very high. It is thought that this
peptide is released from macrophages relatively early in the clinical course 
and that this initiates many of the clinical and metabolic events seen in 
established cases of cancer cachexia or sepsis (Michie et al.. 1988). It is 
therefore difficult to relate the observed plasma TNF-a concentrations to 
severity of cachexia. TNF-a levels are variably raised or normal in septic 
patients (Scuderi êLal-, 1986). Interestingly, Douolas et al.. (1991) reported 
that, in experimental models where rTNF-a with rhIGF-l was infused to one
group of animal, and normal saline with rTNF-a infused to another group of 
animals, the plasma TNF-a concentration fell significantly between 3-4 
hour in both rhIGF-l and normal saline- infused animals, despite the TNF-a 
being infused at a constant rate over this time.
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Ferritin has been used as an indicator for the severity of malignant disease; 
William and co-workers reported that serum ferritin in cancer patients 
correlated positively with the extent and severity of the disease (William et 
al., 1990). The present study provides evidence to support such a 
relationship (Figure 3:2 and Figure 3:4).
The reciprocal relationship between IGF-I and TNF-a in the present study
(see Figure 3:3) again suggests a possible physiological interaction 
between the two. Nevertheless, even in those patients in whom IGF-I rose 
and TNF-a fell, TNF-a levels were still higher than normal (see Figure 3:2). 
This is consistent with the results of Douglas and colleagues who showed 
that the ability of rhIGF-l to reduce the rate of net protein loss is not affected
by simultaneous infusion of TNF-a (Douglas elâl-, 1991). It therefore 
appears possible for IGF-I to be anabolic in severe catabolic states.
Plasma GH levels at the beginning of the study were higher in those 
patients who went on to gain weight. During treatment in these patients, 
there was a fall in GH levels which was followed by a rise in IGF-I. It 
appears, therefore, that weight gain depends upon a combination of a
reduction in TNF- a and an increase in IGF-I which occurs only in patients
with active GH secretion.
Ross et al.. (1991) reported a high basal GH level associated with low 
levels of IGF-I in critically ill patients when fasted and during parenteral
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feeding compared with controls. The infusion of biosynthetic hGH into 
patients recovering from uncomplicated gastrointestinal surgical operation, 
results in positive nitrogen balance ( Jiang et al..1989). Another study of 
hGH treatment in critically ill septic patients has, however shown no effect 
of nitrogen balance on serum IGF-I levels (Dahn et al.. 1988), suggesting 
that this group of patients may differ from uncomplicated post-operative
patients, a high circulating TNF-a may be one factor which results in the
septic patients reacting differently to the uncomplicated gastrointestinal 
surgical patients.
To date, there has been no comprehensive study of the GH- IGF-I axis in 
relation to metabolic change in cancer cachexia or septic patients,
specifically referring to cytokines, such as TNF-a. Tracey et al.. (1989)
reported that the effects of TNF-a in cancer are not specifically 
tumouricidal, but resemble the effects of bacterial endotoxin.
TNF-a may stimulate the synthesis of acute phase proteins and other
factors involved in natural defence of the body directly. Since TNF-a is
bound to high affinity receptors in many tissues including the liver 
(Bakouche et al.. 1988; Kriegler et al.. 1988), it may switch the quality of 
proteins synthesis by the liver, from mainly transport or growth proteins in 
the normal state to acute phase proteins in the septic or cachetic state.
Alternatively the effect of TNF-a may be indirect and mediated via IGF-I,
with inhibition of IGF-I synthesis, which would lead to decrease in growth 
rate. This second possibility is discussed further in chapter 6.
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3:9 Conclusions of Chapter 3.0
Plasma tumour necrosis factor alpha was raised in all cancer patients 
involved in this study (reference range <3pg/ml). During the study patients 
who gained more than 3.0 kg body weight showed a significant decrease
in blood TNF-a levels. Patients who failed to gain weight or who lost weight 
showed an increase in blood TNF-a levels.
Ferritin levels were high in all patients involved in the study. A significant 
decrease was seen in patients who gained weight and a significant 
increase in patients who gained less than 3 kg body weight or who failed to 
gain weight. Ferritin levels may therefore serve as possible indicators of 
the severity of the disease, since the levels of ferritin remain very high 
compared to that of TNF-a.
Finally the increase of plasma levels of IGF-I, accompanied by a significant 
decrease of TNF-a and preceded by a significant decrease of GH was 
observed in patients who gained more than 3 kg body weight. Patients who 
actually lost weight showed a low GH and high plasma levels of TNF-a.
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Chapter 4.0
Metabolic Changes in Tumour-Bearing Mice
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4:1 introduction
Weight loss in animals with cancer is associated with a general increase in 
tissue turnover (Fearon et al., 1988; Hyltander et al., 1991). In addition, the 
catabolic state is characterised by increases in glycogenolysis, 
gluconeogenesis, proteolysis and lipolysis (Frayn, 1986 ; Hyltander et al., 
1991). Many of these characteristic changes in metabolism are 
hormonally-mediated (Frayn, 1986).
The increased rates of whole-body energy expenditure, protein turnover, 
lipolysis and the loss of body mass which are associated with critical illness
can also be induced by TNF- a (Tracey et al., 1988). The shift in the role of
TNF- a from normal haemostatic functions to serving as a mediator of
inflammation is most likely to be related to the changes in tissue levels, 
which are dependent upon autocrine, paracrine and endocrine regulatory 
mechanisms.
TNF- a increases the production of acute phase proteins and accelerates 
glucagon-mediated amino acid uptake (Warren et al., 1987). Adipocytes 
and skeletal myocytes incubated with TNF- a become catabolic (Torti et al., 
1985), and glycogenolysis is markedly stimulated (Lee et al., 1987).
Glycogen is a highly branched polysacharide which is found in animal 
tissues such as liver, kidney and muscle. In metabolic terms, liver glycogen 
stores are the most important; liver glycogen is used to maintain blood 
glucose level during fasting, providing a supply of energy for other tissues.
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The rate of glycogen synthesis from glucose -6-phosphate (G-6-P) is 
increased by insulin, which is secreted in response to systemic 
hyperglycemia. In states of reduced carbohydrate feeding, G-6-P is 
released during glycogen breakdown. The liver contains the enzyme 
glucose -6- phosphatase, which hydrolyses the G-6 P to glucose which can 
then be released into the circulation. Hepatic glycogenolysis is stimulated 
by the hormone glucagon, secreted by A-cells of the pancreas, and by 
catecholamines such as adrenaline and noradrenline. The renal cortex is 
the only other tissue capable of gluconeogenesis and converting G-6- P to 
glucose. Other tissues (e.g. muscles) can store glycogen, but because they 
do not contain the enzyme glucose -6- phosphatase, it is only used locally 
and can not supply other tissues.
4:2 Lewis Lung Tumour (LLT)
The Lewis lung tumour was established in 1951 by Dr. M. R. Lewis,and has 
been extensively utilised as a transplantable tumour system for the 
evaluation of cancer chemotherapeutic agents (Mayo 1972) and to study 
host/tumour relationships (Janik et al., 1980).
Following injection of LLT into the foot pad of mic, LLT cells have been 
shown to invade both lymphatic and blood vessels (Paku et al., 1990). 
However, vascular invasion occurred more frequently; the haematogenous 
route can therefore be considered the main mode of metastasis formation of 
this tumour. The same authors also concluded that the interaction of tumour 
cells with the basement membranes of different tissue types (capillaries, 
veins, muscles, nerve and adipose tissue) is one of the main determinants
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In local and distant dissemination.
In this study the mouse was chosen as an animal model to observe the 
relationship between changes in tissue and plasma. Although there are 
clearly limitations in the use of animal models, studies such as these are 
very difficult if not impossible to undertake in man for obvious reasons.
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4:3 The Aims and Experimental Details of the Study
The aim of this study was to investigate the metabolic changes in plasma 
and tissues arising in mice bearing the Lewis lung tumour. Mice were 
divided into 3 study groups; a test group (tumour -bearing treated with 
MPA), a control group (tumour-bearing but untreated), and a normal group 
(non-tumour-bearing and receiving no treatment)
Forty two mice were included in this study, 14 mice in each of the three 
groups. On day fourteen after induction of the tumour, eight mice from each 
group were sacrificed, to study early metabolic changes in plasma and in 
tissues. At the end of the period of the study (day 21), the remaining six 
animals from each group were killed and treated similarly and their plasma 
and internal organs collected for assessment of different parameters.
Materials and Methods 
4:4 Initial induction of Lewis Lung Tumour in Mice
4:4:1 Materials
C57 black 6 J mice were purchased from Banith and Kingman Universal. 
Aldbrough,Hull, North Humberside U. K. Lewis lung tumour was obtained 
from Institute Of Cancer Research, Belmont, Sutton, Surrey U.K. 
Medroxyprogesterone acetate was a gift from Dr. Rostom, St Lukes 
Hospital Guildford. Iodine (pevidine) purchased from BDH. Anaesthetic 
ether (Diethyl ether) obtained from May and Baker LTD, Dagenham UK. 
Aseptic surgical equipments, disposable syringes and needles and tubes 
for homogenisation.
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4:4:2 Methods 
Inducing the Tumour (LLT)
The tumour-cells which had been stored at - 70°C were injected 
subcutaneously into a group of mice (10). After 14 days 4 mice were used 
as a source of the tumour for this study. The other six mice were used to 
validate the methods used. Under general anaesthesia with diethyl ether, 
these 4 mice bearing the tumour LLT were cleaned using pevidine as an 
aseptic solution. The tumour was dissected and the connective tissue 
removed from the tumour which was minced by knife. The tumour from the 
4 mice was pooled then homogenised by hand for one minute. Using a 1.0 
ml syringe, the tumour was induced subcutaneously into 28 normal mice 
(0.3 ml homogenate per animal). Tumour induction was successful in all 
animals. The tumour was palpable in all the mice after seven days post 
injection.
4:5 Validation of the Methodoiogy
This experiment was performed twice to validate the method used to 
measure glycogen content of tissue. The tissue (liver and muscle) was 
taken from normal mice and mice bearing the tumour (see section 4:6:3:2) 
and homogenated (see section 4:6:4:5).
Triplicates of each sample were assayed for glycogen content.
The homogenate (0.2 ml) and the enzyme amyloglucosidase (0.1 ml) were 
mixed with either DW (samples A), acetate buffer (samples B) or potassium 
carbonate (samples C); samples D contained only the homogenate and the
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enzyme. All samples were incubated in a shaking waterbath at 55®C for 2 
hours (the reaction was stopped by adding perchloric acid) apart from 
samples E which were simply mixed with DW and left to stand on the bench 
at room temperature for 2 hours. All tubes were centrifuged and the 
supernatant taken for glucose determination on a Cobas Mira (Roche). 
Samples which gave the highest glucose values and best precision were 
those from treatment B (Table 4:2) in both liver and muscle from normal 
mice and from mice bearing the tumour. The results from samples D,were 
high in concentration but imprecise especially with muscle tissue. Samples 
E represent the blank homogenate which did not contain the enzyme 
amyloglucosidase.
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Table 4:2 The protocol for validation of conditions for the 
method
Homogenate Amyloglucosidase DW Acetate buffer KHC03 
ml ml ml ml ml
A 0.2 0.1 0.9 ------------
B 0.2 0.1 ---------- 0.9
C 0.2 0.1 --------- — 0.9
D 0.2 0.1 — - — ------------
E 0.2 --------- 0.9 —
4:5:1 Determination of the Appropriate Incubation Period 
Homogenates (0.2 ml) from normal liver and muscle (21 samples of each) 
were mixed with 1.0 ml of acetate buffer and amyloglucosidase in a ratio of
9:1 respectively, and incubated in a shaking waterbath at 55®C. Samples 
(3 from the 21) were taken at 5,10,15, 30, 60, 90, and 120 minutes. The 
samples were then centrifuged for 10 minutes (1500 RPM) and the 
supernatant analysed for glucose content. The glucose concentration of 
the liver and muscle homogenates increased with an increase in incubation 
period from 5 minutes until 30 minutes. Increasing the incubation time 
beyond 30 minutes had no effect indicating that the optimal incubation 
period is 30 minutes.
131
4:6 Experimental Procedures
4:6:1 Grouping of the Mice and Treatment with MPA 
The 28 tumour-induced mice were randomly divided into two equal groups 
which were caged separately . One group served as control and the other 
as a test group. A third group of 14 normal mice were allocated in a 
separate cage to act as the normal group. The animals in the test group 
were treated daily with MPA (50 mg per 100 grams body weight 
intramuscularly) until sacrificed.
4:6:2 Assessment of Food and Water Intake and Measurement of 
Body Weight
The mice in the three groups were allowed free access to water and diet, 
the composition which is shown in table 4:1. The body weight of the mice in 
the three groups was recorded every 48 hours, and the food intake of each 
group determined daily, by subtracting the food remaining in the cage from 
the amount provided originally. All animals were examined daily for any 
signs of ill health.
4:6:3 Collection of Samples 
4:6:3:1 Plasma
Blood samples were taken from 8 mice from each of the three groups via 
cardiac puncture under general ether anaesthesia on day 14. On day 21, 
blood was taken by cardiac puncture from the remaining mice in each 
group. All blood samples were kept on ice and distributed into two tubes.
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the first in heparinised tubes (for IGF-I) and second in EDTA tubes (for TNF- 
a). Approximately 1.0 ml blood was placed in each tube. Samples were 
collected and centrifuged immediately. Plasma was immediately removed. 
Samples were then frozen and maintained at -20°C until assayed.
4:6:3:2 Tissues
Following cardiac puncture, the mice were killed under general 
anaesthesia by cervical dislocation, and their internal organs (liver, kidneys, 
heart and lungs) and muscles of limbs removed. These tissues were 
weighed, wrapped in aluminium foil, then immediately snap frozen in liquid 
nitrogen and transferred to a -70°C freezer until required.
Table 4:1
Food composition of Standard Quality Control, Laboratory 
animal diet No 1 (Product of Special Diets Services Limited, UK)
Ingredients % Examples
Cereal products 88.5 Wheat and barley
Vegetable proteins 6.0 Soya bean meal
Animal proteins 2.5 Whey powder
Fat sources 0.5 Soya oil
Supplementation 2.5 Vitamins, minerals and amino acids
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4:6:4 Determination of Tissue Glycogen (liver, muscle and 
kidney)
Glycogen is a highly branched polysacharide which can be expressed in 
glucosyl units per grams wet weight of tissue
The principle of glycogen assay 
Glycogen is first hydrolysed using the enzyme amyloglucosidase at pH 4.8 
to liberate glucose. Then glucose is phosphorylated by hexokinase in the 
presence of ATP and magnesium at pH 7.5 to glucose-6-phosphate + ADR 
The glucose-6-phosphate formed is then oxidised to 6 phosphogluconate 
in the presence of nicotinamide adenine dinucleotide (NAD). This reaction 
is catalysed by glucose-6-phosphate dehydrogenase. During this oxidation, 
an equimolar amount of NAD is reduced to NADH. The glucose liberated 
after hydrolysis of glycogen is proportional to the increase NADH measured 
by the absorption change at 340 nm. The glucose blank is measured in the 
homogenate without adding the amyloglucosidase enzyme. The glycogen 
content can be expressed in glucosyl units per grams wet weight of tissue 
which is equivalent to the glucose content of the hydrolysed glycogen after 
subtraction of the glucose blank (free glucose before hydrolysis).
Materials
Analytical balance, high-speed homogeniser, water bath with shaker and 
bench centrifuge. Perchloric acid, potassium hydrogen carbonate, acetic 
acid, sodium acetate, glucose hexokinase kit and amyloglucosidase EG 
3.2.1.3, A-3042. (6100 units / ml) were purchased from Sigma.
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Preparation of the Solutions 
The following solutions were prepared; perchloric acid 0.6 M, potassium 
hydrogen carbonate 1.0 M, and acetate buffer 0.2 M pH 4.8. The last 
solution was prepared by dissolving 4.8 ml 96% acetic acid and 9.75 grams 
of sodium acetate in one litre of D W. The enzyme amyloglucosidase 6100 
units / ml was ready to use.
Homogenisation of Tissue for Glycogen Determination 
The appropriate ratio of tissue to perchloric acid required for 
homogenisation was regarded as 20 %(WA^), i.e. 500 pi of perchloric acid
for every 100 mg of wet tissue. This was determined by studying a group of 
normal mice and mice bearing the tumour (see section 4:4:2) to develop 
the appropriate methods used. This is in addition to the 42 mice sacrificed 
for the study. The samples of these mice (used to validate the methods) 
were treated the same as the 42 mice involved in the study.
Measurement of Tissue Glycogen in the Animals 
Involved in the Study 
Homogenates (0.2 ml) of liver or muscle were mixed with 1.0 ml acetate 
buffer : amyloglucosidase enzyme (9:1,v/v), and incubated in a shaking
waterbath at 55°G for 30 minutes, the reaction stopped by adding 
perchloric acid. For the blank sample, 0.2 ml homogenate was mixed with 
1.0 ml DW and left on the bench. All tubes were centrifuged at 1500 RPM 
for 5-10 minutes. Supernatants were removed for glucose measurement. 
Samples were diluted with DW. The concentration of glycogen was
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calculated as the amount of glucose in the samples minus the glucose 
concentration in the blank of the same sample or homogenate. The results
of glycogen content in the tissues were expressed in pmole glucosyl units
per gram wet weight of tissues.
4:6:5 Determination of Tissue Total Protein
Protein measurements were made on tissues (liver, muscle, heart and
kidney) removed from the experimental animals.
Principle : as described by Lowry (Lowry et al., 1951)
Materials
Sucrose, disodium carbonate, sodium hydroxide, copper sulphate, sodium/ 
potassium tartrate, bovine serum albumin (BSA) and Folin reagent.
Preparation of the Solutions
The following solutions were prepared in DW, 0.25% (W/V) sucrose, 0.5 M 
sodium hydroxide, 2% (W/V) sodium carbonate, 1% (W/V) copper sulphate, 
and 2%(W/V) sodium / potassium tartrate. The working solution was 
prepared by mixing 0.5 ml of 1% copper sulphate, 0.5 ml of sodium / 
potassium tartrate and 50 ml of 2% sodium carbonate, this solution is stable 
for 30 minutes. Folin reagent was diluted 1:1 in DW, and BSA diluted in 0.5
M sodium hydroxide and used as standard with 250 pg/ ml as the top
standard. A 10 % (W/V) homogenate in 0.25M sucrose (1.0 ml of 0.25 M 
sucrose per 100 mg of wet tissue) was prepared for each tissue. This was
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then further diluted with sodium hydroxide.
Methods
Samples or standards (1.0 ml) were mixed with 5 ml of copper reagent and 
left to stand for 10 minutes. Diluted Folin reagent (0.5 ml) was then added to 
all tubes, mixed and left for 30 minutes. The absorbance was then read at 
720 nm on a Uvikon 86 spectrophotometer.
Problem in Determination of Muscle Protein
Unlike liver, from which a homogenate can be prepared relatively easily, the 
determination of total protein content of the muscles gave results which 
showed poor precision as assessed by comparing the results from 
duplicate samples. This was probably due to the fact that, with a total weight 
of muscle which is small, there is a relatively high proportion of other tissue 
such as tendon, nerves and arteries. This is difficult to avoid when using the 
mouse as experimental model. This problem has been overcome by using 
more than two duplicates for each muscle sample. Centrifugation of 
samples did not resolve this problem since it resulted in falsely high results. 
This is undesirable especially if comparisons between liver and muscle 
protein content are to be made in this study.
4:6:6 :Determination of Plasma and Tissue TNF-a.
TNF-a was measured by enzyme linked immunosorbent assay (ELISA), by 
the Department of Clinical Chemistry, Royal Liverpool University Hospital. 
The tissue content of TNF-a was analysed after homogenisation of the
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tissue with phosphate buffer and freeze drying of the supernatant of the 
homogenate see method below.
The plasma TNF-a level of the mice was measured directly without an 
extraction or concentration step. Although the samples were sent frozen by 
Red Star Parcel (in November) a few plasma samples defrosted.
Homogenation of the Tissues 
Materials
Liver and muscle of mice (normal, control and test groups) 
phosphate buffer pH 7.4, and 0.5 M.
Ice on a tray.
Homogeniser and a plastic tube for homogenisation.
Method
The tissues and phosphate buffer were kept on ice throughout the 
preparation. Following homogenisation, samples were centrifuged at 4®C, 
1500 RPM for 10 minutes. The supernatant of the tissue homogenate was 
kept at -70°C, then freeze dried to concentrate the TNF-a content, then 
reconstituted into phosphate buffer (Figure 4:1).
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Figure 4:1 Diagram showing the extraction 
of tissue tumour necrosis factor
Tissue Phosphate buffer 2 ml
per 100 mg of tissue
Homogenisation in ice cold tube 
followed by centrifugation
Supernatant kept at - 70°C 
Freeze dried 
Reconstituted with assay buffer
1
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4:7 Results
Subcutaneous injection of Lewis lung tumour cells in C57 black 6J mice 
caused subcutaneous tumours that were measurable from day 7 onwards 
and which continued to grow in tumour-bearing mice whether treated with 
MPA (test group) or not (control group). The experiment was terminated 
(day 21 ) because the tumours became so large in comparison to the 
weight of the mice (20 % of the weight of the mouse) and the fear that the 
tumour may rupture.
4:7:1 Food intake
All animals were maintained on the standard quality control, Laboratory 
animal diet No 1. During the experiment the control group consumed 88% 
of the food intake compared to the normal mice in the three weeks of the 
study (table 4:3). The test group consumed 100%, 88% and 75% during the 
three weeks respectively compared to the normal group.
4:7:2 Body weight
The results of body weight showed that the test and the control groups 
gained body weight due to an increase in their tumour size (Figure 4:2). 
When the weight of the tumour was subtracted from the total body weight 
the normal mice showed a significant increase (P<0.05) in body weight 
compared to mice bearing tumour in the third week.
There were no significant differences in the weight of the liver (table 4:4a) 
and the heart (table 4:4b) or the ratio of organ weight to body weight
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between the normal, control and test group during the period of the study. 
There was a significant increase (P<0.05) in kidney weight of the test group 
compared to the normal mice (table 4:4b).
4:7:3 Total protein and glycogen
The results of total protein content of liver and muscle are given in table 4:6. 
The results indicated a significant increase (P<0.05) in total liver protein in 
the second week in the control group compared to the normal group. There 
was a significant increase (P<0.05) in total muscle protein in the third week 
in the control and test group.
There was no significant change in liver glycogen, but there was a 
significant decrease in muscle glycogen in the second week in the control 
and test group compared to the normal group (table 4:7).
4:7:4 TNF-a in plasma and tissue
Despite the sensitivity of the assay (lower limit of detection 20 pg/ml), no 
TNF-a was detected in plasma in any group at any time during the study 
(results not shown).
The results shown in table 4:8 indicate that the liver of the normal mice 
contained detectable amounts of immunoreactive TNF-a. Treatment of the 
tumour-bearing mice with MPA resulted in a significant decrease in liver 
content of TNF-a in the test group compared to the control group.
In second week muscle of normal mice (Figure 4:4) did not contain
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detectable amount of immunoreactive TNF-a (in third week only one
sample found to be containing TNF-a). In the third week there was a
significant increase in muscle TNF-a in control group (P<0.01) and the test 
group (P<0.001) compared to the second week.
Table 4:3 Amount of food consumed by the groups of mice
during the study
First week n=14 Second week n=10 Third week n=6
Normal group 348 grams 292 grams 150 grams
Control group 304 grams 262 grams 132 grams
Test group 341 grams 260 grams 111 grams
Results expressed as the total amount of food consumed by each group per week.
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Figure 4:2 Mean weight gain of the test, 
control and normal mice.
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Figure 4:3 Standard curve for total protein
measurements, n=2 (Lowry method)
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Table 4:4a The liver weight (grams) of mice in the study
Second week n=8 Third week n=6
Normal group 
Control group 
Test group
1.60 ±0.14 (5.0%) 
1.69 ±0.11 (5.7%) 
2.01 ±0.11 (6.7%)
1.68 ±0.09 (5.9%) 
1.79 ±0.14 (5.6%) 
1.74 ±0.16 (5.7%)
Results expressed as mean ± SEM, % = % of total body weight.
Tabie 4:4b Kidney and heart weight (grams) of mice 
in the study (week 2).
Kidney n=8 Heart n=8
Normal group 
Control group 
Test group
0.36 ± 0.02 
1.1 ±0.05 % 
0.37 ±0.02 
1.26 ±0.06% 
0.43 ± 0.03* 
1.43 ±0.08%
0.19 ±0.01 
0.58 ± 0.04 % 
0.16 ± 0.02 
0.53± 0.04 % 
0.17±0. 01 
0.56 ± 0.02 %
Results = mean ± SEM, % = % total body weight, * = P<0.05 compared to the normal group.
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Table 4:6a Total liver protein of the mice involved in the study
(mg/gram wet weight of tissue)
Time Second week n= 8 Third week n=6
Normal group 103 ±6.5 105 ±5.5
Control group 123 ±5.3* 118 ± 10.8
Test group 114±5.7 116±8.6
Results expressed as mean ± SEM, *= p<0.05 compared to the normal group.
Table 4:6b Muscle total protein of the mice invoived in the 
study, (mg/gram wet weight of tissue)
Time Second week n = 8 Third week n=6
Normal group 42.2 ±4.2 26.1 ±2.5
Control group 48.9 ± 2.8 49.0 ± 3.6 **
Test group 55.0 ±8.0 85.5 ±11.5**
Results expressed as mean ± SEM, **= p<0.05, n= number of mice per group.
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Table 4:7 Liver and muscle glycogen in the study groups
(pmole glucosyl units per gram wet weight of tissue)
Time Second week n=8 Third week n= 6 
Liver muscle Liver muscle
Normal group 648±25 385±23
Control group 623±15 247±29*
Test group 597±27 235±1T
652±37 407±46
603±26 365+39 
615114 323±22
Results = mean ± SEM,*=P<0.05 compared to the normal group.
Table 4:8 TNF-a level in liver of mice.
Time Second week n=8 Third week n=6
pg/ml pg/ml
Normal group 73 + 7 67 + 14
Control group 77+6 81 + 11
Test group 70 + 13 55 + 7*
Results expressed as mean ± SEM, * P<0.05 compared to the control group.
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Figure 4:4 Mean of muscle TNF-a in the mice
involved in the study
* P<0.01, ** P<0.001 compared to day 14.
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4:8 Discussion
In the present study, food intake was measured in all the animals 
throughout the project. In the second week after treatment with MPA, the 
test group consumed less than the normal animals, and in the third week, 
even less than the control group. Despite this there was an increase in the 
body weight of the test group during the same (third) week. This 
combination of an increase in the body weight in the presence of 
decreased food intake in third week in the test group (after taking MPA) may 
have been due to the increase in the tumour mass in the animals which 
may itself, by making the mice more ill, have depressed their appetite 
(Tracey eLaL, 1988). An alternative explanation may be the toxic or 
metabolic effects of substance(s) released either by the tumour or in 
response to its presence.
Among the possible candidates for this is TNF-a, raised serum levels of
which have been described in patients with cancer-associated cachexia
(Beulter et al., 1988). Further evidence for a role of TNF-a in this situation
comes from the work of Yoneda et al.. (1991) who found that the injection of
anti-TNF-a into tumour (sarcoma)-bearing mice resulted in a decrease in
the level of anorexia. In addition, they observed a decrease in tumour size 
but no effect on the animals’ concomitant anaemia.
It is likely that any such effect of TNF-a (on appetite, for example) would 
represent an endocrine action with associated changes in plasma levels of
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TNF-a. One of the problems with the present study is that TNF-a was not
detectable in the plasma of any of the mice in this study. There are a 
number of possible explanation for this. It is possible that the analytical
method used to measure TNF-a was insufficiently sensitive to detect
plasma levels in the mice. Another explanation is the fact that a number of
mouse plasma samples for TNF-a did not remain completely frozen prior to
assay. In view of the instability of TNF-a in non-frozen plasma, this may 
well explain the failure to detect it in any of the samples assayed.
Although there were differences in the levels of TNF-a in both muscle and 
liver, muscle in particular is not a prime site of synthesis of TNF-a, and it is
more likely that these differences would reflected changes in blood levels 
rather than in situ synthesis.
However, failure to detect TNF-a in plasma is consistent with the finding of
Moldawer et al.. (1987) who could not detect either TNF-a or interferon in 
tumour-bearing mice. Furthermore, they also demonstrated the lack of a 
correlation between the plasma levels of TNF-a and tissue levels.
Douglas et al.. (1991) reported that when TNF-a was infused with IGF-I in
one group of animals, and normal saline with TNF-a infused in another
group of animals, the plasma TNF-a concentration fell significantly 
between 3-4 hour in both IGF-I and normal saline- infused animals, despite
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the fact that TNF-a was being infused at a constant rate over this time.
The reasons for this are unclear, but it again suggests that plasma TNF-a 
levels do not correlate with total body levels.
Although the metabolic effects observed in sepsis and in malignant 
disease may differ, the underlying mechanisms involved may be similar. In 
sepsis two important processes- muscle proteolysis and increased hepatic 
protein synthesis- are enhanced. The first of these leads to accelerated 
peripheral release of amino acids; a large portion of these amino acids are 
transported to the liver where they are used for gluconeogenesis and the 
synthesis of acute phase proteins. Glucocorticoids and glucagon are 
considered important mediators of altered protein metabolism in sepsis 
(Frayn, 1986; Douglas & Shaw, 1989; Watters & Wilmore, 1989).
In the present study, there was a significant increase in the total protein of 
the liver in the control group in the second week which persisted (although 
not at a significantly raised level) into the third week. At the same time, the
level of TNF-a in liver was raised in the same group of animals (not
significantly in the second week but significantly in the third week of the 
study). These findings, together with work of other groups, suggest that
TNF-a may also be a mediator of altered protein metabolism, either directly
or indirectly through an effect on glucocorticoids and glucagon (Van der 
Poll et al.. 1991). However any such indirect effect would again be 
expected to depend upon changes in plasma levels which were not found
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in this study.
The change in total liver protein content is accompanied by a change to 
anabolic metabolism (Beisel, 1975), with an increase in the hepatic uptake 
of amino acids released by peripheral tissue partly for use as 
gluconeogenic substrates (Long et al.. 1976; Lang et al.. 1984), and partly 
for synthesis of acute phase proteins, the plasma levels of which rise 
several fold in sepsis and injury (Pepys & Baltz, 1983). This exchange of 
amino acids from muscle to the liver, bone marrow and wounds provides 
support for the anabolic activities of the liver, for cellular proliferation within 
the immune system, and for healing of injured tissue (Rosenblatt et al.. 
1983).
TNF-a infusion has been shown to induce a pronounced increase in the net
forearm efflux of amino acids in patients with cancer, which is largely 
accounted for by alanine and glutamine. The simultaneously measured 
arterial amino acid level fell, which suggests redistribution of amino acid 
from muscle to other tissue such as the liver (Warren et al.. 1987; Starnes et 
ai-, 1988)
An increase in the synthesis of acute phase proteins is a non-specific 
response to injury and metabolic stress such as cancer. This appears to be 
at the expense of increased proteolysis in other organs, especially muscle. 
In the present study the weight of vital organs (liver, heart and kidney) 
expressed as percentage of total body weight was the same in the control, 
test and normal mice, indicating that the loss of weight in the control and the
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test group was not due to loss of liver, kidney and heart mass which were 
relatively preserved at the expense of the skeletal muscle or fat. Torti et al..
(1985) reported that, in an experiment where TNF-a was incubated with
adipocytes and skeletal muscle, there was an increase in both in lipolysis 
in adipocytes, and protein catabolism in skeletal muscle.
In the present study, the increase of muscle TNF-a in the control and test
groups was associated with a significant decrease in muscle glycogen 
content. This supports the finding of Lee et al (1987) who reported an
increase in glycogenolysis when muscle cells were incubated with TNF-a.
Although this was a clearly a direct effect. It may enhanced by change in 
endocrine activity. Van der Poll et al.. (1991) for example, showed that the
administration of TNF-a to normal human subjects induced a pronounced
stress hormone response with increases in plasma levels of cortisol, 
adrenaline, ACTH, GH and glucagon all of which would have the effect of 
increasing muscle glycogenolysis.
The weight and the percentage of the liver, kidney, and heart showed no 
significant differences between the control, test and the normal group. This 
illustrates that the loss of weight (see Figure 4:2b) in the test and the 
control group at least is not from these vital organs, and is probably due to 
loss of muscle and fat. Indeed, at autopsy it was evident that the test and 
the control animals had lost most of their body fats (intrascapular fat pads, 
perirenal and subcutaneous fat). Similar results were reported by Oliff et
âi-, (1987), who found that mice injected with tumour cells producing TNF-a
153
became emaciated with loss of all body fat. In vitro evidence is also 
consistent; Torti et al.. (1985) reported that, when TNF-a was incubated with 
adipocytes, there was an increase in lipolysis in adipocytes.
TNF-a causes an increase in the rate of breakdown of storage fat and
inhibition of its synthesis by retarding the transcription of mRNA from the 
genes coding for the key enzyme (Torti et al.. 1985 ). Thus it is a prime 
candidate for the role of mediator of many of the metabolic changes 
observed in cancer cachexia both in experimental animals and in human 
subjects.
4:9 Conclusions of chapter 4.0
In this chapter the results showed that: The food intake of animal bearing 
Lewis lung tumour (control) was reduced to 88 % (whole period) compared 
to the normal groups. Animals treated with MPA showed no change in the 
first week but food intake was reduced to 75% in week three. Among the
possible candidates for this is TNF-a. Although plasma TNF-a was not
detected (limit of detection = 20 pg/ml) it was detected in the muscle and 
liver of animals bearing tumour. The muscle of normal animals contained
no detectable TNF-a.
The muscle of both control and test group showed a decrease of glycogen, 
and an increase of both total protein and TNF-a. This was accompanied by 
a decreased in body weight.
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Chapter 5:0
Insulin-Like Growth Factor-1 in Mice Bearing Tumour
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5:1 Introduction
Insulin-like growth factor-1 and insulin appear to play a central role in the 
regulation of mitogenesis, since they are required for optimal growth and 
proliferation by virtually all cell types.
Both insulin and IGF-I can activate either the insulin or type I IGF-I tyrosine 
kinase membrane receptors at concentrations proportional to their binding 
affinities (Czech et al.. 1989). Different cells, however, will selectively 
respond to low concentrations of either IGF-I or insulin depending upon the 
relative levels of their respective receptors. For example, fat cells display 
high levels of both IGF-I and Insulin receptors, while most other cell types 
express higher levels of IGF-I compared with insulin receptors. IGF-II, 
whose receptor is the mannose-6-phosphate receptor, also recognises 
these receptors, but at a lower affinity (Clemmons et al..1989).
Further regulation of IGF-I is provided by specific IGF-binding proteins 
present in serum that do not bind insulin. The control of the release of IGF-I 
from its binding proteins probably depends upon a number of factors, for 
example nutritional state and tissue proteases (for more details see section 
1:6).
5:1:1 Effects of IGF-I In Vitro Studies
In vitro studies have shown IGF-I to be mitogenic for fibroblasts (Conover et 
al., 1985; Cook et al..1988). kératinocytes (Ristow et al.. 1988), epithelial 
cells (Deeks et al.. 1988; Ham et al.. 1990), chondrocytes (Vetter et al.. 
1986), osteoblasts, smooth muscle cells (Clemmons, 1984) and neuronal
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cells (Lenoir & Honegger, 1983 ).
IGF-I is one of the few growth factors which has the capacity to specifically 
stimulate chondorocyte proliferation and maintain cartilage phenotype in 
vitro. It increases cellular proliferation and synthesis of collagen and 
proteoglycan in cultured chondrocytes (Vetter et al.. 1986).
There is some evidence for interaction between cytokines and growth 
factors at the tissue level: it has been been reported that the suppression of 
cartilage-specific phenotype induced by IL-I (Tyler & Benton, 1988 ) can be 
reversed by incubation of chondrocytes with IGF-I. (Tyler, 1988; Tyler, 1989).
5:1:2 IGF-I of non- Human Species
There is remarkable conservation of IGF-I between species, indicating the 
metabolic importance of this peptide. The amino acid sequence of bovine 
IGF-I has been shown to be identical to that of human IGF-I (Honegger & 
Humbel, 1986) and, in addition, Tavakkol and co-workers (1988) have 
shown that porcine IGF-I as deduced from cDNA clones, is also identical to 
the human peptide.
IGF-I has been isolated from rat serum and a partial N- terminal amino acid 
sequence was reported. Of the 26 amino acids identified, no differences 
noted between rat and human IGF-I (Rubin et al.. 1982. The complete 
sequence of rat IGF-I was deduced from the nucleotide sequence of the rat 
IGF-I gene . Only three amino acids differences were noted between rat 
IGF-I and human IGF-I, proline for aspartic acid at position B20, isoleucine
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for serine at position C35, and threonine for alanine at position D67 
(Shimatsu & Rotein, 1987).
Four amino acids differences were reported between mouse IGF-I and 
human IGF-I. In addition to the three amino acid substitutions noted in rat 
IGF-I, there is one additional substitution alanine for serine at position D69 
(Bell et al..1986).
5:1:3 IGF-I in Different Tissues
The effects of growth hormone on skeletal growth are thought to be 
mediated via alteration of the systemic levels of IGF-I or changes in the 
local production of this factor (Schlechter et al., 1986). Additional 
mechanisms include increased proliferation of target cells such as 
chondrocytes or the number of IGF-I receptors on these cells. At the tissue 
level, growth hormone-dependent somatic growth Is thought to be mediated 
by autocrine and paracrine mechanisms (D’Ercole, 1984) involving either 
local production of IGFs or regulation by low molecular weight binding 
proteins which has been identified in many tissues (McCusker & 
Clemmons,1988; Mohan sLâl-, 1990). It is therefore important to relate 
plasma levels of IGF-I to changes in tissue level.
There is now evidence that IGF-I is synthesised in multiple tissues such as 
fibroblasts, (Conover et al., 1985; Cook et al..1988). chondrocytes (Vetter el 
aL, 1986), neuronal cells (Lenoir & Honegger 1983 ) and epithelial cells 
(Deeks et al.. 1988; Ham et al.. 1990). IGF-I has also been isolated from a
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number of tissues such as liver, lung, kidney, heart, muscle, bone, brain, 
testes, prostate, lymph node cartilage and submaxillary glands (D’Ercole 
al-, 1984; Yahvaet al.. 1990). However, it is important to remember that the 
presence of IGF-I in a tissue is not necessarily evidence for local 
production; it may represent sequestration of IGF-I by locally produced 
binding proteins.
Yahya and co-workers reported IGF-I levels in muscle (1.28 nmol/kg) and 
bone (8.0 nmol/kg) compared to plasma level (46.3 nmol/L) in rats 
supplemented with a 20% (w/w) protein diet (Yahya et al.. 1990). The 
same authors demonstrated a significant reduction in plasma and muscle 
IGF-I levels when protein intake was reduced to 0.5% in these animals for 
three weeks.
5:1:4 IGF-I and Cancer
As the role of oncogenes in transformation and tumourigenesis emerged, 
demonstrated that they could code for proteins involved in the regulation of 
cell growth was eagerly awaited. Oncogenes have subsequently been 
found to encode for proteins which are homologous to growth factors.
It is now clear that most, if not all, oncogenes so far identified encode for 
proteins that are involved in the cascade of events by which growth factors 
stimulate normal cell division. Those that do not directly encode for growth 
factor specify proteins that are transducers of growth factors responses, or 
transcription factors mediating growth factor-induced gene expression 
(Dickson et al., 1989; Gill, 1989)
159
5:1:4:1 IGF-I as Tumour Growth Factors 
It has been suggested that IGF-I may play a role in neoplastic 
transformation and metastasis. Kohn and co-workers suggested that IGFs 
and Insulin stimulate the motility of breast, bladder, and ovarian cancer cell 
lines in the human, even with levels of both insulin and IGFs lower than 
required for optimal migration (Kohn et al.. 1990).
In cultured human melanoma cells, the typel receptor has been shown to 
mediate a high potent motility response to IGFs and insulin, an effect which 
enhances the potential for local and distant cancer spread (Stracke et al..
1989).
Primary lung tumours possess IGF-I binding sites as shown by 
autoradiography, with the highest density of receptors in squamous cancers 
and small cell lung cancer (Shigematsu et al.. 1990). These receptors are 
functional, since exogenous IGF-I has been shown to cause mitogenic 
response in small cell lung cancer (Jacques et al.. 1988; Macaulav et al..
1990) and non small cell lung cancer (Siegfried, 1989). Immunoreactive 
IGF-I is also detectable in extracts of cultured small cell lung cancer and 
non- small cell lung cancer cells and their condition media (Siegfried, 1989; 
Jacques et al.. 1988; Macaulav et al.. 1990). Immunoreactive IGF-I is also 
detectable at higher levels in primary lung tumour than in normal lung 
tissue ( Macaulav et al.. 1988a). However, IGF-I levels are not raised in the 
serum of lung cancer patients and levels are unrelated to the bulk of the 
disease or response to treatment of cancer. Both normal and malignant
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lung tissue therefore appear to make an insignificant contribution to blood 
levels when compared to hepatic IGF-I production (Macaulay et al.. 1988b; 
Macaulav et al.. 1988c).
Importantly, Jacques and co-workers (1989) demonstrated that lung cancer 
cells produce IGF-binding proteins. These may permit the sequestration of 
IGF-I's in lung tumour tissue where they may act as paracrine or endocrine 
growth factors.
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5:2 The Rationale of the Study
The aim of this study was to investigate the metabolic change in plasma 
and tissues in relation to IGF-I levels in mice bearing the Lewis Lung 
tumour. The effect of treating the animals with medroxyprogesterone was 
also studied.
IGF-I levels were measured in samples taken from the mice in the study 
described in Chapter 4. For detail of the study see section 4:4.
5:3 MATERIALS & METHODS
5:3:1 Collection of Samples 
5:3:1:1 Plasma
Blood samples were taken on day 14 and on day 21 as described 
previously (section 4:2). Approximately 1.0 ml of blood for measurement of 
IGF-I was taken into heparinised tubes and stored on ice. Samples were 
collected, centrifuged and plasma was immediately separated. Samples 
were then frozen and maintained at -20°C until assayed.
5:3:1:2 Tissues
Animal were killed under general anaesthesia by cervical dislocation and 
their liver and muscle samples removed as described in Chapter 4.0.
These were immediately snap frozen in liquid nitrogen and then transferred
to a -70°C freezer until analysis.
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5:3:2 Tissue IGF-I Extraction
Tissues were extracted by method developed by D’Ecole and co-workers 
(1984). A 20% homogenate was processed with acetic acid and the 
supernatant dried (Figure 5:1), reconstituted with NaOH and dried again. 
Finally the dried material was reconstituted with IGF-I assay buffer, the 
amount of assay buffer used depending upon the amount of the tissue. This 
was then treated in the same manner as the extracted blood samples.
5:4 Measurement of Plasma and Tissue IGF-I
Insulin-like growth factor -1 was measured by a radioimmunoassay method 
developed at St Luke Hospital, Guildford (Teale & Marks 1986).
Principle
Plasma samples containing protein-bound IGF-I, are extracted with acid- 
ethanol to precipitate the binding protein (tissues extracted as shown in 
Figure 5:1) . Tris(hydroxymethyl-methylamine) is incubated with the 
supernatant to yield a second precipitate. The IGF-I in the extract (plasma
and tissue) competes with an "^^^l-IGF-l derivative for limited binding sites 
on a specific mouse monoclonal antibodies. Incubation at 4®C over night 
allows equilibrium to be reached. The free and antibody-bound fraction are 
separated by the addition of an anti-mouse globulin raised in a donkey. 
Polyethylene glycol (PEG) is used to aid the precipitation of the double 
antibody complex. The pellets are counted and read against a standard 
curve.
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Stock Reagent
See section 2:4:10 apart from acetic acid, hydrochloric acid, sodium 
hydroxide and ethanol (Sigma) .
Instrumentation
LKB Wallac 1260 Multigamma counter; Coldt ray (MK Refrigeration 
Limited), 200 |il repeating pipette (Hamilton company), LP3 polystyrene 
tubes, adjustable pipettes, and disposable plastic tips
Working Reagents
See section 2:4:10 apart from the followings;
Acid-ethanol (87.5% (v/v) ethyl alcohol and 12.5% (v/v) HCL (2 mol).
0.5 mol/L NaOH.
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Figure 5:1 Tis sue IGF-I Extraction
Tissue + acetic acid (20%) 
e.g. 1.0 gram of tissue + 5 ml acetic acid
Homogenisation and supernatant dried
I
Reconstitution with NaOH
I
Dried and reconstituted with IGF-I assay buffer
I
IGF-I measurement
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Assay Procedure
All manual procedures were carried out on the cold tray to limit sample and 
reagent deterioration.
Plasma samples, control and standard were prepared as shown below;
Serum (\i\) Acid/ethanol (pi)
Standard 200 800
Control 100 400
Sample 100 400
Mixed and stand at 4°C for 10 minutes, centrifuged at 4°C and 3000 rpm for 
15 minutes. The supernatants were mixed with 10% Tris 3:2 (VA/) mixed 
and left to stand at 4®C for 60 minutes, then finally centrifuged at 4°C and 
3000 rpm for 30 minutes.
The supernatant from the standard is double diluted in the assay diluent to 
produce a range of values (0.031, 0.062, 0.125, 0.25, 0.5 and 1.0 U/ml).
300 pi of sample extract diluted with 300 pi of diluent would be sufficient for
standard curves. The extracted plasma and tissue samples were treated in 
the same way in the assay protocol as described previously (section 
2:4:10).
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5:5 Calculating the Recovery of Tissue IGF-I
For calculating the recovery from tissues samples (liver, kidney, heart and 
muscle), a sample of tissue was spiked with IGF-I before homogenisation; a 
further similar sample (equal amount from the same tissue) was 
homogenised without addition of IGF-I. A third sample of pure IGF-I (the 
same amount as added to the spiked tissues) was dissolved in IGF-I assay 
buffer. The recovery was calculated as follows;
(Tissue spiked with IGF-I - plain tissue)
Recovery =   X 100
Pure IGF-I in assay buffer
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5:6 Results
The results Indicated that the recovery of IGF-I was 80 % in liver and 
kidney, and 75% in the muscle and heart (results not shown here). The 
results of plasma IGF-I levels showed that there was a slight decrease (not 
significant ) in the second week of mice bearing tumour; in the third week 
there was a significant decrease (P<0.05) in the control group compared to 
the normal mice (table 5:1). The results of liver IGF-I indicate that, although 
there was a significant decrease of liver content of IGF-I in the control group 
(P<0.005) and the test group (P<0.05) compared to the normal mice in the 
second week as shown in table 5:2, there was no significant change in the 
third week.
The results of muscle IGF-I indicate that, although there was a significant 
decrease of muscle IGF-I in the control group (P<0.05) and the test group 
(P<0.05) compared to the normal mice in the second week, there was no 
significant change of muscle IGF-I in the third week (table 5:3).
The results of kidney and heart IGF-I indicate that there was no significant 
change of kidney and heart IGF-I when compared to the normal, control and 
the test group in the second week (table 5:4).
In the normal animals the kidney and liver appears to contain more IGF-I 
than the heart and the muscles if expressed as lU per gram of wet tissue. 
The presence of the Lewis lung tumour appears not to alter the contents of 
IGF-I of each tissue compared to another tissue within the same animal (the 
ratio of IGF-I between organs within the same animal). The results (table 
5:5) indicate that the kidney contains more IGF-I than the liver, the latter
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contains more IGF-I than the heart. The muscle IGF-I level is the lowest of 
all tissues containing IGF-I measured in the this experiment.
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Table 5:1 Plasma IGF-I levels in the mice.
Time Second week n=8 third week n=6
■
lU/ml lU/ml
Normal group 0.388 ±0.169 0.375 ±0.184
Control group 0.251 ±0.156 0.173 ±0.091*
Test group 0.229 ±0.101 0.242 ± 0.064
Results expressed as mean ± SD, * P<0.05 compared to the normal group.
Table 5:2 Liver IGF-I levels in the mice.
Time Second week n=8 third week n=6
lU/gram lU/gram
Normal group 2.83 ±0.15 3.09 ±0.57
Control group 2.27 ± 0.36** 2.58 ±0.65
Test group 2.55 ±0.08* 2.89 ± 0.57
Results expressed as mean ± SD, statistically differ from the normal 
“  = p<0.005, * = p<0.05.
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Table 5:3 Muscle IGF-I levels in the mice.
Second week n=8 third week n=6
lU/gram lU/gram
Normal group 1.17±0.12 1.07 ±0.13
Control group 0.38 ±0.1* 1.05 ±0.29
Test group 0.61 ±0.13* 0.79 ±0.31
Results expressed as mean ± SEM, * = p<0.05 compared to the normal group.
Table 5:4 Kidney and heart IGF-I levels In the mice.
Kidney n= 8 Heart n=8
lU/gram lU/gram
(2nd week) (2nd week)
Normal group 3.34 ±0.09 1.73 ± 0.42
Control group 3.25 ± 0.05 1.63 ±0.31
Test group 3.15±0.22 1.70 ±0.41
Results expressed as mean ± SEM.
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Table 5:5 IGF-I level in different tissues
Normal group Control group Test group
2nd 3rd 2nd 3rd 2nd 3rd week
Plasma (lU/ml) 0.39 0.38 0.25 0.17* 0.23 0.24
Liver (lU/G) 2.83 3.09 2.27** 2.58 2.55* 2.89
Kidney (lU/G) 3.34 3.25 3.15
Heart (lU/G) 1.73 1.63 1.70
Muscle (lU/G) 1.17 1.07 0.38* 1.05 0.61* 0.79
Tumour (lU/G) 1.22 0.98 1.01 1.3
Results expressed as mean, *P<0.05, ** P<0.005 compared to the normal group.
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5:7 Discussion
The study described in this chapter was undertaken to evaluate plasma and 
tissue levels of IGF-I in tumour-bearing mice in relation to other metabolites 
as described in chapter 4.0. In the present study, there was no difference in 
plasma IGF-I between normal mice and control (tumour-bearing, but 
untreated with MPA) animals in the second week after induction of the 
tumour. Similar results were found by Macaulay and co-workers (Macaulay 
et al.. 1988b; Macaulav et al.. 1988c). In third week, plasma IGF-I levels in 
the control group were significantly reduced compared to the normal 
(P<0.05) and lower (although not significantly) than the test animals 
(tumour-bearing treated with MPA). The explanation for this is not clear. 
Plasma IGF-I levels are known to fall with reduced nutritional intake.
D’Ercole and co-workers, for example, reported a reduction in plasma IGF-I 
in rats fed on a low protein diet (D’Ercole et al.. 1984). However, in the 
current study, food intake was lowest in the third week in the test animals 
and there was thus no apparent correlation between food intake and IGF-I 
levels. Alternatively the fall in IGF-I could be related to the development of 
the tumour itself. Although the factors involved may not be identical, IGF-I 
production has been shown to be inhibited in human sepsis (Dan et al., 
1988) although the cause is unknown.
Growth factors regulate not only the replication and functional differentiation 
of cells; they may also act as systemic or local regulators of cell metabolism. 
Plasma levels of insulin -like growth factors may be affected in a variety of 
diseases. In tissues where IGF-I is produced and where it acts as an
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autocrine or paracrine regulator of cell function, local production of IGF-I 
may also be affected. In a number of tissues such as muscle and fat, the 
endocrine effects of IGF-I appear to be most important and the source of 
IGF-I in these tissues is mainly from the liver. Any disease affecting the 
synthesis of IGF-I in liver will also result in metabolic disturbance in these 
target tissues.
In the present study, the tissue IGF-I level was shown to be higher in the 
liver than in heart or muscle in all the groups. This is consistent with the 
findings of other investigators (D’Ecrole et al.. 1984; Yahya et al.. 1990). 
Expressed as unit per gram of wet weight of tissues, the kidney was found 
to contain almost the same amount of IGF-I as the liver. These results also 
agree with those of other authors (D’Ercole et al.. 1984; Macaulay 1988). 
Despite this high tissue content, the kidney is unlikely to make such a major 
contribution to plasma levels as the liver, since the weight of the liver was 
seven times the weight of the kidney. In addition, the liver functions as a 
storage organ in addition to synthesising many plasma proteins while the 
kidney is virtually lacking in these functions.
In the present study, IGF-I content in muscle was significantly reduced in 
both groups bearing the tumour compared to the normal group in the
second week. At the same time, muscle TNF-a was markedly increased in
the same groups. These findings indicate that a reduction in muscle IGF-I 
content is an early feature of the catabolic state. Low muscle IGF-I levels 
were accompanied by a low levels of IGF-I in the liver at the same time, and 
in the plasma one week later at a time when the animals were showing
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poor growth. This is consistent with the results of others (Kogawa et al.. 
1982; Murphy, 1987) who found that a fall in tissue IGF-I levels preceded a 
fall in the plasma level. In the third week muscle IGF-I level was increased 
when expressed as lU/gram. This may be explained by a reduction of 
muscle mass due to the catabolic state rather than an increase in IGF-I 
content in the muscles as a whole.
As discussed above, the low IGF-I content in the liver and muscle does not 
appear to be due to a reduction in nutrition since food intake was not 
significantly reduced at that period. It is tempting to speculate that the rise
in muscle TNF-a (see Chapter 6.0) may be causally related to the fall in
IGF-I level although such an association has not been described previously. 
However, such a relationship does not explain the reduction in liver IGF-I
since there was no parallel rise in liver TNF-a; indeed, there was a fall in 
liver TNF-a in week three in the test group of animals.
In the present study the glycogen content of the muscle in the control group 
was reduced compared to the normal group. This consistent with the results
of other investigators who incubated TNF-a with muscles and observed that
glycogenolysis was increased (Lee et al.. 1987). These findings suggest 
the reduction in the glycogen contents may be due to the catabolism of the 
skeletal muscles (Torti et al.. 1985). The combination of a high level of TNF-
a and a low IGF-I in the muscles could be the main factors which 
predispose to a reduction in muscle mass which, in turn, contributed to the 
decrease in body weight in tumour- bearing the mice when compared to the
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normal animals. Although Jacob and co-workers reported that IGF-I is an 
anabolic factor in severe catabolic states (Jacob et al., 1989), this may 
depend on the severity of the condition, with the anabolic effects of IGF-I
unable to overcome the catabolic effects of other factors such as TNF-a in
more severe conditions.
In the present study the IGF-I contents of the tumour tissues were not 
consistent in the test group or the control group and had no relation to the
TNF-a and IGF-I levels in tissue and plasma, or the observed changes in
body weight.
It is possible to postulate an interaction between TNF-a and IGF-I in the
septic state since TNF-a is bound to high affinity receptors in many tissues
including liver, lung, kidney, muscle and intestine (Bachouche et al.. 1988; 
Kriegler et al.. 1988), at the same time, these tissues contain IGF-I either 
synthesised locally or transported from an endocrine source.
The metabolic adaptation which occurs during starvation or cachexia 
includes increased catabolism. Sullivan and co-workers postulated that the 
reduction in plasma IGF-I associated with starvation might be a permissive 
metabolic response in starvation (Sullivan et al., 1989). The same
postulation with the effect of TNF-a can be applied to cachexia associated
with cancer.
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5:8 Conclusions of Chapter 5.0
Plasma IGF-I levels in the control group were significantly reduced in the 
third week of the study compared to the normal animals. These results 
support the concepts that the liver remains the main source of endocrine 
IGF-I whether in normal, control or the test animals with possible 
contribution from other organs such as kidney and lung.
Insulin-like growth factor-1 concentration in the tumour tissues were not 
consistent in both groups (control and test) of animal bearing tumour.
A low IGF-I level with a high TNF-a level in muscle could be the main factor 
which predisposes to catabolism of the skeletal muscle and hence a 
reduction in muscle mass. In a severe catabolic state, the anabolic effects of 
IGF-I cannot overcome the catabolic effect of other factors such as tumour 
necrosis factor alpha.
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Chapter 6.0
The Control of IGF-I Secretion by a Hepatoma Cell Line
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6:1 Introduction
It has been concluded from a numbers of studies described previously in 
Chapters 1-5, that the liver is the major source of IGF-I in the circulation. 
Therefore, the study of the nutritional and hormonal factors which influence 
synthesis and secretion of IGF-I from liver cells may provide a good model 
to investigate the factors which control IGF-I secretion.
Previous investigators have used isolated livers from hypophysectomised 
rats to investigate the effects of insulin and growth hormone on the release 
of IGF-I (Daughaday et al.. 1976), while Scott et al.. (1986) used 
hepatocytes cultured from diabetic and insulin-treated diabetic rats to study 
the production of IGF-I and its binding proteins.
The synthesis of plasma proteins, a specialised function of liver 
parenchymal cells, has been studied in vitro in liver slices from 
experimental animals (Peters, 1973), in suspension and in primary cultures 
of isolated hepatocytes (Jeejeebhoy et al.. 1975; Crane et al.. 1977 ), and 
in hepatoma-derived cell lines (Tsukada et al.. 1974; Bernhard et al..
1973). In the present study, the human hepatoma cell line HEP G2 was 
used to produce IGF-I.
6:1:1 The Human Hepatoma Cell Line HEP G2 
The human hepatoma cell line (HEP G2) secretes several major plasma 
proteins including albumin, a- fetoprotein, a2-macroglobulin, p-lipoprotein, 
retinol-binding protein and others (Knowles et al.. 1980).
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Povoa et al.. (1985), used serum-free medium conditioned by the human 
hepatoma cell line HEP G2 to isolate the IGF-I binding-protein. They 
observed a binding protein with a molecular mass of about 35 kDa in the 
condition media. Aliquots of serum-free medium from HEP G2 cells were 
taken at 4, 8 , 12, 16, 20, 24, 36, 48, 72, and 96 hours in order to determine 
the time course for the release of the immunoreactive somatomedin-binding 
protein. The concentration of immunoreactive somatomedin-binding 
protein increased continuously from 109 ng/ml at 4 hour to 684 ng/ml at 36 
hours. Thereafter the concentration decreased and was 345 ng/ml after 96 
hours (Moses et al.. 1983; Povoa et al.. 1985). The human hepatoma cell 
line HEP G2 offers a potential model for the study of the regulation of the 
synthesis and secretion of IGF-I.
The HEP G2 cell line was initially derived from tissue minces of hepatoma 
biopsies placed on feeder layers of the irradiated mouse cell line STO 
(Martin et al.. 1975) in William's Eagle medium supplemented with 10% 
fetal bovine serum. This method of isolation promotes the growth of cells 
that have fastidious requirements while preventing fibroblastic overgrowth. 
After an initial period of apparent cell proliferation, growth was restricted to 
single colonies that were maintained in flasks for several months. Cells 
from flasks containing single large colonies were dissociated by 
trypsinization (0.25% trypsin, 0.1% EDTA in phosphate buffer saline) and 
transferred to new feeder layers, eventually producing proliferating cell 
lines that have now been serially passage more than 50 times. Sublines of 
HEP G2 have been selected for feeder independence. These cell lines 
resemble liver parenchymal cells morphologically. This cell line contains
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distinctive rearrangements of chromosome 1. When HEP G2 was injected 
under the kidney capsule of athymic (nude) mice, no tumours were 
observed.
6:1:2 Factors Which Control the Secretion and Synthesis 
of IGF-I in Liver.
The ability of bovine growth hormone, at a concentration of 10 pg/ ml,
added to perfusates of isolated normal rat liver to stimulate the release of 
somatomedin-like activity has been reported (McConaohev et al.. 1969; 
McConaghey, 1972). In these experiments, the somatomedin-like activity 
was assayed on hypophysectomised rat cartilage.
The possible inter-relationship between insulin and growth hormone in the 
regulation of somatomedin release has been studied by a number of 
authors. Daughaday et al.. (1976) used isolated livers from 
hypophysectomised rats. The experiment continued for 6 hours during 
which the serum-free medium was changed every 30 minutes. They
reported that the addition of insulin 100 pU/ml with growth hormone was
without significant effect while the addition of insulin 1000 pU/ml with
growth hormone led to a significant stimulation of somatomedin release. 
Meanwhile the addition of each hormone separately had no significant 
effect (Dauchadav et al.. 1976).
Growth hormone and prolactin are structurally homologous and have 
functional similarities in mammals. Prolactin in concentrations as low as 50
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ng/ml ( In Waymouth’s medium) was capable of stimulating the release of 
somatomedin-like activity from perfused normal rat liver (Francis et al.. 
1975; Schalch et al.. 1979).
Blood levels of IGF-I increase in well-nourished animals and are low in 
children with protein-calorie malnutrition compared to normal children of 
the same age (Grant et al.. 1973; Hintz et al.. 1978). Circulating IGF-I levels 
are also reported to be low in starved rats (Phillips & Young, 1976) and 
during fasting in normal humans volunteers (Clemmons et al.. 1981). This 
may be due to decreased mRNA for IGF-I, which is restored on refeeding.
6:1:3 Interaction of Cytokines and Growth Factors 
The modulation of cytokine or growth factor actions may offer new 
strategies for limiting the loss of weight in cancer patients or other diseases 
such as severe infections. Cytokines (e.g;- interleukin 1 alpha, interleukin 1
beta, and tumour necrosis factor -a) inhibit proteoglycan biosynthesis in a 
dose-dependent manner. By contrast, the growth factors (IGF-I and 
transforming growth factor beta) have the opposite effect to the cytokines in 
that they increase the synthesis of proteoglycan (Hardingham et al.. 1992).
Bertolini and co-workers (1986) reported that human tumour necrosis 
factors (alpha and beta) stimulated bone resorption and inhibited bone 
formation while insulin-like growth factors stimulate the incorporation of 
sulphate into cartilage (Salmon & Daughaday 1957).
It has been reported that injections of recombinant cytokines into normal
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animals can cause tissue wasting. Furthermore, the suppression of 
cartilage-specific phenotype induced by IL-I (Tyler & Benton, 1988 ) can be 
reversed by incubation of chondrocytes with IGF-I. (Tyler, 1989; Tyler,
1988). Raised serum levels of TNF-a have been observed in cachetic
patients with cancer (Beulter et al.. 1988). It is, therefore, possible to 
speculate that, in the presence of cancer, there may be an interaction
between IGF-I and TNF-a, the net result of which is to produce severe
wasting.
6:1:4 Measurement of IGF-I in tissue culture medium 
Acid-ethanol extraction of plasma and other biological fluids has been extensively 
used for the dissociation and precipitation of binding proteins prior to IGF-I assay. 
More elaborate procedures for cleaning up samples, involving acid gel filtration 
and gel permeation with high performance liquid chromatography, were 
recommended for effective removal of the IGF-binding proteins (Mesiano et 
al.,1988). Bruce et al (1991) compared the acid ethanol extraction and gel 
filtration processing steps prior to immunoassay of IGF-I sheep plasma. They 
found that the IGF-I values obtained by the acid -ethanol extraction correlated 
closely (P<0.001) with the corresponding values derived after gel filtration.
In the present study, IGF-I in the cell culture medium was measured by 
radioimmunoassay. Both the acid-ethanol extraction and the gel filtration of the 
medium were carried out before the immunoassay in order to assess the 
interference of IGF-binding proteins. Gel filtration of radiolabelled IGF-I was also 
carried out in parallel and the eluent fractions monitored for radioactivity.
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6:2 The Aim and Description of the Experiment
In this experiment, the role of nutrition and hormonal factors (human growth 
hormone, insulin, tumour necrosis factor-alpha, medroxyprogesterone and 
cortisol) individually and in combination were studied by adding these 
hormonal factors with medium to culture dishes containing cells from the 
human hepatoma cell line HEP G2.
Undernutrition was simulated by reducing the glutamine content of the 
medium. The normal medium (with normal nutrition) alone was regarded as 
the control group. The effect of the hormonal factors and nutrition on the 
hepatoma cell line HEP G2 was investigated by measuring the IGF-I 
secreted by the cells, and by calculating the number of cells in each group 
by the end of the experiment.
Having obtained significant result from this experiment, the entire 
experiment was repeated on a further occasion to confirm these results.
6:3 Materials & Methods
6:3:1 Materials
Dulbeco's Modified Eagle Medium (DMEM) and fetal calf serum (FCS) was 
supplied by GIBCO BRL, Life Technologies Ltd., Paisley U.K. For the 
contents of the medium see Table 4:1.
Liver cell line HEP G2 ~ 5x10^ cells/ vial with dimethylsulphoxide (DMSO) 
under liquid nitrogen, a gift from Dr. R. King , Imperial Cancer Research 
Fund, School of Biological Sciences, University of Surrey, Guildford, UK.
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Trypsin, versene, and glutamine supplied by Sigma Chemical Company 
LTD. Poole, Dorset, England.
Sterile 9 cm diametre tissue culture dishes, sterile capped centrifuge tubes, 
and sterile pipettes 5 ml and 10 ml.
6:3:2 Preparation of Medium
The following solution was prepared
The DMEM with 10% fetal calf serum (PCS) at 37°C.
Trypsin solution, 2.5 g /L.
Versene solution, 2.5 g /L.
6:4 Experimental Procedures
6:4:1 Day 1 ; Removing Cells from Liquid Nitrogen 
The cells (4 vials) were removed from liquid nitrogen and placed 
immediately in a small beaker in a 37®C water bath. Cells were thawed, 
mixed by sucking up in a pipette and transferred (the content of 4 vials) to 
80 ml of media and distributed into 8 dishes, and kept in a incubator at 
37OC.
6:4:2 Day 2; Changing the Medium 
Method
The medium was aspirated from the culture dishes to remove dead cells 
and dimethylsulphoxide. Warm medium (10 ml) 5% PCS was added to
each dish and incubated at 37®C.
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Table 6:1 Synthetic Culture Media Component Dufbeco’s 
Modified Eagle Medium
Inorganic salts & other mg/L Amino acids mg/L
Cacl_2. 2H2Ü 264 L-glutamine 584
Fe(No3)2.9H20 0.1 Glycine 30
KOI 400 L-histidine 42
MgS04.7H20 200 L-lsoleucine 105
NaCI 6400 L-Leucine 10
NaHCOa 3700 L-Lysine 146
NaH2P04.2H20 141 L-Methionine 30
D-Glucose 4500 L-Phenylalanine 35
Phenol red 15 L-Serine 42
Folic acid 4 L-Threonine 95
Vitamins L-Tryptophan 16
6:4:3 Day 4; Harvesting the Cells 
Method
The medium was aspirated from the 8 culture dishes. The culture dishes 
were then washed with 2 ml trypsin/ versene (1:4) to wash off the medium. 
Trypsin and versene (2 ml) were added to each dish, and incubated at 
37^0 until the cellular matrix was digested by trypsin ( until the cells formed 
a single cell suspension under the microscope). A cell suspension was
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made using a Pasteur pipette. The medium containing cells (16 ml) were 
centrifuged at 800 revolutions per minute (RPM) for 3 minutes, medium was 
aspirated and the cells (the contents of 8 dishes) resuspended in 10 ml 5% 
PCS.
6:4:4 Calculating the Number of Cells 
Materials
Haemocytometer and cell count sheet provided by ICRF.
Inverted microscope (Leitz Germany).
The medium containing the cells to be counted.
Methods
Drops of the medium were placed into a haemocytometer and cells were 
counted under the microscope. Four squares were counted, the average
was taken and multiplied by 10^ to obtain the cell number /ml.
The number of cells /ml = 8x10^. The amount of medium = 10 ml. The total
number of cells = 8x10^ X 10 =8 x 10®.
6:4:5 Subculturing the Cells:
The cells were suspended in Eagle medium with 5% PCS and distributed 
into culture dishes, incubated at 37®C and left for 5 days. The number of 
cells per plate = 4X10^.
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6:4:6 Day 9; Medium Renewal & Addition of Hormones to Dishes 
Materials
RPM! 1640 medium without glutamine and insulin supplied by GIBCO BRL, 
Life Technologies Ltd., Paisley, U.K.
Tumour necrosis factor-a, somatotrophin ( human growth hormone) and
hydrocortisone 21- hemisuccinate sodium salt (cortisol) supplied by Sigma. 
Medroxyprogesterone acetate was kindly supplied by Dr. Rostom,St Lukes 
Hospital Guildford, U.K. For the contents of the dishes see table 6 :2.
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Table 6:2 The Content Of The Dishes
Dish No No of cells per dish Nutrition T reatment
4 4 X 1 0 5 Normal hGH
4 4 X 1 0 5 Normal hGH+insulin.
4 4 X 1 0 5 Normal hGH+insulin +TNF-a
4 4 X 1 0 5 Normal hGH+insulin +cortisol
4 4 X 1 0 5 Normal TNF-a + MPA
4 4 X 1 0 5 Under nutrition Nil
4 4 X 1 0 5 Normal hGH+TNF-a + cortisol
4 4 X 1 0 5 Normal Nil
4 4 X 1 0 5 Under nutrition cortisol + hGH.
5 4 X 1 0 5 Normal insulin.
5 4 X 1 0 5 Normal TNF-a.
5 4 X 1 0 5 Normal insulin + TNF-a.
3 0 .0 Normal Nil
Preparing the Medium 
A number of different treatment mediums were made up (1-3) as below;
1) DOFOS was added to DMEM to make 5% DCFCS. Other working 
solutions are insulin /DW (100 ng /ml), hGH/DW (4 lU/ml), MPA /ethanol
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(390 ug/ml) and TNF-a / DW (3200 lU/mL). All medium contain glutamine
and red phenol. Medium without glutamine or red phenol were designated 
as -glutamine, -red phenol (- = without).
2) The following working media were prepared:
Medium Addition
2a)50 ml of 5% DCFCS. None
2b) 50 ml of 5% DCFCS 10 pi of insulin.
2c) 50 ml of 5% DCFCS 50 pi of hGH.
2d) 50 ml of 5% DCFCS 10 pi of insulin + 50 pi of hGH.
2e) 50 ml of 5% DCFCS 50 pi of TNF-a
2f) 50 ml of 5% DCFCS 50 pi of TNF-a +10 pi of insulin
+50 pi of hGH.
2g) 50 ml of 5% DCFCS 50 pi of TNF-a +10 pi of insulin.
2h) 50 ml of 5% DCFCS - glutamine - phenol red
2j) 50 ml of 5% DCFCS 5o pi of hGH + cortisol+50 pi of TNF-a.
2k) 50 ml of 5% DCFCS - phenol red.
21) 50 ml of 5% DCFCS 50 pi of TNF-a,+25 pi of MPA in ethanol.
3) All the media were warmed at 37®C.
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Methods
The media from the culture dishes was aspirated and a medium prepared, 
as shown above was added to the culture dishes which had been allocated 
randomly for different hormonal factors as shown in table 6:2. All dishes
were incubated at 37®C.
In day 11 and day 13 the same above procedure was carried out on all 
dishes. Medium ± glutamine ± hormone(s) were added to the specific tissue 
culture dishes after aspirating the old medium from the dishes. Cells left to 
grow in DMEM + 5%FCS to sub-confluence. When the HEP G2 cell line 
had grown to confluence, the medium was replaced with 10 ml of DMEM + 
1% DCFCS.
6:4:7 Day 14: Addition of Conditioned Medium 
Materials
1- Fibronectin supplied by Sigma, stored at -20®C.
2- Transferrin supplied by Sigma, stored at +4®C.
3- HEPES, supplied by Boehringer; Mannheim, Germany.
Preparing the solutions:
The following solutions were prepared
1- Transferrin 5 mg/ml in DW.
2- Fibronectin 0.75 mg/ml in DW.
3- For working solution (medium without FCS) the following were added:- 
1M HEPES (1:100), final concentration = 10 mM.
Transferrin 1 mg / ml ( 1:1000). Final concentration = 1 pg/ml
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Fibronectin 0.75 mg / ml (1:1000).
Final concentration = 0.75 pg /ml.
Methods
After 24 hours of treatment with 1% DCFCS, the medium (3 ml) was 
changed to RPMI + 10 mM HEPES + transferrin+ fibronectin. After 24 hours 
the cell medium (3 ml) was collected and centrifuged briefly to remove
cellular debris. The collected conditioned medium was stored at -70®C.
At the end of experiment the condition medium (3 ml) was lyophilised by
freeze drying (to concentrate the hormone), reconstituted into 300 pi IGF-I
assay buffer and assayed for IGF-I content (see figure 6:1). The method 
used for the analysis of IGF-I was described previously in section 2:4:10.
The procedure in sections 6:3:1- 6:3:7 was repeated for the second 
experiment in which the same hormonal and nutritional factors were added 
to the the human hepatoma cell line HEP G2.
6:5 The Number of Cells at the End of the Experiment 
6:5:1 Principle;
Cells were lysed using Zaponin, and nuclei counted using a Coulter 
Counter.
6:5:2 Materials & Methods
Hepes 1M, MgCl2 (5mM), isoton, Zaponin* and Coulter Counter* model ZM
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( * = supplied by Coulter Electronics LTD Northwell Drive, Luton Beds UK.) 
After the condition medium had been collected for IGF-I analysis, all dishes 
were washed twice with phosphate buffer (2 ml ) and aspirated to clean the 
medium. Hepes 2 mM (2 ml) with 1.5 mM MgCl2 was added, + 4 drops of 
zaponin. After 10 minutes the cells were mixed thoroughly until all the cells 
were lysed. 500 pi of Hepes containing the cells was mixed with 20 ml of 
isoton. 100 pi of this solution was taken to calculate the cells.
The No of cells in each dish = The No X800.
6:6 Hormonal Assessment
In order to assess the concentration of GH in the medium following its 
addition to the culture, medium was aspirated from the cells. Fresh medium 
was added, and aspirated after incubation for 48 hours. GH concentration 
was measured in this second aspirate and compared with the concentration 
in the fresh medium.
6 :6:1 Method
The concentration of the hGH added to the condition medium was 
assessed in a fresh medium (when added to the dishes) and after the 
medium was aspirated so as to calculate the disappearance of hGH.
6:7:1 Calculating the Recovery of IGF-I.
This method is designed to calculate any loss of IGF-I resulting from the 
freeze drying procedure and the reconstitution of the dried powder with IGF- 
I assay buffer.
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6:7:1:1 Materials
IGF-I pure standard, 2.5 pg/20 pi in phosphate buffer, supplied by Royal 
Surrey County Hospital. Condition medium 
Freeze dryer (Edwards, Modulyo)
6:7:1:2 Methods
Pure IGF-I standard of various concentrations were dissolved in IGF-I assay 
buffer and in condition medium (0.2, 0.25, 0.4 and 1.0 U/ml). IGF-I in assay 
buffer was kept frozen at -70oC. The IGF-I in condition medium was diluted 
to a volume of 3 ml with condition medium, freeze dried, and reconstituted 
into 300 pi IGF-I assay buffer (Figure 6:1). All samples were assayed for 
IGF-I, and the recovery of the IGF-I was calculated (Table 4:3) by the 
following equation.
Recovery = IGF-I / condition medium X 100 
IGF-I/ assay buffer
Table 6:3 The recovery of IGF-I
IGF-I/assay buffer IGF-I/condition medium Recovery
U/ml U/ml %
1.0 0.87 87
0.4 0.37 90
0.25 0.19 76
Mean recovery — 84
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6:7:2 Acid Gel Filtration of Extracted Tissue Culture Medium 
This gel filtration method was based on those of Bruce et al., (1991) and Holly 
1993 (personal commmunication). A column (1x100 cm) was packed with 
Sephadex G50 (Pharmacia Fine Chemicals, Sweden) swollen in distilled water. 
After generation of the column by adding 20 ml of 1M acetic acid at a flow rate of 
8ml/hour, dextran blue (2000 kDa) was added to assess the void volume. The 
column was then washed with 1M acetic acid to remove any trace of dextran blue. 
The molecular mass standards were a recombinant 27 kDa heat shock protein 
(HSP27) (a gift from Dr. R King, School of Biological Sciences, University of 
Surrey) and labeled IGF-I (7.5 kDa). HSP27 was chosen because its size 
approximates to that of IGF-binding proteins1-3. A pure IGF-I standard (Peninsula 
laboratories INC), extracted human plasma and extracted TCM mixed with dextran 
blue and HSP27 were chromatographed, the fractions collected and 
subsequently assayed for IGF-I immunoreactivity. In separate runs, ‘•25| labelled 
IGF-I was mixed with dextran blue, chromatographed and the radioactivity 
measured in the column fractions. HSP27 was kindly measured by Dr. R. King 
using an immunoblotting technique (Dunn et al., 1993). These chromatographed 
samples have been run twice.
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Figure 6:1 Method for concentrating IGF-1 in the condition 
medium and the process of calcuiating recovery 
of IGF-1
Concentration
Condition medium 
3.0 ml
kept at -70 0
t
Freeze dried
reconstituted into 
300 pi assay buffer
Control
Pure IGF-1 in 
assay buffer 300pl
t
iCid-ethanol extraction
Neutralization 
with 10% Tris
îF-1 measurement
IGF-1 measurement
Recovery
Pure IGF-1 in assay 
buffer 300pl + 2.7 ml 
condition medium
kept at - 70 C
Freeze dried
reconstituted into 
300 pi assay buffer
t
Acid-ethanol extraction
Neutralization 
with 10% Tris
IGF-1 measurement
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6:8 RESULTS
The protocol of this experiment was performed twice with consistent 
results. The serum-free medium conditioned by the human hepatoma 
cell line HEP G2 ± hormonal factor(s) was found to contain considerable 
amounts of IGF-I. The number of cells at the end of experiment was 
calculated.
6:8:1 IGF-I Released by the HEP G2 Cells Treated with 
Hormonal Factors.
The results in Table 6:4 indicate significant reductions in the synthesis of 
IGF-I content of dish culture containing TNF-a alone ( P <0.02) or both
TNF-a and insulin (P<0.05). There is no significant change in dishes
containing insulin alone compared to the dishes containing the medium 
only.
The experiment showed in Table 6:5a was performed twice. The first and 
second experiments gave almost consistent results. The results indicate 
that there was no significant change in dishes containing hGH 
compared to the dishes containing the medium only. There was a 
significant increase in the synthesis of IGF-I in culture dishes containing 
both hGH and insulin (P<0.01). But this significant increase was
abolished by adding TNF-a to hGH and insulin. The results also show a
highly significant decrease (P<0.001) in IGF-1 content of dishes that 
received less glutamine. The IGF-I content of the three dishes containing 
the medium only without HEP G2 cells was almost zero (results not 
shown).
197
The results (Table 6:5b) indicate that there was no significant difference 
between the amount of IGF-I synthesised by one million cells in condition 
medium whether there was hGH alone, or hGH + insulin or hGH + insulin
and TNF-a.
The results (Table 6 :6) indicate that there was a reduction (not statistically 
significant) in the number of cells in dishes containing TNF-a alone 
compared to the dishes containing the medium only (Control). The addition 
of MPA to the dishes containing TNF-a was without significant effect.
When the experiment was repeated (results not reported here) the only 
difference between the two experiments was that there was a significant
reduction in the number of cells in all dishes whether treated with TNF-a 
alone or with both TNF-a and MPA when compared to the control group.
6:8:2 The Number of Cells at the End of the Experiment 
In the present study the ability of these factors to increase the number of 
cells was also studied (Figure 6:2). Human growth hormone (Figure 6:3b) 
added to the DMEM containing HEP G2 significantly increased (P<0.05) the
number of cells (from 4 X10^ cell per dish to 10.04 ± 1.13 x 10^, compared 
to the control 6.09 ± 0.45 X 10® mean ± SEM (see figure 6:3a). With the 
combination of hGH and insulin (Figure 6:3c) a highly significant increase 
in the number of growing cells (to 15.79 x 10®). The combination of hGH , 
insulin and TNF-a (Figure 6:3d) produced no significant change (increased
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to 9.99± 1.4 X 10®). Although in dishes with less glutamine (malnourished),
see figure 6;3e, the number of cells increased from day one (from 4X10®
cell to 7.5 X I0®), there was nevertheless a highly significant reduction in
the number of growing cells compared to the control group. When TNF-a
and medroxyprogesterone were added to the medium there was a slight 
decrease (not significant) in the number of cells. The addition of hGH +
TNF-a and cortisol results in an increase (8.48 ±0.99 X I 0®) but this was not
statistically significant.
In the present study the addition of TNF-a to the medium resulted in a
significant decrease in the number of cells of the hepatoma cell line HEP 
G2 (Table 6:6, Figure 6:3f). Figures 6:3a-6:3f are photographs showing 
high magnification views of cells attached to the dishes. Note that dishes 
with hGH and insulin had high population of cells( dense cells) while those
with TNF-a or reduced glutamine had less cells (sparse cells) compared
with the control.
In the present study (Table 6 :6) the addition of MPA with TNF-a to the 
condition medium did not result in an increase in the number of the cells 
compared with the medium containing TNF-a, at the end of the study. This 
illustrates that the treatment with MPA is unable to antagonise the effect of 
TNF-a on liver cells.
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6:8:3 Growth Hormone Utilisation and Degradation 
The results showed in table 6:7 indicate that, there were no significant 
differences between the groups, although the hGH appears to have been 
utilised by cells treated with hGH+insulin to a greater extent than by those
cells being treated by hGH+ insulin + TNF-a.
6:8:4 IGF-I Immunoreactivity of the Fractions Collected after Acid 
Gel Filtration
The elution profile of gel acid chromatography of pure IGF-I disclosed two peaks of 
apparent IGF-I immunoreactivity both eluted after HSP27 (Figure 6:1:1, page 203). 
The first peak of higher molecular weight (A) and the second peak (B) constitute 
the bulk of im mu noreactive IGF-I. The same pattern was obtained when IGF-I 
was chromatographed and the radioactivity was measured in the column fractions 
(Figure 6:1:2). Plasma that had been acidified and centrifuged prior to 
chromatography also showed a similar elution profile (Figure 6:1:3) to that of pure 
IGF-I. Column chromatography of TCM after acidification and centrifugation 
(Figure 6:1:4) was similar to that seen with pure IGF-I and plasma but with two 
interesting differences. The peak (a1) was present in the same position as peak A 
(see above) but an additional small peak (a2), not seen previously, was observed 
with TCM. The major peak of activity (B) was eluted corresponding to a slightly 
higher molecular weight than that seen with pure IGF-I.
The recovery of IGF-I activity from the different preparations is presented in Table 
6:8 (Page211). In all cases, the bulk of the material was recovered in the low 
molecular weight peak. Apparent differences in the high molecular weight 
fractions are discussed in the next section (Page 215).
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Table 6:4 IGF-I In medium secreted by liver cells 
(ng per dish)
Treatment Mean SEM
Control 24.6 0.6
+insulin 22.4 1.1
+TNF-a 17.0* 0.3
+insulin + TNF-a 19.8* 0.8
Control dishes contain the celis + normal medium, + = control + other hormone. SEM =
standard error of the mean, * = (p<0.05) compared to the control. No of dishes = 4-5 dis
/ assay.
Table 6:5a IGF-I In medium secreted by liver cells
(ng per dish)
Treatment First experiment Second experiment
+hGH 22.5 ±0.49 18.6 ±4.5
+hGH+lns. 30.1*±1.10 26.7* ±3.2
+ hGH+lns+TNF-a 21.5 ±1.80 19.6±1.8
- glutamine 03.3**±0.01 11.0 *±4.8
control 23.0 ±1.20 19.6±1.1
Results expressed as mean ±SEM, * = p <0.05, ** = p<0.001,
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Table 6:5b IGF-I In medium related to the number of liver ce l ls
Treatment ng / dish ng / 106 cells
+hGH 22.5 ±0.49 
+hGH+lns. 30.1 ±1.10
+ hGH+lns+TNF-a 21.5 ±1.80
4.4±1.1 
3.9± 0.5
4.3 ±0.4
Results expressed as mean ± SEM.
Table 6:6 The effect of MPA on HEP G2 cells
Treatment Contents of dish No of cells IGF-I (ng / dish)
Control Medium only 6.09 ± 0.45 x 10®. 23.0 ±1.2 
TNF-a M +TNF-a 3.31 ± 0.73 x 10®*. 16.4 ±3.2 
MPA+TNF-a M+TNF-a + MPA 5.14± 0.47 x 10®. 18.0±2.7
Results expressed as mean ± SEM, M= medium, MPA =medroxyprogesterone acetate, 
*= p<0.05.
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Figure 6:1:1 (Below) Elution profile of gel filtration of pure IG F -I standard 
immunoreactivity, 500 |il of 100 ng/ml. Column Ix  100cm. Buffer IM  acetic 
acid+0.05% BSA. Flow rate 7 ml/hour for 8 hours. Integrated area under the
E
TO
u.
(D
curve A= 6.7 ng and B= 31.5 ng.
8
6
HSP(27kDa)
4
Dextran blue
2
0
301 0 20 40 50 600
Fractions (ml)
F igure 6 :1 :2  (Blelow) Elution profile of gel filtration of 
labeled IG F -I radioactivity. Column as Figure 6:1:1.
Integrated area under the curve A= 1105 CPM and B = 19030 CPM.
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S  2000
Dextran blue
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3010 20 40 50 600
Fractions (ml)
203
Figure 6:1:3 (Below) Elution profile of gel filtration
of extracted plasma (500 ul) IGF-I immunoreactivity. Column as 6:1:1.
Integrated area under the curve A = 35.2 ng and B = 86.4 ng.
10 -I
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<D
30 40 6020 50100
Fractions (ml)
Figure 6:1:4 (Below) Elution profile of gel filtration of 
1 ml extracted tissue culture medium (34 ng/ml.) IGF-I immunoreactivity 
Column as Figure 6:1:1. Integrated area under the curve al+ a2 = 11.7 ng
and B= 19.7 ng.10
8
6
O) HSP(27kDa)
Dextran blue
2
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30 4020 50 601 00
Fractions (ml)
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Figure 6:2 The Effect of Various Treatm ent on 
HEP G2 Cell Number
20 - I
15 -
10 -
Results expressed as mean, bar =±SEM, *=P<0.05,**=P<0.001 
M=control, G=hGH, ins=insulin, T=TNF-a, -glu= -glutamine.
hGH G+ins G+ins+T
Content of dishes
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Table 6:7 The concentration of hGH In fresh medium and in 
medium aspirated from dishes after 48 hours incubation.
Treatment Control +hGH
mU/L mU/L
+GH+ins. +GH+ins.+TNF-a. 
mU/L mU/L
Freshly prepared 1.1 22 ± 2.0 
After aspiration 2.2 18.8 ±1.3
22 ± 2.0 22 ± 2.0 
15.5±2.4 20.2 ±1.6
Results expressed as mean ± SEM, +GH= dishes treated with hGH, +GH+ins.= dishes 
treated with hGH+insulin, GH+ins.+TNF-a= dishes treated with hGH + insulin + TNF-a.
Table 6:8 Recovery % of Original Activity
of the Acid Gel Filtration (Figure 6 :1:1-6:1:4)
Radioactivity immunoreactivitv
Chrom. peak 2^5( |Qp_| pure IGF-I Plasma Conditioned medium
High MW (A) 06 13 
Low MW (B) 86 63
22 35* 
58 58
Chrom. peak = chromtographed peak, * = combined a1 +a2.
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6:9 Discussion
In the research for human cells releasing IGF-I or IGF- binding proteins, 
Moses et al.. (1983), observed that medium conditioned by the human 
hepatoma cell line HEP G2, contained considerable amounts of proteins 
with capacity to bind somatomedins. Povoa et al.. (1985) isolated 
somatomedin-binding proteins from the human hepatoma cell line HEP G2. 
Since these cells are of human origin, they offer a source to study the 
factors which control the synthesis and release of IGF-I. In the present 
study, the human hepatoma cell line HEP G2 was used to study the 
hormonal and nutritional factors which control IGF-I synthesis and release 
from liver cells.
In the present study, insulin and hGH significantly increased IGF-I synthesis 
in the hepatoma cell line HEP G2 when compared with the control (cells + 
medium alone). The ability of hGH and insulin to stimulate the release of 
IGF-I from isolated liver has been reported (Dauohadav et al.. 1976). The 
failure in the present study of either hGH or insulin when given separately 
to increase release of IGF-I is consistent with the findings of other 
investigators (Daughaday et al.. 1976; Schalch et al.. 1979).
The endocrine abnormalities detected in anti-TNF antibody-treated mice 
showed a decrease in IGF-I serum levels (Kossodo et al.. 1992). This 
finding was associated with normal GH level without malnutrition. In 
addition, the animals showed no sign of hepatic disease, which can cause 
decreased IGF-I production (Kossodo et al.. 1992). Thus, it appears that
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TNF-a influences the somatotroph axis through mechanisms which are not 
yet understood.
In the present study the addition of TNF-a counteracted the ability of both 
insulin and hGH to enhance IGF-I production. This has not been previously 
described. However, the three factors together (insulin, hGH and TNF-a) 
had no effect on IGF-I synthesis by HEP G2 when compared to the control 
group.
In the present study, TNF-a alone has been shown to decrease cell number 
rather than IGF-I production from individual cells by the end of the 
experiment. This demonstrated that TNF-a may play a role in suppression 
of the regenerating liver cell (± other organs). This may explain one of the 
mechanism by which TNF-a may complicate weight loss. The association of
weight loss with tumour secreting TNF-a has been reported by Oliff et al., 
(1987).
In hepatocytes, TNF-a enhances the production of acute phase protein and
accelerates glucagon mediated amino acids uptake (Warren et al.. 1987).
In the present study, TNF-a appears to counteract the stimulatory effect of
both hGH and insulin on liver cells to release IGF-I. The finding of Warren et 
al., (1987) along with our finding in this study may explain the mechanisms 
of hormonal regulation of both anabolic and catabolic response to acute
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injury or sepsis. The outcome will shift the liver (and possibly other organs) 
from synthesis of growth or transport proteins to mainly defence proteins as 
an adaptation to the abnormal to either infection or cancer. As a
conclusion, the main effect of TNF-a on metabolism is probably an indirect
one.
The reduction of IGF-I in undernourished cells in the present study 
compares favourably with the findings of other workers for example Miura et 
al., (1992) who investigated the effect of quantity and quality of dietary 
proteins on plasma immunoreactive IGF-I, and content of IGF-I mRNA in rat 
liver. Plasma immunoreactive IGF-I concentration in rats given a casein diet 
was higher than that in rats given a protein-free diet. Their results also 
showed that IGF-I mRNA decreased significantly when rats were fed on the 
protein-free diet.
In the present study the influence of these factors on the number of cells 
was also studied. Human growth hormone increased the number of cells, 
hGH and insulin highly significant increased the number of growing cells.
The combination of hGH, insulin and TNF-a produced no change.
Although in dishes with less glutamine (malnourished), the number of cells 
increased from day one, this resulted in a significant overall reduction in the
number of growing cells compared to the control group. When TNF-a and 
medroxyprogesterone were added to the medium there was a slight 
decrease in the number of cells. The addition of hGH + TNF-a and cortisol 
resulted in considerable increase in the number of cells.
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In the present study the addition of TNF-a to the medium resulted in a 
significant decrease in the number of hepatoma cell line HEP G2 cells. This 
is the first time that TNF-a has been shown to play a role in the suppression
of the regenerating of liver cells. Since the liver cell has a specific life span, 
this may result in a decrease in the number of functioning cells in the liver. 
Similarly the same effect may occur in other cells of the body where TNF-a 
suppresses growing cells. This may explain one of the mechanisms by 
which TNF-a may complicate weight loss. The association of weight loss
with tumour secreting TNF-a has been reported by Oliff et al.. (1987).
Concern about the effect removal of IGF-binding proteins by acid-ethanol 
extraction from TOM was addressed by comparing elution profiles following gel 
chromatogarphy of pure standard of IGF-I, TOM and plasma (for more details see 
page 193). The first chromatographic peak (A) obtained with pure IGF-I (Figure 
6:1:1) probably represents aggregation of IGF-I leading to a products of molecular 
weight less than 27kDa. This pattern, seen in conjunction with that derived from 
125|-ig F-I (Figure 6:1:2) suggests that the larger peak B is due to 7.4 kDa IGF-I. 
This component B also accounted for 58% of the IGF-I immunoreactivity of the 
human plasma (Figure 6:1:3).
TOM, on the other hand, showed two “high molecular weight” peaks a1+a2 
(Figure 6:1:4), but like plasma a large proportion of the immunoreactivity 58% 
(Table 6 :8) was located in fraction B. In the case of TOM, fraction B eluted slightly 
earlier than those from plasma and pure IGF-I. This may not be significant,
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however, because the same difference between runs also occured with dextran 
blue.
The present study, therefore, indicates that a substantial part of IGF-I measured by 
radioimmunoassay in the unchromatographed acid/ethanol of the tissue culture 
medium (Tables 6:4-6:6) was due to7.4 kDa IGF-I. On the basis of the molecular 
weight, the other fractions a1 and a2 are unlikely to be the known IGF-binding 
proteins. While some minor contribution from such binding proteins cannot be 
totally ruled out, one likely source for these larger peptides in the TOM could be 
incomplete processing of IGF-I. Larger precursor forms of 7.4 kDa IGF-I have been 
reported (Goldstein & Phillips 1991). A 18-19 kDa form of IGF-I with 
immunological and biological properties similar to circulating IGF-I was 
demonstrated in the rat liver (Goldstein & Phillips 1991). Similarly, cells in culture 
were shown to secrete a large form of IGF-II (Lee & King.,1994).
6:10 Conclusion of Chapter 6.0
The study described in this chapter was undertaken to evaluate the factors 
which control the release of IGF-I by human hepatoma cell line G2. The 
results indicated that both insulin and hGH increased significantly synthesis 
of IGF-I by these cells, while the addition of insulin and hGH separately was 
without significant effect. The addition of tumour necrosis factor to both 
insulin and hGH counteracted or abolished the ability of both insulin and 
hGH to increase the synthesis/release of IGF-I by the human hepatoma cell 
line. The amount of IGF-I released correlated to the number of the cells at 
the end of the experiment. The reduction of glutamine resulted in a 
significant reduction of IGF-I release by these cells.
216
Chapter 7.0
General Discussion and Overail Conclusions
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As reviewed in Section 1:1, the exact cause of weight loss and the 
development of cachexia in patients with cancer is frequently unclear. The 
syndrome is not simply the result of semi-starvation alone, but represents a 
complex and almost certainly multifactorial problem. A wider study of the 
role of nutrition and growth factors has therefore been undertaken in order 
to gain better understanding of the relationship between these elements in 
the development of cancer cachexia. Detailed study of the metabolic 
factors involved is difficult in human subjects for obvious reasons and in 
this thesis, a range of experiments carried out in several different systems is 
described. Experiments were conducted:
1- In patients with malignant disease.
2- In animals bearing Lewis lung tumour.
3- In tissue culture using the human hepatoma cell line HEP G2.
A further objective of the work was to investigate the reported efficacy of 
medroxyprogesterone acetate (MPA) and to attempt to elucidate the 
mechanisms which underlie the clinical improvement which has been 
described with its use.
Cancer cachexia is characterised clinically by anorexia, weight loss, 
anaemia and marked asthenia. Previous studies have investigated 
changes in the activity of the host tissue enzymes, in endocrine 
homeostasis and in immunological mechanisms. The underlying 
relationship between loss of appetite and weight loss and some of the 
endocrine and related factors has also been studied.
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The major question which this thesis attempts to address is whether it is 
possible to define a relationship between nutrition, growth factor and 
cancer cachexia.
7:1 Anthropometeric and Blood Changes in Cancer 
Patients Losing Weight
The clinical study described in chapter 2 and 3 demonstrated that in 
addition to poor appetite and weight loss, cancer cachexia is associated
with low levels of serum IGF-I, and high levels of TNF-a. Levels of growth
hormone and cortisol were also relatively high.
Anorexia is a frequent symptom in cancer patients and is clearly one of the
major determinant of cancer cachexia (Theologides 1979). However, the 
precise mechanism underlying the development of anorexia is unknown. 
Many factors are known to influence eating behaviour and to cause loss of 
appetite. These include lesions in lateral hypothalamus (Anand & Brobeck 
1951), systemic administration of drugs (e.g., amphetamine), hormones 
such as glucagon, adrenaline (Penick & Hinkle 1963), and cholecystokinin 
(Defry et al.. 1975). Infusion of lactic acid also causes anorexia and nausea 
(Pitts & McClure 1967). However, none of these factors has been shown to 
be of particular importance in cancer patients.
In the research for circulating factors which may be involved in modulating
the metabolic changes underlying weight loss, a variety of host-derived and
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tumour cell products have been identified in the serum of cancer patients. 
Peptide hormones including ACTH, PTH, cortisol, glucagon and 
prostaglandins are secreted by certain tumour cells (Benson et al., 1974; 
Odell and Wolfsen 1980). Many of these can induce physiological changes 
that lead to weight loss.
The results obtained in this study in those patients treated with MPA give a 
possible insight into some of the factors involved. After treatment of cancer 
patients with MPA (Chapter 2.0 and 3.0) there was an improvement in 
appetite. Weight gain of more than 3.0 kg was accompanied by an 
increase in plasma level of IGF-I, a decline in GH and cortisol levels, and a
reduction in the serum level of TNF-a. The results suggest a relationship
between IGF-I and other factors , particularly TNF-a, in the metabolic 
response to treatment in patients with malignant cachexia.
The mechanism of improvement of appetite and weight gain in patients is 
unknown, but it is possible that changes in levels of both IGF-I and TNF-a 
may be involved. There is evidence from the work of Beulter & Cerami 
(1988) and others (Oliff et al., 1987; Yoneda et al., 1991), that TNF-a may 
play important role in the cachexia associated with tumours. However, 
since circulating levels of TNF-a are not consistently elevated in patients
with cancer cachexia (Chapter 2.0) in both man (Socher et al., 1988) and 
animals (Moldawer et al., 1987) other factors are probably involved. Short­
term infusion of TNF-a is known to cause nausea, but long-term 
administration to human subjects is not feasible for obvious reasons and
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the effects on appetite remain unknown. Nevertheless, it is possible that 
TNF-a itself may predispose to loss of appetite and that the reduction seen 
in response to MPA treatment in this study may have induced an increase in 
appetite with a secondary rise in IGF-I in response to increased food intake.
An alternative explanation for the rise in IGF-I in association with the fall in 
TNF-a is that TNF-a actually suppresses the production of IGF-I from the 
liver and/or other tissues. Such an action has not previously been ascribed 
to TNF-a but it may help to explain the suppression of IGF-I seen in acutely 
ill patients even in the presence of high GH levels and apparently adequate 
nutrition.
7:2 Plasma and Tissues Changes in Mice Bearing LLT
The studies in Chapter 4.0 and 5.0 describe the metabolic changes in 
plasma and tissues in animals bearing the Lewis lung tumour. The tumour- 
bearing mice showed signs of anorexia and consumed less than the 
normal mice. This was accompanied by a reduction in the levels of IGF-I in
plasma and tissues. TNF-a levels were also high in tissues but it was
undetectable in plasma in all groups of mice (normal, control and test) 
during the study period. Although it has previously been shown that
plasma level of TNF-a may not correlate with the total body levels (Douglas
et al., 1991), the complete absence of TNF-a in plasma is surprising. 
However, if a real observation, it provides no support for the suggestion 
(above) that circulating TNF-a may cause anorexia.
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Despite the absence of TNF-a in plasma, a reciprocal relationship was
again demonstrated between levels of TNF-a and IGF-I, on this occasion in 
both muscle and liver. This again suggest the possibility of a causal 
relationship between these two factors, with TNF-a suppressing IGF-I 
synthesis in liver and, possibly, inhibiting the uptake by muscle of IGF-I from 
the IGFBP complex in the circulation
The combination of low IGF-I and high TNF-a in muscle was also found to
be associated with loss of non-tumour tissue mass, both fat and muscle. In 
addition, there were important changes in the composition of muscle with a 
marked fall in glycogen content and an apparent increase in protein 
content. The reduction in glycogen levels presumably reflects the increase 
in glucose turnover which is known to occur in patients with malignant 
cachexia. It may also indicate a reduction in glycogen synthesis; this has 
not previously been reported in association with malignant disease. The 
apparent increase in muscle protein content is more difficult to explain 
since an increase in protein degradation would be more expected in this 
situation. It probably reflects only a relative increase in protein content, ^  
largely due to the decrease in glycogen content of the same tissue.
Although patients appear to benefit in the short term at least from treatment 
with MPA, the effect of the drug in tumour -bearing animals raises questions 
about its clinical value. It has long been a concern that some treatments 
and, in particular, nutritional support given to patients with cancer, may have
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the undesirable effect of enhancing tumour growth at the expense of 
healthy host tissue. This appears to have been the effect of MPA in this 
study. It is important to note that both the loss of muscle mass and the 
compositional changes were most marked in the animals treated with MPA. 
Although the Lewis lung tumour is not hormone-dependent, tumour growth 
was greater in those animals treated with MPA. It is not possible to make a 
direct comparison between the Lewis lung tumour and the bronchial 
carcinoma of the patients studied, but these findings suggest that caution 
should be exercised in using MPA treatment in patients with tumours of this 
type before adequate resection or radiotherapy.
7:3 The Effect of TNF-a on Liver Cells
Final support for the suggestion that TNF-a may have a direct effect on
tissue IGF-I levels comes from the results of the studies performed on the 
HEP G2 liver cells (Chapter 6.0). Secretion of IGF-I by these cells was 
increased by hGH but only in presence of insulin. If insulin is taken as 
characteristic of the fed state, this finding emphasises the importance of 
nutrition in IGF-I production, confirming the finding previously described in 
the isolated liver preparation (Daughaday., 1976), and provides further 
evidence for the fact that the effect of nutrition may be mediated by a direct 
action of insulin on hepatic production of IGF-I.
The addition of TNF-a to both insulin and hGH resulted in a decrease in 
both IGF-I content and the number of cells. This finding clearly 
demonstrates the effect of TNF-a on IGF-I production by liver cells. The
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effect appears to counteract the stimulatory effect of the combined growth 
hormone and insulin treatment. Since TNF-a may be involved in the
metabolic response to disease, it is possible that TNF-a may, by influencing
hepatic IGF-I production, directly influence circulating levels of IGF-I. This 
strongly suggests that IGF-I levels may not be solely a reflection of 
nutritional status.
Whatever the effect of medroxyprogesterone in patients with malignant 
disease, it appears to have no direct effect on the production of IGF-I by 
liver cells. It remains possible, however, that MPA may enhance production 
of IGF-I secondary to stimulation of appetite and food intake as suggested 
by studies in patients.
7:4 Overall Conclusions
Weight loss is a major clinical problem in patients with a wide range range 
of diseases including cancer and frequently results in slow recovery and 
prolonged convalescence. In the highly catabolic ill patient, nutritional 
support and supplementation is frequently disappointing and fails to 
reverse weight loss.
The metabolic response which characterises this clinical situation includes, 
a long with an increase in cortisol, vasopressin and catecholamine 
secretion, a parallel fall in circulating levels of IGF-I despite high levels of 
GH. Although this may, in part at least, be due to reduced nutritional intake, 
in the presence of severe catabolism, supplementation may not result in a 
restoration of normal GH-IGF-I dynamics. Indeed, there is currently
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considerable interest in the use of recombinant IGF-I in such patients in an 
attempt to halt the catabolic process although results have, as yet, proved 
disappointing.
The present studies throw some tight on the reason for the resistance to 
treatment in catabolic state. The secretion of IGF-I appears to depend not 
only on nutritional factors and growth hormone, but also to be influenced by 
other factors, in particular TNF-a.
The patients studied demonstrated the characteristic features of cancer 
cachexia. Poor appetite and weight loss as evidence of reduced body fat 
(indicated by low skin folds) and protein, levels of GH and cortisol were in
the high normal range associated with elevated TNF-a, and ferritin, and
low blood levels of insulin-like growth factor-1.
Plasma and liver levels of IGF-I were lower in tumour-bearing than normal
animals, levels were also lower in muscle. TNF-a levels were markedly
increased in muscle of all tumour-bearing animals. This was associated 
with a decrease in muscle glycogen content and an apparent increase in 
muscle protein content.
Differences have been observed between early starvation and weight loss 
in cancer patients. Elevated levels of IGFBP-1 have been reported in 
fasting and early starvation. Baxter and Colwell (1987) reported a rise in 
plasma concentration of IGFBP-1 after an overnight fast with reduction in
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the levels following ingestion of a mixed meal or glucose infusion. A low 
IGF-I has been reported in malnutrition and after fasting for more than 24 
hours. These findings (high IGFBPs and low IGF-I) can be explained by a 
reduction in the insulin-like effect of IGF-I because of the reduced food 
intake (Figure 7:1). The adaptive changes which occur in cancer cachexia
include a rise in TNF-a; which may act to reduce the availability of IGF-I.
The way in which this may act is illustrated in Figure 7:1
Since IGF-I is known to be mitogenic and TNF-a is known to exert a 
suppressive effect on cell growth, the regenerative capacity of tissue in 
patients with cancer cachexia may be adversely affected by a contribution
of low IGF-I and raised TNF-a. In addition, the secondary effects of these
factors on endocrine, immune and the metabolic responses of the host may 
also contribute to many of the features and complications of cancer 
cachexia.
The vital organs (liver, kidney and lung) of the animals in this study were 
found to contain higher levels of IGF-I when compared to muscle. This may 
help to explain the catabolic selectivity seen in cancer cachexia and 
starvation with relative preservation of vital organs and loss of skeletal 
muscle.
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Figure 7:1 Schematic representation of possible action of IGF-1 
and IGFBPs.
(1) In normal state IGF-BP II carry IGF-I to different tissues.
(2) In early starvation IGF-BP1 will traçp/more IGF-I in the blood.
(3) Low nutrients with ?TNF-a reduce IGF-I synthesis.
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Appendix 1
MPA STUDY- PATIENT INFORMATION
Thank you for considering taking part in this study, if you are happy to do so, would 
you please sign the consent form and bring it with you on your next visit.
On this occasion would you please have nothing to eat and no more than 
one cup of tea or coffee (with no sugar) to drink before you come to St 
Lukes. Please go first to the radiotherapy outpatients where a small amount of 
blood will be taken from you, and you will be given your first dose of tablets. You 
will then be allowed breakfast before going up to radiotherapy or other treatment. 
On the same day you will asked for a second blood sample before you going 
home.
You will be visiting the Radiotherapy Department frequently in the near future. For 
the next four weeks, you will again be asked to have no breakfast before coming 
on one morning each week. On these occasions, a second blood sample will not 
be taken and you will be able to go home straight after your Radiotherapy 
appointment.
The Tablets
You should not notice any unpleasant side-effects from the tables which you will 
be taking . However, if you are in any way concerned would you please tell either 
Dr. Rostom or Dr. Elbashir when you see them, or telephone Dr. Wright’s secretary 
on Guildford 571122, extension 2145.
Appointments
Date Time 12:30 pm
Date Time 9.00 am Fasting
Date Time 9.00 am Fasting
Date Time 9.00 am Fasting
Appendix 2
MEDROXYPROGESTERONE ACETATE (MPA) STUDY
Patient’s name-----------------------------
Date of visit ------------------------------
Questionnaire
1- Have you had any of the following during the past week?
Nausea Yes/No Diarrhoea Yes/No
Difficulty swallowing Yes/No Vomiting Yes/No
2- Have you been at work during the past week? Yes/No
3- Please mark on the line below how good your appetite has been during the 
past week? I have no My appetite
appetite fo r  is as
food at all good as ever
4- Have you had any pain during the last week?
I have had
no pain _____________________
at all
I have had 
_worst pain
have ever had
Clinical Assessment
Blood pressure
Weight Kg Height
Triceps skin fold thickness —
 cm BMI
cm Mid-am muscle circumference cm
UNVERSITY OF SURREY .
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